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This section provides a medium through which
Canadian surgeons can declare themselves,
briefly and informally, on the day-to-day affairs of surgery.
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Autotranfusion Has Many Forms
S.E. Carroll, MD, FRCSC
Professor o f Surgery, University o f Western Ontario, London, Ont.

►

►

f

>
►
-

ince the advent of the AIDS
epidemic, there has been much
interest in using the patient’s own
blood for transfusion. In this issue
of the Journal (pages 458 to 462),
Graham, Burdon and Symes de
scribe a system of autotransfusion
using suction, a cardiotomy reser
voir and pump. This system is simi
lar to ones that have been used by
cardiac surgeons for several years,
but there are others which might be
considered.
Perhaps the simplest form of au
totransfusion for elective surgery is
to have patients to donate their own
blood before operation. By making
a second donation with exchange, 2
or 3 units of the patient’s blood can
be obtained. This system has been

S

The Canadian Journal of Surgery
1867 Alta Vista Dr.
Ottawa, Ont. K1G 3Y6

instituted by the Red Cross Blood
Bank in Ontario.
Another simple method is the
Solcotrans system. A bottle contain
ing anticoagulants is used during
surgery and the blood is reinfused.
This may be quite suitable for repair
of an aneurysm of the abdominal
aorta. The patient is usually hepari
nized and the volume of blood re
placed is relatively small.
During the past few years a cell
saver system has been developed,
using a suction apparatus to collect
blood, washing the erythrocytes
and restoring these to the patient.
The apparatus costs approximately
$35 000.00 and requires a techni
cian for the operation. The rate of
blood replacement is limited, so that
Tel.: (613)731-9331
Telex: 053-3152
Fax: (613) 523-0937

this system might be most useful
for repair of an aneurysm of the
descending thoracic aorta or thora
coabdominal aorta.
The system described by the au
thors is not so expensive as the
cell saver, although a technician is
still required. It has the added ad
vantage of providing a high volume,
rapid rate transfusion. It, therefore,
may be the preferred method when
larger volumes are required, as in
repair of the abdominal aortic aneu
rysm which has ruptured into the
inferior vena cava, a large thora
coabdominal aneurysm, or a pene
trating injury of the abdominal
aorta or inferior vena cava. Further
developments in this field are an
ticipated. ■
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Aptitude Testing in Surgery
D. Michael Grace, MD, DPhil, FACS, FRCSC
Member, Editorial Board, Canadian Journal o f Surgery. Associate Professor, Department o f
Surgery, University o f Western Ontario, University Hospital, London, Ont.

n this issue (pages 467 to 470),
Squire and colleagues have
added a new worry to those of
senior surgeons, faced with failing
eyesight, stamina and memory, in
their finding that surgical consul
tants performed more poorly than
surgical or medical residents in
tests of manual dexterity. I can hear
surgeons across the country stir
ring with indignation and preparing
to challenge our medical colleagues
or surgical residents to a shootout
on the golf course! On further
reflection, the paper raises impor
tant issues. What makes a good
surgeon and how do you measure
performance? How should surgical
residents be selected and surgical
performance predicted? How can in
terest in surgery among medical
students be stimulated and techni
cal skills in medical and surgical
fields be encouraged?
Squire and colleagues conclude
that manual dexterity should not be
used in assessing candidates for
surgical residency training posi
tions. The same conclusion was
reached by Schueneman and associ
ates,1 who stated that “pure psy
chomotor skill (manual dexterity) is
not the major dimension distin
guishing the proficient surgical per
formance from the mediocre”. Abili
ty to tolerate stress and complex
visuospatial organization correlated
much better with assessments of
operative skill.1 Others2 have agreed
that older residents may show “less
speed and coordination and more
caution” but no difference in rated
surgical skills. Although specific
tasks may be performed more slow
ly, surgical experience does result

I
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in quicker operations and reduced
postoperative complications.3 Many
factors other than pure technical
skill influence success in surgery.
Spencer4 stated that a skilfully per
formed operation is 75% decision
making and 25% dexterity.
The desirable qualities of a good
surgeon are open to debate. A
group of surgical faculty and resi
dents rated the qualities of surgical
house officers;5 their list included
admission of errors, good discipline,
considering all facts, high motiva
tion, consistency, ability to listen,
decisiveness, teamwork, flexibility
and a positive attitude. Non-sur
geons might have other ideas. The
aim is to obtain the maximum num
ber of positive qualities in surgical
trainees, realizing that some of us
already in the field may be deficient
in a few of these attributes.
Traditional methods of resident
selection are based on academic
records, personal interviews, refer
ences, and often direct observation
on the ward or in the operating
room. Academic records may pre
dict ability to pass examinations but
correlate poorly or even negatively
with surgical skills.1 Unstructured
group interviews may be no more
successful than random selection in
assessing ability, motivation and
personality, which predict later per
formance.6 References are rarely
critical or detailed enough to be of
real help in selection. Direct obser
vation during electives or internship
may be helpful, but, unfortunately
for the student, the elective is used
to impress surgical selection com
mittees rather than to gain experi
ence in varied medical fields. An
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opportunity to travel is lost and
those who need medical and cultur
al breadth of knowledge become yet
narrower in outlook. A standardized
selection procedure less dependent
on interviews and impressing the
selection committee might allow a
return to broadly based electives in
clerkship and internship and more
accurate prediction of surgical suc
cess.
In England, surgeons have begun
aptitude testing67 and have de
scribed the present system as “sub
jective and haphazard”.7 Yet selec
tion becomes more important as
residency positions decline and ap
plications increase. The problem is
to get the right people into the
right jobs. In a symposium on per
sonality assessment and aptitude
testing in the selection of surgical
trainees, it was pointed out that
such testing is now widely used in
industry and in assessing suitability
for military service.6 Clarke and
Wigton,8 in the United States, rated
applicants under five criteria:
knowledge, judgement, work hab
its, interpersonal skills and techni
cal skills. However, this system may
be more helpful in organizing infor
mation than in predicting future
success, and technical skills could
not be assessed accurately. The
Dutch9 have used an initial detailed
questionnaire to grade prospective
surgical residents. They assess ver
bal, spatial and numerical reasoning
with paper and pencil and use com
puter testing to assess manual dex
terity and stress tolerance. Candi
dates are rated according to intelli
gence, operative skill, stability and
organization (stress tolerance, corn-

APTITUDE TESTING

mon sense, time management),
work attitudes (motivation, accura
cy, energy), and cooperation (team
spirit, leadership, self-criticism and
empathy). A psychologist aids sur
geons in the selection process. By
this technique, 10% to 20% of appli
cants are selected, although far
more are judged suitable for train
ing. The Dutch emphasize that
there is room for individuals and no
single profile of the ideal surgeon.
Are surgical skills innate or
learned? Neuropsychologic testing
designed by Schueneman and col
leagues1 and the Dutch9 attempts to
determine innate skills and avert
technical skill problems late in sur
gical residency. However, more can
be done to encourage technical
skills during residency. Some sur
geons, such as the late Dr. A.D.
McLachlin, are renowned for their
emphasis on teaching and encour
aging good surgical technique. The
system of graded responsibility en
courages technical experience but
defers it to the later years of resi
dency when the early years may be
of crucial importance for acquiring
basic skills.10 The recent develop
ment of microvascular laboratories
in many centres has encouraged the
learning of fine motor skills. In the
past, operations on animals allowed
residents to acquire surgical skills,
but such opportunities have de
creased as a result of opposition to
the use of animals for experimenta
tion. Many ingenious alternatives
can be developed in the laboratory
for teaching fundamental surgical
skills to surgical residents,10 and
such methods can also be applied to
medical students. Orthopedic sur
geons have been pioneers in evalu
ating and teaching surgical
skills.1112
In these days of limited training
positions and hospital resources, it
is important that we select the right
candidates for residency and a ca
reer in surgery. Squire and col

leagues have shown that assess
ment of manual dexterity should
not, by itself, be used to select
prospective surgeons. However,
methods of predicting technical
skills and determining aptitude for a
surgical career are being developed
in other countries. We should con
tinue this process in Canada.

References
1. S chueneman AL, P ickleman J, H esslein
R, et al: Neuropsychological predictors
of operative skili among general surgical
residents. Surgery 1984; 96: 288-295
2. Barnes RW, L anc NP, W hiteside MF:
Halstedian technique revisited. Innova
tions in teaching surgical skills. Ann
Surg 1989; 210: 118-121
3. Yau W, Fan S. Chu KW, et al: Influence
of surgeons’ experience on postopera
tive sepsis. Am J Surg 1988; 155: 322326
4. S pencer FC: Competence and compas
sion: two qualities of surgical excel

lence. Bull Am Coll Surg 1979; 64: 1522

5. G reenburc AG, McC lure DK, P enn NE:
Personality traits of surgical house offi
cers: faculty and resident views. Surgery
1982; 92: 368-372
6. Personality assessment techniques and
aptitude testing as aids to the selection
of surgical trainees. Report of a sympo
sium. Ann R Coll Surg Engl 1988; 70:
265-279
7. Gough M, B ell J: Introducing aptitude
testing into medicine. Br Med J 1989;
298: 975-976
8. C larke JR, W icton RS: D evelopm ent o f
an objective rating system for residency
applications. Surgery 1984; 96: 302-

306
9.

van de Loo RPJ: Selection of surgical
trainees in The Netherlands. Ann R Coll
Surg Engl 1988; 70: 277-279
10. Barnes RW: Surgical handicraft: teach
ing and learning surgical skills. Am J
Surg 1987; 153: 422-427
11. K opta JA: The development of motor
skills in orthopedic education. Clin Orthop 1971; 75: 80-85
12. Idem: An approach to the evaluation of
operative skills. Surgery 1971; 70: 297303

SESAP VI Question
Item 222
For a patient with a superficial femoral artery occlusion with only
posterior tibial artery runoff, which of the following signs or symptoms
would be the WEAKEST indication for femorotibial bypass?
(A) Nonhealing ischemic ulcer
(B) Ischemic rest pain of the forefoot
(C) Severely limiting intermittent claudication of the calf
(D) Gangrene of the great toe
(E)

Cyanotic toes secondary to ischemia

For the question above, select the one answer that is best of the five
given.
For the critique of Item 222 see page 444.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa
tion and Self-Assessment Program No. 6. For enrolment in the Surgical
Education and Self-Assessment No. 6, please apply to the American
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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T h e CJS — Yesterday, Today and
Definitely Tomorrow
C.B. Mueller, MD, FRCSC; L.D. MacLean, MD, FRCSC
Coeditors, Canadian Journal o f Surgery

vents of the past 2 or 3 years,
and particularly those of the
spring and summer of 1989, have
forced the Canadian Journal o f Sur
gery to review its status, its man
date and its support. Your coeditors
take this opportunity to review the
past, describe the present and pres
ent some personal thoughts about
Canada, its surgical community and
its national identity.

E

A Bit of History
In 1957, the first volume of the
Canadian Journal o f Surgery was
published by the Canadian Medical
Association. It appeared quarterly
in a 7 X 9-inch format. Dr. R.M.
Janes, chairman of the Department
of Surgery at the University of
Toronto was the first editor and
chaired an editorial board composed
of the chairmen of all the university
departments of surgery in Canada.
The editorial policy was for the
Journal to be a publication of recent
scientific activities within Canadian
surgical departments. A full-time
editorial assistant and a part-time
associate editor were appointed, and
the Journal was distributed on a
subscription basis. In 1964, Dr.
Janes relinquished the editorship to
Dr. Fred Kergin, also of Toronto.
By 1971, the frequency of publica
tion had increased to six issues per
year and the circulation had grown
to 1500. In 1972, Dr. Kergin gave
up his editorial responsibilities,
398

partly because the editorial offices
were being moved from Toronto to
Ottawa. Drs. L.D. MacLean and
C.B. Mueller then accepted the re
sponsibility of coeditorship.
About the same time, a commit
tee of the Royal College of Physi
cians and Surgeons of Canada, with
representation from the Canadian
Medical Association, the Canadian
Society for Clinical Investigation
and l’Association des medecins de
langue franqaise du Canada agreed
that it “was desirable to try to
ensure the survival of the Canadian
Journal of Surgery...perhaps broad
en it to include greater coverage of
the surgical specialties...an affilia
tion with or sponsorship by
RCPSC...would merit serious con
sideration”.
In 1973, a proposal to the Coun
cil of the Royal College suggested
that it should send “CJS to its
surgical members as a function of
membership...arrange for it to re
late to all members...for purposes of
continuing education, a chance to
disseminate information of general
interest and be a medium of com
munication”. With Council approv
al, the following policies were estab
lished:
• The publication would be a
joint undertaking.
• The CMA would own the
Journal.
• The Royal College would set
editorial policy, appoint the editors
and the editorial board and receive
periodic reports.

CJS, VOL. 32, NO. 6, NOVEM BER 1989

• The CJS would be sent to
every Fellow in the Division of
Surgery and any Fellow in the Divi
sion of Medicine who desired it.
• A board of management would
be appointed from the two organi
zations.
• An annual grant of money
from the Royal College would be
provided to the CMA to help cover
expenses.
• The Royal College would pro
vide a mailing list.
The CMA portion of this arrange
ment was to provide office space,
reimbursement for the coeditors
and editorial staff, manuscript pro
cessing, copy editing and prepara
tion of manuscripts for publication,
journal production with respect to
layout, style and format, contract
ing for printing and mailing, and
advertising sales staff. By 1974, a
new editorial board had been consti
tuted and a new position created in
the CMA editorial office. This ar
rangement has continued to the
present. The circulation of the Jour
nal is now 9000 per issue, the
annual budget is approximately
$300 000 per year, and, in 1988,
the cost to the Royal College for
this arrangement was approximate
ly $2.00/yr per Fellow.

The Events of 1989
In May 1989, the Council of the
Royal College voted to “ ...support
financially only one journal and that

THE CJS

journal be the Annals”. The Royal
College agreed to continue financial
support for a short period, but
fiscal pressures now weigh heavily
upon the Canadian Medical Associa
tion. From a net gain of approxi
mately $50 000.00 in 1984, the
CJS showed a net loss of approxi
mately $100 000.00 in 1987 and
1988. This deficit, absorbed by the
CMA at approximately $3.00/yr
per member, is partly explained by
rising costs, but it results chiefly
from a major decrease in advertis
ing revenue — an item which must
create 50% to 60% of the Journal’s
income. The CMA General Council
in a recent action narrowly defeated
a motion to discontinue publication
of the CJS. Thus, discomfort with
the present arrangement within the
Royal College and a deficit in the
Journal’s budget have brought the
CJS to the point where a new look,
new ideas and new arrangements
are in order.

Personal Thoughts
This is an appropriate time to
acknowledge the productive associ
ations of the past as we contem
plate the future of CJS. It has been
a stimulating and rewarding experi
ence for us, your coeditors, for we
have enjoyed many warm relation
ships with the editorial board and a
host of reviewers over the past 17
years.
The Journal has grown both in
the amount and quality of editorial
material, which reflects the in
creased interest of an ever-increas
ing number of authors. The Journal
reflects the excellence of Canadian
surgery in many areas, including
transplantation, critical care, trau
ma, cardiovascular surgery and co
lorectal surgery. We hope this Jour
nal will encompass the interests of
all surgeons in the future.
Royal College support permitted
us to circulate the Journal to over

9000 surgeons. Many changes in
format, together with this large
circulation, have made the Journal
attractive to a wide audience on
which readership surveys are excel
lent.
The staff of the communications
committees of both the Royal Col
lege and CMA have been most help
ful. We have enjoyed full rein in all
editorial matters, but the time has
come for the CJS to take the next
step in development. The Journal
must appeal to all surgeons in Can
ada, and it must do this with a
balanced budget.
We must offer more than good
science, we must be a sounding
board for the many issues that
uniquely affect surgeons. Some of
these issues are physician liability,
reimbursement, the management of
hospitals where we do most of our
work, quality control and audit of
surgical practice in and outside the
hospital, the inadequate financial
support available for research in
areas of surgical interest, the pro
motion of research related to health
care policy with focus on outcome
analysis in all surgical disciplines.
We should promote the develop
ment of multidisciplinary clinical tri
als across this great nation.
How can this be accomplished at
a time when the CMA can no longer
absorb deficits in the budget and
the Royal College has made the
decision to support only one jour
nal, the Annalsl
We need an umbrella organiza
tion which has appeal to all surgical
specialties, an organization that
would set editorial policy, appoint
the editors and editorial board.
The Canadian Conjoint Council
on Surgical Education and Re
search, which is now being consti
tuted, has as its contemplated func
tions and goals many of the above
requirements for the future of the
CJS.
Members of the provisional exec

utive committee of this new organi
zation responsible for developing an
inaugural meeting in September
1989 were Drs. Jean R. Brunette,
Jean Couture, John Duff, Robert
McMurtry, David S. Mulder and
Bryce Weir. The founding organiza
tions include the following:
Canadian surgical chairmen
Royal College of Physicians and
Surgeons of Canada
Canadian Society of Cardiovascu
lar & Thoracic Surgeons
Canadian Critical Care Society
Canadian Association of General
Surgeons
Canadian Neurosurgical Society
Canadian Orthopaedic Associa
tion
Canadian Society of Otolaryngol
ogy
Canadian Association of Paediatr
ic Surgeons
Canadian Society of Plastic Sur
geons
Canadian Society for Surgery of
the Hand
Trauma Association of Canada
Canadian Urological Association
Canadian Society for Vascular
Surgery
Canadian Ophthalmological Soci
ety
Society of Obstetricians and Gy
naecologists of Canada.
A journal of surgery is a national
obligation for a country of 26 mil
lion with a unique health delivery
system at a time of enormous
change in patterns of health care
delivery, many of which affect sur
geons very specifically. A new, more
broadly based Canadian Journal o f
Surgery with input, control, even
ownership, by all branches of sur
gery should play an important role
in our future. We hope the new
Canadian Conjoint Council on Sur
gical Education and Research and
the Canadian Journal o f Surgery
can prosper together for the benefit
of our patients and the welfare of
all surgical disciplines.*
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Coeditor Recipient of 1989 Gairdner Foundation Award

Dr. L.D. MacLean, coeditor of
the Canadian Journal o f Surgery,
has been named winner of the
1989 Gairdner Foundation
Wightman Award. He received
the award from Dr. J.C. Polanyi,
the president of the Foundation,
at a ceremony in Toronto on
Oct. 20, 1989.
The Gairdner International
Foundation, which was estab
lished in 1957, recognizes, annu
ally, outstanding contributions
to medical science. This year
eight scientists (three from Cana
da, two from the United States,
one from Belgium and two from
West Germany) received five
awards amounting to more than
$250 000. Of the 205 scientists
so far honoured, 33 have sub
sequently received a Nobel prize.

400

The Wightman Award is giv
en, from time to time, to a
Canadian who has shown out
standing leadership in medicine
and medical science.
In his citation, Dr. R.B. Salter
stated: “Dr. MacLean is eminent
ly suited to be a recipient of the
Gairdner Foundation Wightman
Award which is given, from time
to time, ‘to a Canadian who, in
the opinion of the Foundation,
has demonstrated outstanding
leadership in medicine and medi
cal science consistent with the
purposes of the Foundation’. He
is being recognized as Canada’s
most outstanding surgeon-scien
tist-teacher-administrator over a
long and productive career. As a
general surgeon, his clinical
skills are widely respected

CAS’, VOL. 32, NO. 6, NOVEMBER 1989

throughout Canada. As a surgi
cal scientist, he has consistently
conducted exciting and signifi
cant basic research on shock and
the nutritional needs of surgical
patients. As a teacher, he has
taught surgery and surgical re
search to undergraduate and
postgraduate students over a pe
riod of 27 years. As an adminis
trator, he has served with great
distinction as professor and
Chairman of the Department of
Surgery at McGill University, and
Surgeon-in-Chief of the Royal
Victoria Hospital, Montreal, for
27 years.”
Dr. C.B. Mueller, coeditor of
the Journal, and the editorial
staff offer their congratulations
to Dr. MacLean on winning this
prestigious award.

HOW I DO IT

Hidden Loop Colostomy
S. Walfisch, MD; H. Stern, MD, FRCSC; K. Witkowski, RN

A

lthough one-stage operations
for obstructing cancer of the
colon have become popular, loop
colostomy is frequently the proce
dure of choice for inoperable colon
ic cancer or unresectable abdominal
cancer, invading the distal colon.1 3
It may also be indicated when ob
struction is imminent. The rationale
for this is the avoidance of another
operation and the morbidity associ
ated with the creation of a colosto
my.4 This is particularly true for
patients who have advanced disease.
The purposes of a “hidden colosto
my” are to allow the option of a
colostomy if obstruction occurs,
which can be simply done with only
local anesthesia, and to delay the
need for colostomy for as long as
possible.5 In some patients, death
from systemic disease occurs first
and the need for the colostomy is
avoided entirely.

cial opening as for construction of a
standard loop colostomy. The colon
is retracted with a Penrose drain
and, underneath, the fascia is loose
ly approximated with 0 Prolene
sutures through the opening in the
mesocolon (Fig. 1). The colon
should rest loosely on the Prolenefascial bridge. The skin is then
reapproximated above the loop. It is
most important to create the loop
without tension on the fascia. If the
bowel becomes obstructed it is im
portant to ascertain whether the
obstruction is in the small or large
bowel. If the obstruction is colonic,
the patient is given a local anesthet
ic at the bedside, then the skin is
incised over the hidden loop. The
dilated colon will bulge into the
wound. The colonic loop is opened
across the antimesenteric border
and sutured to the skin (Fig. 2).

absolute contraindications, but
clearly there are no advantages to
the procedure if the colon is com
pletely obstructed at the initial lapa
rotomy.
A hidden loop colostomy is easily
constructed and is simple to open
whenever needed. We have per
formed this procedure on three pa
tients and in two, opening the co
lostomy was delayed several
months. We recommend that con
struction of this type of colostomy
be considered in the appropriate

Discussion
Surgical Technique
Transverse or sigmoid colon may
be used. In addition to the midline
laparotomy incision, another stan
dard, small, transverse incision is
made for the colostomy, usually in
the left upper or lower quadrant of
the abdominal wall. An opening is
made in the mesocolon and the loop
of colon is pulled through the fas

We believe this procedure is
probably best suited to elderly,
blind, arthritic patients or to those
who would find it difficult to adjust
to life with a colostomy, and in
whom complete obstruction is im
minent. This is clearly a subjective
finding at laparotomy, but support
ive evidence can be gained from
barium x-ray films. There are no

FIG. 1. (Top) Loop of colon resting on
fascial bridge. (Bottom) Lateral view.
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FIG. 2. When obstruction occurs, skin
and bowel are opened along antime
senteric border.
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patients with impending obstruc
tion.
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A minor drawback to this book is
that some of the chapters overlap with
other books in the series. This is to be
expected, and the other chapters more
than make up for this minor problem.
Aortic Surgery should be read by
all vascular surgeons and will make an
excellent addition to any library.

the ongoing criticism of carotid endar
terectomy, it is imperative that the
vascular surgeon have these facts and
figures at hand.
The presentation of upper-limb prob
lems is interesting; the section on sub
clavian and brachial artery occlusions is
presented clearly with many good dia
grams and angiograms. The chapter on
cervical and first-rib excisions helps to
place in perspective the elusive thoracic
outlet syndrome.
The section on lower-limb ischemia is
the longest and possibly the most con
troversial. The chapter on intra-arterial
thrombolytic therapy is a review of the
author’s personal experience, and the
advocated technique of thrombolytic
therapy on the ward may not be accept
able in Canada.
In the chapter on surgery of the deep
femoral artery, the author states that
“even when the superficial femoral ar
tery is patent, lesions of the profunda
should be corrected prophylactically in
relation to aorto-femoral reconstruc
tions”, but this may not be standard
practice for all vascular surgeons. Also,
most vascular surgeons would not be
willing to use the “pulse-rise time as
measured by a hand-held pressure
transducer over the femoral artery”
instead of angiography to detect aortoiliac inflow disease preoperatively.
Although the section on venous dis
ease is short, it is well written and
presents a clear view of venous opera
tive indications.
In summary, this readable textbook
summarizes most indications in vascu-

5. Sanz C: A new method to avoid colosto
my in obstructions of the colon due to
non-operable carcinoma. Am J Proctol
1970; 21: 127-136

BOOK REVIEWS

AORTIC SURGERY. Edited by John J.
Bergan and James S.T. Yao. 574 pp.
Illust. W.B. Saunders Company Cana
da Limited, Toronto, 1989. $142.75.
ISBN 0-7216-2914-8.

This text continues a well-established
series of multiauthored books on select
ed vascular subjects. The successful
format has been combined and contin
ued with the contributions of some
excellent authors.
The chapters are clear and concise,
the illustrations good and the refer
ences up to date, it was satisfying to
see a chapter on historical perspectives,
which reminds us of how much we owe
to the pioneers in aortic surgery.
Rare problems in aortic disease, in
particular Takayasu’s disease, arteriomegaly, aortic lesions in children and
Marfan’s syndrome, are well covered, as
is the excellent chapter on urologic
injuries, a rare problem.
The chapters on basic considerations,
development of atherosclerosis and an
eurysm formation are particularly inter
esting. The sections on concomitant
surgical procedures and on the contro
versial areas of concomitant coronary
artery surgery, cholelithiasis and com
bined aortic and renal reconstruction
are handled well and are informative.
Up-to-date information is given on alter
native aortic surgical procedures, and
the chapter on the use of descending
thoracic aorta for arterial reconstruc
tion is particularly concise, clear and
well illustrated. Complications of aortic
surgery are well covered, particularly
the management of the acutely ischemic
limb and sexual dysfunction.
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INDICATIONS IN VASCULAR SUR
GERY. Edited by Roger M. Greenhalgh. 446 pp. Illust. W.B. Saunders
Company, Philadelphia; W.B. Saun
ders Company Canada Limited, Toron
to, Ont., 1988. $136.95. ISBN
0-7216-2623-8.

This book, a collection of papers pre
sented by authors who are recognized
experts in their fields, helps to fill a gap
between a traditional textbook and
journal articles. Because it covers vas
cular surgery in its entirety, it is an
invaluable aid to those who wish to
have these indications in one succinct
book.
The section on cerebrovascular dis
ease is excellent; carotid disease is
divided into all its categories and each
is reviewed in detail, all recent impor
tant journal articles being noted. With
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Symposium on the Management of
Carcinoma of the Esophagus: a Continuing
Controversy
1. Introduction
R.J. Ginsberg, MD, FRCSC
he management of carcinoma
of the esophagus continues to
be controversial. Despite advances
in all disciplines associated with the
management of the disease, the
overall survival and cure rates for
patients suffering from carcinoma
of the esophagus remain dismal.
Unfortunately, in North America
this disease usually presents late
when the patient is already suffer
ing from local or distant metastases
and the cure rate is poor. Until
methods are found to make an early
diagnosis, medical oncologists, radi
otherapists and surgeons will find
themselves challenged in attempt
ing to treat patients with relatively
advanced tumours.
A symposium on management of
esophageal cancer was held at the
1988 annual meeting of the Royal
College of Physicians and Surgeons
of Canada under the auspices of the
Canadian Society of Cardiovascular

T

and Thoracic Surgeons. We were
fortunate in having four distin
guished lecturers present their
views on the current management
of carcinoma of the esophagus, and
their papers are presented in the
following pages. Dr. Andre Duranceau (Montreal) outlines the current
controversies in surgical manage
ment (pages 415 to 419). Dr.
David Skinner (New York) empha
sizes his preference for radical surg
ical excision in early stage disease
(pages 420 to 423). Dr. David
Kelsen (New York) reviews the role
of adjuvant treatment in carcinoma
of the esophagus, indicating the
need for prospective randomized tri
als to find out whether neoadjuvant
chemotherapy and radiotherapy
should play a role in the manage
ment of this disease (pages 410 to
414). Dr. Albino Flores (Vancou
ver) reviews the experience of the
Cancer Control Agency of British
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Columbia in managing patients with
carcinoma of the esophagus, utiliz
ing a combination of brachytherapy
and external beam irradiation; for
patients whose disease was in its
early stage this was combined ulti
mately with surgical resection
(pages 404 to 409).
From these articles, it is obvious
that there are more questions than
answers related to management of
carcinoma of the esophagus. The
answers to these controversial is
sues will only be achieved by ade
quate staging of patients before
their treatment and by utilizing ran
domized, controlled, clinical trials
to pose questions concerning the
best management of this disease.
Unfortunately, as yet, this type of
studied approach to carcinoma of
the esophagus has not been done.
Because of the relatively low inci
dence of this disease in North
America, any type of clinical trial
with meaningful results will require
the cooperation of many centres
throughout the continent. We hope
that the various disciplines involved
in treatment can reach suitable
compromises so that these very
necessary studies can be done. Until
then, the management of carcinoma
of the esophagus will remain con
troversial. ■
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2. Cancer of the Esophagus and Cardia:
Overview of Radiotherapy
A.D. Flores, MD, FRCPC

Cancers of the esophagus and cardia are aggressive; they behave similarly and are
associated with an extremely poor prognosis. Because current treatments (surgical
esophagectomy and irradiation) have failed to cure the disease, critical analysis is
needed to determine the reasons for this failure. The following problems in disease
management have been identified: (a) most patients are old, frail, undernourished
and have locally advanced disease at the time of diagnosis, (b) 80% of patients die of
locally recurrent disease and aspiration pneumonia caused by the persisting cancer,
(c) there is no consensus as to what constitutes the optimum curative treatment for
the disease and (d) there is no agreement on the technical aspects and extent of the
surgical treatment required or on radiotherapy.
Les cancers de l’oesophage et du cardia sont des tumeurs agressives. Ils se
comportent de fafon similaire et sont lies a un tres mauvais pronostic. Comme les
traitements actuels (oesophagectomie chirurgicale et irradiation) se sont reveles
inefficaces a guerir cette maladie, une analyse critique s’impose si Ton veut
determiner les raisons de cet echec. Les problemes suivant propres au traitement de
cette maladie ont ete identifies: a) la plupart des patients sont ages, fragiles,
sous-alimentes et souffrent d’un cancer localement etendu au moment du diagnostic,
b) 80% des patients meurent d’une recidive locale et de pneumonie de deglutition
causee par la persistance du cancer, c) il n’y a pas consensus sur ce qui represente le
traitement a visee curative optimum de cette maladie et d) on ne s’entend pas sur les
aspects techniques et sur I’etendue de la chirurgie requise ou sur la radiotherapie.
I review the experi
I nencethisofpaper
the Cancer Control Agen

cy of British Columbia with the
overall management of cancer of
the esophagus and cardia, discuss
our recommended radiotherapy pro
tocol (combined intracavitary and
external irradiation) based on that
experience, and describe the results
in a series of patients who received
this treatment.

Historical Cases
Between 1970 and 1980, 483
patients with cancer of the esopha
gus and cardia were seen at the
Cancer Control Agency of British
Columbia by a joint esophageal tu
mour group, comprising surgeons
as well as radiation oncologists.
These patients made up 60% of the
total number of cancer cases regis

tered in British Columbia during
that period. Of the total group, 401
patients had tumours larger than 5
cm (T2), and in 288 (60%) the
disease had extended beyond the
esophageal wall (T3). Eighty-nine
(18.4%) presented with distant me
tastasis. The overall 5-year survival
rate for the 331 patients who had
locally advanced disease and were
treated by external beam radiother
apy was only 9%; a selected group
of 70 patients who had lesser dis
ease and were treated by esophagec
tomy had a 5-year survival rate of
20% (Figs. 1 and 2). The 121
patients who had radical external
beam radiotherapy had a similar
overall 5-year survival (Fig. 3).
Analysis of the pattern of failures in
these cases showed that most pa
tients died of persistent disease at
the primary site and that the main
cause of death was aspiration pneu
monia due to obstruction caused by
the persisting cancer (Table I).
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FIG. 1. Survival curve for all patients
treated.

RADIOTHERAPY FOR ESOPHAGEAL CANCER

Combined Intracavitary and
External Irradiation
Rationale

The radiobiologic effect on the
tumour is directly proportional to
the dose of radiation given. At
tempts to improve local control by
increasing the dose of external radi
ation have not been successful be
cause this exceeds the tolerance of
the adjacent normal tissues (spinal
cord, heart, lung) and has led to
serious complications. The dosime
try provided by a 10-cm linear
source for esophagus is shown in
Fig. 4. The short distance from the
radioactive material to the tumour
(4 mm) results in a high dose at the
surface of the tumour but gives
much lower doses at depth, thereby
sparing the adjacent normal tissue
from unnecessary radiation. The
combination of intracavitary irradia
tion and external irradiation is very
attractive for esophageal tumours

because the most exophytic, super
ficial and necrotic intraluminal dis
ease can be irradiated to higher
doses by the intracavitary compo
nent without substantially affecting
normal tissue; external irradiation
provides a deeper dose to a portion
of the tumour which is probably
better oxygenated and hence the
more sensitive portion of the eso
phageal cancer (Fig. 5).

and a cylinder measuring 6 X 6 X
16 cm was exposed to 4.0 Gy in
15 treatments over 3 weeks, at 100
cm source axis distance (SAD). For
patients with potentially resectable

Method

Placement of the esophageal bou
gie for intracavitary radiation at our
institution is a very simple outpa
tient procedure done under local
anesthesia or with the patient only
mildly sedated.1 Treatment is stan
dard for all patients. A cylinder
measuring 2 X 2 X 10 cm was
exposed to 1.5 Gy over 1.5 hours.
A course of external irradiation was
started on an outpatient basis; it
was applied to three fields, one
anterior and two posterior oblique,

FIG. 3. Survival for patients treated by
radiotherapy.
T a b le 1. C a u se o f D eath
C ause

FIG. 2. Survival for patients with adenocarcinomas.

N o. of
cases

P n e u m o n ia (a s p ira tio n , fis tu la )
C e re b ro v a s c u la r
B le e d in g
S uicid e
P o s to p e ra tiv e c o m p lic a tio n s

349
32
15
5
23

T otal
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FIG. 4. Isodose distribution
brachytherapy in esophagus.
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disease (lower esophagus and
cardia), the external beam radio
therapy was the same, but the oper
ative procedure was arranged 6
weeks after the last treatment.
Patients
From February 1985 to June
1988, 211 patients were treated at
our institution by a combination of
intracavitary and external irradia
tion. Of these, 171 patients were
followed up for at least 10 months
and were available for an analysis of
tolerance, quality of life and surviv
al. The youngest was 43 years of
age and the oldest 89- years (median
68 years). One hundred and ten
patients had squamous cell car
cinomas and 59 had adenocar
cinomas of the lower esophagus or
cardioesophageal junction (Table
II). One had an adenocarcinoma of
the middle portion of the esophagus
and another had similar disease in
the upper esophagus. Computed to
mography revealed advanced dis
ease with extension beyond the eso
phageal wall in 131 patients. Twen
ty-two (12.9%) had distant metastases at the time of presentation, but
all are included in the analysis.
Forty-three patients underwent
surgery after the radiotherapy.
Twenty-six underwent resection,
but 17 had abdominal carcinomato
sis or liver metastasis (worse surgi
cal stage). The remainder of the
patients had tumours in the upper
(20) or middle portion (50) of the
esophagus or had inoperable cancer
located in the lower third of the
esophagus or cardia (47).

pneumonitis. This was a patient
with advanced chronic pulmonary
disease who was treated for recur
rent disease 6 months after the
initial radical external beam radio
therapy. The complication was
thought to be unrelated to the
intracavitary component of the
treatment. Radiation esophagitis, al
though common, was only mild in

most cases, but was severe in 25
patients (14%), and it persisted until
death in all of them. This complica
tion was, however, superimposed
on, and confused with, the persis
tent and progressive malignant con
dition. None of the patients suffered
tracheo- or bronchoesophageal fis
tulas as a consequence of the thera
py, but in eight patients a fistula

PORT 1

10 cm

---------------- 1

□

3000

^

1500

□

750

FIG. 5. Isodose distribution for combined treatment.

T a b le II. S ite D is trib u tio n
S ite

No. of p a tie n ts

C e rvica l e s o p h a g u s
U p p e r th o ra c ic
M id -th o ra c ic
L o w e r th o ra c ic
C ardia

CCABC
c la s s ific a tio n *

11
9
50
42
59

T o ta l

67
104

171

'C a n c e r C o n tro l A g e n c y o f B ritis h C o lu m b ia , ca n c ers a b o ve and b e lo w tra c h e a l b ifu rc a tio n .

T a b le III. Q u a lity o f L ife - P e rfo rm a n c e S ta tu s *

Treatment Results
No patient died of complications
related to the procedure. One pa
tient died 3 months after the in
tracavitary treatment as a conse
quence of possible radiation-induced
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did occur subsequently, 6 months
after therapy, and was probably
related to progression of the dis
ease. An early analysis of the quali
ty of life (Tables III to VI) of 112
patients at 6 months after therapy
in relation to their performance sta
tus, swallowing ability, weight and
pain showed substantial improve
ment in all areas. Ninety-seven of
171 patients (56%) had complete
restoration of their swallowing abili
ty for solids. Most patients (154 of
171 [90%]) had improved swallow
ing lasting for 3 to 4 months,
although 60 (35%) required dila
tions later to maintain their nutri
tional status.

Of the 171 patients, 61 (35%)
were alive at 10 months after treat
ment, 30 of 90 (33%) at 1 year, 14
of 55 (26%) at 2 years and 5 of 26
(19%) at 3 years after combined
intracavitary and external irradia
tion. All patients who had metasta
sis died within 8 months.
Of the 43 patients considered
suitable for preoperative irradiation,
only 26 actually underwent resec
tion after exploratory laparotomy.
Of these patients, 19 (73%) were
alive from 10 to 30 months. Of the
17 patients who underwent explora
tion only, 8 were dead within 6
months. Eight died between 10 and
16 months after treatment and one

T a b le IV. Quality of Life - Swallowing*
S w a llo w in g
a b ility

B efore
tre a tm e n t, no.

None (complete obstruction)
Clear fluids
Blended food
Soft food
Any food
Totals

A fter
tre a tm e n t, no.

5
52
25
26
4 (3%)

-

3
13
32
64 (57.1%)

112

112

*EC0G system.

T a b le V. Quality of Life - W eight*

Body w e ig h t, %

Loss
5
10
20
>20
Same weight
Gain
5
10
15
20
Totals

B efore
tre a tm e n t, no.

After
tre a tm e n t, no.

17
30
28
27
5

25
10
1
-

38
19
8
2
1

-

-
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was still alive at 36 months. All had
good swallowing almost to the time
of their death. The overall survival
for all patients who underwent re
section and for those having radio
therapy only is shown in Fig. 6,
although this also includes patients
who had distant metastases, and
although only a few patients have
lived beyond 3 years, the trend
suggests possible improvement in
the overall survival rates. This trend
is even more noticeable in those
who underwent resection after irra
diation, although the follow-up is
still short (30 months). Of the 171
patients treated with intracavitary
and external irradiation and fol
lowed up for 10 months, 61 pa
tients were still alive and of those
who died, only 31 (18%) died of
pneumonia, which is proportionally
less than in historical cases (Table
I). Twenty-two patients (13%) died
of abdominal carcinomatosis, but
without dysphagia, which was com
mon in the past (Figs. 7 and 8). We
did not have any operative deaths.
The resected specimens from 26
patients were available for review.
Eighteen were adenocarcinomas
and 8 squamous cell carcinomas.
Even though most tumours were
large and locally advanced adeno
carcinomas, the changes after ra
diotherapy were dramatic. In 23 of
the 26 specimens, there was no
recognizable gross tumour (Fig. 9).
The microscopic findings did con-

104

*EC0G system.
T a b le V I. Quality of Life - Pain Related to Swallowing *
P ain

None
Sometimes present
Always present
Totals
*EC0G system.

B efore
tr e a tm e n t, no.

67
23
22
112

A fter
tre a tm e n t, no.

93 (83%)
16
3
112

20 ■

O

------ ----- ----- ------ ------1
7

1
t4

1
22
Time, mo

1
29

1
36

FIG. 6. Survival for patients treated by
combined intracavitary and external
irradiation.
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firm the absence of residual disease
in the intraluminal component of
the specimen where the higher dose
of irradiation was given. Deeply, in
the submucosa, there were marked
changes with pyknosis and cell de
generation with questionable viabili
ty (Fig. 10).

Discussion
Although there is no consensus
as to whether the primary treatment
for patients who have esophageal
cancer should be surgery or radio
therapy, it appears that a combina
tion of the two could provide better

survival for patients who suffer
from a disease that usually cannot
be controlled locally. From the sur
geon’s viewpoint, an adjuvant treat
ment program is desirable, one that
would not increase operative mor
bidity or mortality but would im
prove resectability and prevent local
recurrence. The radiation oncolo
gist would like to enhance the ther
apeutic ratio (i.e., to increase the
amount of radiation and increase
the effect but without increasing
morbidity to normal tissues).
Although many investigators2-5
are actively trying to improve the
therapeutic ratio of external irradia
tion by new fractionation schedules,
radiation sensitizers, hyperthermia
and other radiation modifiers, in
tracavitary irradiation is a wellestablished and recognized method
of treatment. It is of proven value in

other organ systems (uterus), and
recent technologic advances have
facilitated its application in other
hollow organs (esophagus and
bronchus).
The simplicity of intracavitary ir
radiation, convenience of the short
treatment time and the safety pro
vided by the remote after-loading
system make this treatment ideal
for palliation in cancer of the esoph
agus. Our clinical experience over
the past 3 years, using the combi
nation of intracavitary and external
beam irradiation has demonstrated
that this treatment is safe, has low

FIG. 9. Gross specimen after treat
ment.

FIG. 7. Before treatment with com
bined intracavitary and external beam
irradiation.
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FIG. 8. After treatment.
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FIG. 10. Microscopic findings show
changes in submucosa with pyknosis
and cell degeneration (hematoxylin and
eosin, original magnification X 40).

RADIOTHERAPY FOR ESOPHAGEAL CANCER

morbidity and appears to provide
reasonable palliation. Intracavitary
irradiation improves the therapeutic
ratio of external beam radiotherapy
alone by delivering higher doses to
the more exophytic, more hypoxic,
intraluminal portion of the esopha
geal disease, while sparing the nor
mal tissues. External beam irradia
tion provides sufficient dose in
depth to the better oxygenated,
more peripheral, probably more sen
sitive portion of the cancer. The
palliative potential is certainly supe
rior to surgery in metastatic or
unresectable disease, and since it
does not increase the morbidity or
mortality associated with eso
phagectomy, it provides a better
selection of patients by limiting re
section to only potentially curable
cases.
Patients who have tumours
below the tracheal bifurcation
should be considered for surgery
with adjuvant programs using irra
diation preoperatively, and patients
with tumours above the tracheal
bifurcation should be allocated for
radiotherapy with adjuvant pro
grams which could involve chemo
therapy, hyperthermia or sensitiz
ers.
Our recent experience leads us to
suggest that the combination of
intracavitary and external beam ir
radiation should be the optimal ra
diotherapy treatment arm for these
clinical trials, either as primary
treatment for upper esophageal le
sions or as adjuvant therapy for
potentially operable cancers, partic
ularly those in the lower esopha
gus, below the tracheal bifurcation.

with low morbidity. The potential
benefits of this combined therapy
are as palliative treatment of all
cases, as a potentially curative
treatment for upper esophageal can
cer and as an adjuvant preoperative
treatment for cancers of the lower
esophagus and cardia. Trials are
needed to further enhance the ther
apeutic ratio using radiation sensi
tizers, chemical modifiers or hyper
thermia.
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3. Neoadjuvant Therapy of Esophageal
Cancer
David Kelsen, MD, FACP
Neoadjuvant (preoperative) chemotherapy, with or without radiotherapy, is under
intense study. There are theoretical and practical reasons for the preoperative use of
systemic therapy: (a) laboratory studies support the use of preoperative treatment in
animal models, (b) the relapse pattern of esophageal cancer is primarily systemic and
(c) the impact on palliation if response is associated with an improved resection rate.
Three techniques involving systemic therapy are currently under investigation:
(a) chemotherapy alone followed by a planned surgical procedure; (b) chemotherapy
and concurrent radiotherapy followed by a planned surgical procedure; (c)
chemotherapy and radiotherapy without surgery. Phase II trials of the first
technique have demonstrated its feasibility without an increase in operative
morbidity or mortality. Two small-scale phase III trials have confirmed
chemotherapy’s efficacy but have not clearly demonstrated an impact on survival.
Large-scale phase III trials are under way, or about to begin, to test definitively the
hypothesis that neoadjuvant chemotherapy improves disease-free and overall
survival in operable patients.
The second technique has also been tested in small-scale phase II trials. Most
recently, a large-scale phase II trial has been reported which suggests that this
technique has not had a major effect on resection rates or on long-term survival for
most patients.
These treatment plans are tolerable if careful attention to detail is given.
Definitive phase III trials testing the superiority of multimodality treatments over
radiotherapy alone or surgery alone are under way.

La chimiotherapie (preoperatoire) neoadjuvante, associee ou non a la radiotherapie,
fait l’objet d’une recherche intensive. II existe des motifs theoriques et pratiques
pour administrer une therapie preoperatoire systemique: a) des etudes sur des
animaux de laboratoire soutiennent l’utilisation d’un traitement preoperatoire, b)
dans le cancer de l’oesophage, 1’evolution caracteristique de la recidive est avant
tout systemique et c) une reponse therapeutique s’accompagne d’une amelioration
tant au plan palliatif qu’a celui du taux de resection.
Trois techniques faisant appel a une therapie systemique sont presentement a
l’etude: a) la chimiotherapie seul suivie d’une intervention chirurgicale planifiee; b)
la chimiotherapie accompagnee d’une radiotherapie concomitante et suivie par une
intervention chirurgicale planifiee; c) la chimiotherapie avec radiotherapie, mais
sans chirurgie. Les essais de phase II de la premiere technique ont demontre qu’elle
pouvait etre employee sans augmentation de la morbidite ou de la mortality
operatoire. Deux petites etudes de phase III ont confirme l’efficacite de la
chimiotherapie sans toutefois demontre d’effet net sur la survie. D’importants essais
de phase III sont presentement en cours ou sur le point de demarrer; ils visent a
verifier de fa?on definitive l’hypothese voulant que la chimiotherapie neoadjuvante
ameliore la survie jusqu’a la recidive et la survie totale chez les patients operables.
La deuxieme technique a aussi fait l’objet de petits essais de phase II. On a
recemment rapporte les resultats d’une vaste etude de phase II qui indiquent que
cette methode n’a pas eu d’effet important sur le taux de resection ou sur la survie a
long terme de la plupart des patients.
Ces modalites de traitement sont supportables a condition d’accorder une
attention minutieuse aux details. Des etudes de phase III presentement en cours,
tenteront d’etablir de fa?on definitive si les traitements multiples sont superieurs a
la radiotherapie seule ou a la chirurgie seule.
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reoperative chemotherapy has
been used as part of the treat
ment for patients with “localized”
esophageal carcinoma, because of
the disappointing results achieved
using surgery and radiotherapy,12
which are aimed only at the local
process. These methods fail because
many patients have disseminated
disease at the time of diagnosis.
The extent of the disease has been
studied in several autopsy series.3' 5
It was found that in spite of a short
duration of illness, the majority of
patients, with or without residual
local tumour, had disseminated can
cer. The major sites of metastatic
disease were the lung, liver and
lymph nodes. Thus, chemotherapy
as an early part of a multimodality
approach has a strong rationale.
Neoadjuvant chemotherapy trials
can be divided into three groups: (a)
chemotherapy alone followed by a
planned surgical procedure, (b) con
current chemotherapy and radio
therapy followed by a planned sur
gical procedure and (c) chemothera-
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py and radiotherapy without opera
tive intervention.
There are theoretical advantages
to chemotherapy before surgery:
first, its superiority has been dem
onstrated by laboratory studies;6
second, preoperative treatment,
when the metastatic burden is low,
may minimize spontaneous drug re
sistance as postulated by Goldie and
Coldman.7 Since surgery is usually
performed within 4 to 8 weeks of
induction chemotherapy, removal of
the primary tumour (containing the
bulk of tumour burden) may help to
decrease the emergence of a drugresistant tumour recurrence.
In esophageal cancer, there are
two more practical advantages.
First, reducing the size of the pri
mary tumour may increase the re
section rate, and this has important
implications for both palliation and
cure. Second, chemotherapy, when
given as a single modality allows an
in-vivo assessment of the effective
ness of a drug or drug combination.
The rationale for using chemo
therapy and radiotherapy concur
rently is that radiotherapy alone has
at least some effectiveness. A num
ber of the chemotherapeutic agents
chosen have both cytotoxic and
radiosensitizing properties. By com
bining chemotherapy and radiotherapy, it may be possible to enhance
local control and destroy systemic

micrometastases. The risks of con
current chemotherapy plus radio
therapy are that toxicity may be
increased, and objective tumour re
sponse rates cannot be ascribed to
either modality alone.
Almost all of the studies reported
to date can be characterized as
phase II nonrandomized trials. They
have demonstrated the feasibility of
this approach and the toxicities
associated with it but have not
proven a survival advantage over
conventional therapy.

Chemotherapy Followed by
Surgery
At least 13 studies of chemother
apy followed by a planned operative
procedure have been reported and a
total of 312 patients treated.8 As for
combinations used in advanced dis
ease, cisplatin is the common de
nominator. There appears to be
little difference between the various
drug regimens with respect to re
sponse rate (Table I9~17). Operability
and resectability rates were fre
quently not reported. With the ex
ception of one study, operative mor
tality did not appear to be increased
over that reported with surgery
alone (range from 5.6% to 11.7%).
Median duration of survival, when
reported, ranged from 17 to 24
T a b le

S eries
refe re n c e

9

10
11
12

13
14
15
16
17

Cell
type

E
E
E
E
E
E
E
B
E

D ru g
co m b in atio n

DDP,
DDP,
DDP,
DDP,
DDP,
DDP,
DDP,
DDP,
DDP,

BLE
MIT, BLE
DVA, BLE
FU, VLB
DVA, BLE
FU
DVA, MGB
VLB, MGB
FU

1. Selected Phase II Trials of Chemotherapy-Surgery*

N o. p a tie n ts
e n te re d

No. p a tie n ts
e v a lu a te d

R esp o n se
ra te , %

Op,
no.

Res,
no.

34
15
34

34
15
34

34

23
24
14
29
26

23
24
14
27
25

17
55
53
NS
43
54
NS
44
44

26
NS
28
18
18
19

20

months. The follow-up period for
most of these trials was short, so
that long-term survival was rarely
available. One exception is the
phase II trial reported by Kelsen
and associates11 in which 34 pa
tients were treated with one or two
cycles of a combination of cisplatin,
vindesine and bleomycin before eso
phagectomy. The minimum follow
up for this study is now 6.5 years;
the 5-year survival rate was 17.6%.
No relapses were seen after
3V2 years.
At present, a number of such
randomized trials are under way.
They compare chemotherapy fol
lowed by surgery to surgery alone,
or chemotherapy followed by sur
gery to radiotherapy followed by
surgery. Preliminary data are avail
able from two studies. Roth and
colleagues18 gave cisplatin, bleomy
cin and vindesine for two cycles and
followed chemotherapy by a
planned operation and then mainte
nance chemotherapy. The standard
arm underwent surgery and did not
receive chemotherapy postoperatively. Radiotherapy was given to
selected patients in both groups.
The response rate to chemotherapy
was 47%. The operative death rate
was 11.7% and the median duration
of survival was 21 months. There
were no statistical differences in
operative morbidity (which was less

20

12
34
20
20
22
13
25
24

12
10

25

%
100
80
100
100

Op ra te ,

87
92
93

86

96

R e s ra te
°/o

76
NS
82
90
78
79

86
86

38

Op d e a th
ra te , %

S u rv iv a l,
mo

45

NS
16
NS
NS
NS

11
6
6
19
4
7

0

0

10

8

14
18

'Adapted from Kelsen D: Chemotherapy of esophageal cancer. In Orringer MB, Zuidema G: (eds): Surgery o f the Alimentary Tract: The Esophagus,
Saunders, Philadelphia (in press).
'Some patients received definitive radiotherapy without surgery.
MIT = mitomycin C, DDP = cisplatin, FU = fluorouracil, BLE = bleomycin, MGB = mitoguazone, VLB = velban, Op = operability, Res = resection, E
= epidermoid, B = both epidermoid and adenocarcinoma, NS = not stated.
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in the chemotherapy arm) or in
survival. In a subgroup analysis,
survival for patients responding to
chemotherapy was compared with
that of the whole group. The medi
an duration of survival was signifi
cantly (p < 0.05) longer for re
sponding patients than nonrespond
ing patients. However, this type of
analysis has its drawbacks.
At our institution, 96 patients
with local regional epidermoid car
cinoma of the esophagus were ran
domly assigned to receive either
radiotherapy (RT) preoperatively
(55 Gy over 5 to 6 weeks) or two
cycles of cisplatin, vindesine and
bleomycin chemotherapy (CT).19
Surgery was performed on day 56.
Postoperative crossover to the op
posite arm depended on the findings
at surgery. The objective response
rate to CT and RT was measured by
barium esophagography and as
sessed by an independent radiolo
gist. The preliminary findings
showed similar complete and partial
response rates on the two arms
(55% CT and 64% RT, respectively).
There was also no difference in the
operability or resectability rates;
75% of patients underwent surgery
and 60% had resection. Local fail
ure was seen in 20% of resectable
patients; an additional 11% of pa
tients had unresectable cancer.
Thus, surgery was unable to con
trol local disease in a total of 31%
of patients. Toxicity was acceptable.

Because many patients receive post
operative therapy in this trial, dis
ease-free or overall survival as a
function of initial therapy cannot be
analysed. At present, approximately
20% of the 96 patients are alive and
disease-free with a median follow-up
of 34 months.
A third trial supported by the
European Organization for the Sta
tistical Study of Oesophageal Dis
eases (OESO) is a three-arm study
comparing surgery alone, surgery
followed by radiotherapy and neoad
juvant chemotherapy. This trial has
accrued approximately 200 patients
and is ongoing.

3 weeks. Preliminary reports from
Wayne State University suggested
that in one study,20 there may have
been an improvement in long-term
survival and perhaps in cure rate,
but there was a high (27%) opera
tive mortality. However, in a recent
report, using chemotherapy plus ra
diotherapy but no operation, Leichman and associates21 noted that all
patients in the original study with
complete remission subsequently
died of recurrent disease.
In a single-arm phase II trial,
the Southwest Oncology Group
(SWOG) extensively tested the
Wayne State University regimen,
consisting of cisplatin-5-fluorouracil
(5-FU) plus concurrent radiothera
py. The only change in the treat
ment plan was to decrease the cis
platin dosage to 75 m g/m 2. This
study22 was recently reported in
final form (Table II20’22-26). In all,
113 patients were available for
study. Initially all were believed to
have operable disease; however, at
the end of the radiotherapy and
concurrent chemotherapy, only 62%
of patients underwent operation.
The resection rate was 48% and
included 14% of patients in whom
the tumour was described as being
“debulked”. It is important to note
that the most recent surgery-only
series2 have reported resection rates
of 60% to 80%. The operative death
rate was 11%. Seventeen percent of
patients had no histologic evidence

Preoperative Chemotherapy
Plus Concurrent Radiotherapy
As for trials involving chemother
apy as a single modality before an
operation, studies in this area have
been of the phase II single-arm
type. Except for two early trials
(using methotrexate plus radiother
apy or bleomycin plus radiothera
py), recent studies have involved
combination chemotherapy with cis
platin and fluorouracil, mitomycin
and fluorouracil, or cisplatin and
other agents. To date, trials involv
ing 483 patients have been report
ed. The dose of concurrent radio
therapy ranged from 20 to 45 Gy.
The majority of trials used approxi
mately 30 Gy, given during the first

Table II. Selected Studies of Chemotherapy Plus Radiotherapy Before Surgery*
Series
reference

Cell
type

RT dose,
Gy

RT
duration,
wk

20
22
23
24
25
26

E
E
E
B
E
E

30
30
30
30
20
30

3
3
4
3
1
3

Concur

Drug
combination

Y
Y
Y
Y
N
Y

DDP, FU
DDP, FU
BLE
MIT, FU
MTX
MIT, FU

No.
No.
patients patients
entered evaluated
21
128
70
89
93
37

21
113
65
89
93
37

Op,
no.

Res,
no.

Op
rate,
%

Res
rate,
%

19
71
38
43
55
36

15
37
35
31
NS
27

90
63
58
48
59
97

71
33
54
35
NS
73

Op death Survival,
rate, %
mo
27
11
NS
10
15
11

18
12
6
NS
26
NS

‘ Adapted from Kelsen D: Chemotherapy of esophageal cancer. In Orringer MB, Zuidema G (eds.): Surgery o f the Alimentary Tract: The Esophagus
Saunders, Philadelphia (in press)
RT = radiotheraphy, E = epidermoid, A = adenocarcinoma, Concur = concurrent radiotherapy, Y = yes, N = no, DDP = cisplatin, FU = fluorouracil,
MTX = methotrexate, MIT = mitomycin C, BLE = bleomycin, OP = operability, Res = resection.
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of residual cancer. The median du
ration of survival for the entire
group was 12 months, no better
than that associated with surgery
alone.
The potential toxicity of concur
rent radiotherapy and chemothera
py before surgery was further dem
onstrated by Adelstein and associ
ates.27 They treated a small group
of eight patients using cisplatin, a
fluorouracil infusion and metho
trexate. Concurrent radiotherapy to
a total dose of 30 Gy was given
over 3 weeks. Although major re
sponses were seen in all patients
and although during the operative
procedure the fractional intake of
oxygen (F,02) was carefully con
trolled, severe pulmonary toxicity
developed in five patients, three of
whom died. The authors concluded
that the use of simultaneous che
motherapy and radiotherapy led to
an unacceptable surgical morbidity
and mortality.
In summary, there are to date no
randomized trials that demonstrate
superiority of chemotherapy plus
concurrent radiotherapy followed
by an operation over surgery alone.
Although one randomized study
using bleomycin as the only chemo
therapeutic agent was a negative
trial, this is not surprising in view
of the extremely low level of activity
seen with that agent. More disap
pointing is the large scale SWOG
trial that gave dismal results. The

approach of neoadjuvant chemo
therapy before surgery (without
concurrent radiotherapy) should be
considered experimental.

Chemotherapy Plus
Radiotherapy Without Surgery
There have been two approaches
to chemotherapy plus radiotherapy
trials for esophageal cancer: in one,
chemotherapy is given first (for one
or two cycles) then definitive radio
therapy (50 to 60 Gy); in the other,
chemotherapy and radiotherapy are
given concurrently. Most of these
trials are single-arm, phase II pilot
studies, involving fewer than 50
patients; many involve fewer than
20 patients. However, there are
several older prospective random
ized studies.
In the largest phase III trial, the
Eastern Cooperative Oncology
Group28 compared bleomycin given
concurrently with 50 to 60 Gy of
radiation with the same dose of
radiation alone in a group of 77
patients. There was no difference in
survival (median 6.2 months for
chemotherapy plus radiotherapy
and 6.4 months for the radiothera
py alone) (Table I I I 2128-32).
More recently, the results of sev
eral multidrug regimens plus con
current radiotherapy have been re
ported.
Several groups have used cis-

Table III. Esophageal Cancer: Chemotherapy Plus Concurrent Radiotherapy
Series
Radiotherapy,
No. patients
Survival,
Drug
reference combination
Gy
evaluated
CR, %
mo
21
28

DDP-FU
BLE-MIT
BLE

30

20

NS

22

5 0 -6 0
60
50
45

40
37
30
20
15

3 0 -5 0
40

17
15

NS
NS
87
NS
NS
NS
NS
20

6.2
6.4
21
8
12
12
8
NS

-

29

FU-MIT

30

MIT-FU

31
32

DDP-MIT
ADR, BLE

ADR = Adriamycin, BLE = bleomycin, DDP = cisplatin, FU = fluourouracil, MIT = mitomycin C,
CR = complete response, NS = not stated.

platin or mitomycin C plus a 5-FU
infusion with concurrent radiother
apy. Coia and colleagues29 have
treated both adenocarcinoma and
epidermoid carcinoma with concur
rent radiotherapy, mitomycin-C and
5-FU. In a recent update, the re
sults in 50 patients were de
scribed;29 30 patients who had no
distant metastases received chemo
therapy plus 60 Gy radiotherapy;
20 who had more extensive disease
received the same chemotherapy
plus 50 Gy of radiotherapy. The
median duration of follow-up was
24 months. Of the 30 patients
treated for potential cure, 87%
achieved complete response as seen
by barium swallow roentgenogra
phy and endoscopy. Seven patients
had local recurrence, either alone or
with simultaneous distant metasta
ses. Nine others had distant disease
only. The median time to relapse
was 10 months. Although Coia and
colleagues reported a 32% 5-year
survival, only three patients were
actually at risk for 5 years. Of the
total of 50 patients, 5 required
hospitalization because of severe
esophagitis. There was one treat
ment-related death.
Similar results have been seen,
using different radiotherapy and
chemotherapy schedules, by Keane
and associates30 and John and col
leagues.31
Taylor and associates33 in a re
cent study evaluating the use of
cisplatin with 5-FU plus concurrent
radiotherapy questioned the as
sumption that the local control rate
is high. They treated 17 patients
(14 squamous cell, 3 adenocarcino
ma) and found that although 76%
of patients had complete or partial
responses, 8 of 15 recurrences were
local. The median time to recur
rence was 7 months, no better than
that with radiotherapy alone.
As with studies of neoadjuvant
chemotherapy before surgery, pre
liminary results suggest benefit but
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also the potential for severe toxici
ty .21 Carefully controlled prospec
tive randomized studies of radio
therapy alone versus radiotherapy
and chemotherapy (either sequential
or concurrent) are required before
accepting this technique as superior
to standard care.
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4. Controversies in Esophageal Cancer
Surgery
Andre Duranceau, MD, FRCSC
The current management of esophageal cancer is controversial. Parenteral nutrition
in selected patients resulted in lower complication and death rates than in untreated
patients. With respect to surgical management, esophagectomy without thoracotomy
has given survival rates similar to more radical operations. The pattern of
recurrence as well as morbidity and mortality necessitate a well-planned assessment
in order to compare it with esophagectomy using a standard approach. An
esophageal anastomosis in the neck seems to be at a higher risk for fistula
formation than reconstruction in the chest. An instrument-made anastomosis results
in fewer fistulas but a higher stricture rate than hand-made anastomosis. A large
proportion of patients with esophageal cancer will receive only palliative benefit
because of nonresectability; esophageal bypass offers a good quality of survival but
is associated with high morbidity and mortality. Palliative intubation seems to offer
the quickest and simplest method of restoring reasonable swallowing.

espite improvements in the in
vestigation and operative and
postoperative management of eso
phageal cancer, overall long-term
survival rates remain dismal. In this
paper, I evaluate current manage
ment methods and review current
thinking on the subject in an at
tempt to determine what is the
safest approach in treating this dif
ficult problem.

D

Parenteral Nutrition
L’approche du patient porteur d’un cancer oesophagien demeure discutable sous
plusieurs aspects. L’alimentation parenterale totale chez des groupes selectionnes
de ces patients entraine une diminution de la morbidite et de la mortalite lorsque
compares a des patients non traites. L’approche chirurgicale demeure sujet de
controverse: l’oesophagectomie sans thoracotomie montre des survies comparables a
celles des operations plus radicales. Le site des recidives ainsi que la morbidite et la
mortalite des deux approches demande des etudes bien planifiees avant de conclure
aux avantages de l’une sur l’autre. L’anastomose oesophagienne cervicale semble
s’accompagner d’une plus grande incidence de fistule anastomotique que lorsque la
reconstruction est intrathoracique. La compilation de series publiees revele que les
anastomoses oesophagiennes completees par autosutures entrainent moins de
fistules mais plus de stenoses anastomotiques. Une proportion importante de
patients porteurs de cancer oesophagien ne pourront beneficier que de moyens
palliatifs en raison de non resequabilite. Le court-circuitage avec reconstruction
proximale a la tumeur resulte en une morbidite et une mortalite elevee. L’intubation
oesophagienne palliative semble etre la methode la plus rapide et la plus simple
pour obtenir une qualite de deglutition acceptable.
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Whenever patients with esopha
geal cancer cannot get adequate
nutrition through the gastrointesti
nal tract, parenteral nutrition is
indicated. If access to the gastroin
testinal tract remains acceptable
and nutrients can be given, even
through a nasogastric tube, paren
teral nutrition should not be of
fered. It is important not to procras
tinate in restoring a normal nutri
tional balance in these patients.
Holter and Fischer1 reported that
parenteral nutrition could be benefi
cial in preoperative management if
administered to selected patients for
at least 72 hours. Grant2 proposed
that the intravenous support should
be for at least 5 days. Patients who
have suffered a 20% w eight loss
due to lack of dietary intake and in
whom an additional 12 to 15 days
of nutritional restriction is expect
ed, should be considered for nutri
tional support before treatment is
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initiated. If assessment of inspi
ratory and expiratory muscle pres
sure is completed in these patients,
marked improvement may be seen
within 2 weeks of instituting ag
gressive nutritional support.2 A
weight of 80% to 90% of the ideal is
considered mild weight loss. At 70%
to 80% of the ideal weight a patient
is considered to have moderate mal
nutrition. When the weight is less
than 70% of normal, severe malnu
trition is considered to be present.
Shizgal and colleagues3 noted that
when malnutrition was evaluated as
a percentage of weight loss only,
there was a marked underestima
tion of the nutritional depletion,
since the extracellular fluid volume
actually increases with starvation.
The nutritional assessment as
studied by weight, percentage
weight loss, albumin, transferrin
and total protein levels, mid-arm
muscle circumference, triceps skin
fold thickness, lymphocyte count
and delayed hypersensitivity reactiv
ity were reported by Buzby and
colleagues.4 From their findings, if
a predicted risk was less than 30%,
the incidence of the complications
was 11.7% and the death rate 2%. If
the predicted risk factor was 30% to
50%, the complication rate was
36.8% and the death rate 7.9%.
When the predicted risk was above
59%, morbidity reached 81% and
the mortality 59%. Prognosis was
evaluated in patients who under
went a variety of surgical proce
dures. Generally, patients who are
to undergo an esophagectomy and
who are in a state of severe to
moderate malnutrition should be
given preoperative nutritional sup
port and be maintained postoperatively with intravenous nutrition
until an adequate oral diet is re
sumed.
The use of parenteral nutrition
perioperatively in unselected pa
tients who undergo major surgery
is not justified. However, high-risk
416

patients may benefit. Severely mal
nourished patients without evidence
of metastatic disease who undergo
an elective esophagectomy should
receive parenteral nutrition. Moder
ately malnourished patients, previ
ously well, whose investigation and
surgery will result in a period of 10
or more days of inadequate nutri
tion, should receive nutrients
through a feeding tube or a jejunostomy but not total parenteral
nutrition, which should be used if
subsequent postoperative complica
tions limit access to the alimentary
tract.5 These recommendations are
based on statistical evaluation of 11
randomized studies. Groups of pa
tients receiving parenteral nutrition
had substantially lower complica
tion and death rates than a nontreated group. In most studies, fail
ure to restrict entry to malnour
ished patients only may have limited
the ability of these trials to show
the true effectiveness of periopera
tive parenteral nutrition. More re
cently, Warnold and associates6 re
ported that total parenteral nutri
tion in moderately malnourished pa
tients with stable disease did not
promote synthesis of the majority
of body proteins, and skeletal mus
cle remained in negative protein
balance even at high loads of total
parenteral nutrition.

Transhiatal or Transthoracic
Esophagectomy?
What is the evidence favouring a
radical operation that follows the
principles of a “good” cancer oper
ation over an operation done
through the mediastinum without
thoracotomy and without systemat
ic dissection of the lymphatic
chains? Is survival of the patient
with esophageal carcinoma related
more to the nature of the tumour
and its stage at operation than to
the extent of resection?
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The most extensive experience of
transhiatal esophagectomy is that
reported by Orringer7 on 152 pa
tients. The most frequent complica
tions were recurrent laryngeal nerve
palsy (24%), anastomotic leaks (6%)
and chylothorax (2%). The death
rate was 6%, and 88% of the pa
tients left the hospital in 21 days or
less. Peracchia and colleagues8 re
ported their experience with 127
patients. In their study, blood losses
were minimal, recurrent laryngeal
nerve palsy was seen in 12% of
patients and anastomotic leaks be
came clinically evident in 8.7%; 34
additional patients also had a radiologically evident anastomotic leak.
Their hospital mortality was 12.5%.
Zilberstein and associates9 and Gurkan and associates10 reported anas
tomotic leakage in 23% and 6% of
patients with a hospital death rate
of 13.5% and 6% respectively.
Teichman and colleagues11 in their
study reported a 38% incidence of
cervical anastomotic fistula in the
neck. Only Orringer7 has reported a
cumulative survival: 52% at 1 year,
32% at 2 years, 22% at 3 years and
17% at 4 years.
If the esophagectomy is complet
ed through the chest, using a stan
dard dissection technique or a radi
cal en-bloc resection followed by an
intrathoracic anastomosis, the over
all reported survival varies. In Postlethwait’s review12 of over 12 000
patients, there was a 4.6% overall
5-year survival in those series in
which this could be determined. In
large series, in which the carcinoma
was resected, the survival rates
showed a progressive improvement
over the decades during which this
operation was carried out. The im
proved survival was possibly due to
better selection of patients, surgical
and anesthesia techniques and post
operative management. Most large
series have shown that esophagec
tomy still carries an 8% to 30%
death rate and a 5-year survival of
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3% to 20%. In an updated experi
ence, Skinner13 reported 11 deaths
in a group of 111 patients who
underwent a systematic en-bloc dis
section of the mediastinum. This
operation helped to classify the pa
tients by extension of the tumour,
depth of wall penetration and the
number of positive nodes. Results
in these carefully staged patients
showed an overall 5-year survival of
25% with documented mediastinal
recurrences in 5%. Survival depend
ed on wall penetration and node
status. When there was neither full
thickness wall penetration nor in
volved lymph nodes, the 5-year sur
vival was 55%. When the esopha
geal wall was fully invaded but
there was no lymph-node metasta
sis, the 5-year survival was 15%.
When there was full-thickness pen
etration and when the lymph nodes
were involved, the 5-year survival
was less than 10%. One-third of all
patients had full-thickness wall pen
etration and more than five positive
nodes; not one of them survived 5
years.
Although there is little controver
sy about the feasibility of eso
phagectomy using a radical tech
nique or an approach through the
neck and the abdomen, without a
thoracotomy, it remains to be estab
lished that esophagectomy without
thoracotomy causes less morbidity
and mortality. The natural evolu
tion of the disease may not be
affected and depends on the stage
of the disease when resection is
carried out. A radical, systematic
dissection seems to offer excellent
local and regional control of the
disease along with a careful stag
ing. The “blunt” approach needs to
be assessed for the quality of its
staging and the number of early
and late mediastinal recurrences.
These questions must be answered
in order to compare both the early
and late results of these two tech
niques.

Neck or Chest Reconstruction?
Does neck reconstruction follow
ing an esophagectomy mean less
morbidity and mortality? Richelme14
studied the length of resected
esophagus obtained by both ap
proaches. When the anastomosis is
completed in the right apex, 2 to 5
cm more of esophagus is needed to
complete the reconstruction, de
pending on whether it is completed
high in the pleural dome or midway
between the azygos vein and the
apex. This is important when the
resection margin from the upper
border of the tumour is less than 10
cm. Wong and Tam15 reported that
47% of anastomotic recurrences
were detected when the esophagus
was transected less than 6 cm from
the tumour but none when a mar
gin of more than 10 cm was ob
tained. Therefore a cervical ap
proach is recommended for recon
struction when a safe margin can
not be obtained through a thoracot
omy approach. They also found
that the curative or palliative nature
of the operation and the lymphnode status did not influence the
frequency of anastomotic recur
rences.
Despite the intent of the opera
tion, if anastomosis is carried in the
neck, it is much more likely to leak.
The O.E.S.O. survey16 showed that
19% of cervical anastomoses result
ed in fistula formation, as opposed
to 12% of thoracic anastomoses.
Huang and colleagues17 reported
fistulas in 23.5% and leaks in 3.5%
of 1305 intrathoracic anastomoses.
Ancona and associates18 also
showed increased leakage with cer
vical anastomoses (19.6%) as op
posed to chest anastomoses (11%).
Launois (personal communication,
1987) studied a group of 123 pa
tients, randomized to receive either
thoracic or cervical stapled anasto
moses; fistulas occurred in 26% of
neck anastomoses compared with

leakage in only 4% of chest anasto
moses. The death rate was 9% for
the cervical approach and 14% for
the chest. These reports showing a
high incidence of complications
with neck reconstruction must be
taken in perspective with the large
series of Orringer7 and Akiyama
and associates19 who, with the sys
tematic approaches that they have
developed, reported an incidence of
anastomotic fistulas of 6% and
5.2%, respectively. Delicate manipu
lation of tissues, intact circulation
for the remaining esophagus and
proximal stomach, and the absence
of tension on the anastomosis prob
ably remain the most important
factors accounting for these differ
ences.
Is the esophageal anastomosis
more morbid than other digestive
reconstructions, and is there an
anastomotic technique that offers
better success with less morbidity?
It remains true that 50% of deaths
after esophagectomy are due to
failure of the anastomosis. Howev
er, a careful approach with meticu
lous handling of tissues can be
followed by superior results.20 Mathisen and colleagues20 reported no
cases of fistula and a 2.9% death
rate in a series of 104 patients
whose reconstruction was through
the chest using a two-layer anasto
motic technique. In the O.E.S.O.
survey in 1984,16 one aspect of the
investigation was the making of the
anastomosis. It was found that a
majority of the surgeons in Europe
an countries used the hand-made
anastomosis. When a single-layer
anastomosis was made, a fistula
occurred in 9% of cases, usually
within 5 days. If the anastomosis
was made in two layers, the rate
was 19%, half appearing within 5
days of operation. Of the 200 pa
tients who had a stapled anastomo
sis, 10% presented with a fistula.
Postlethwait,12 from an extensive
review of the literature and his own
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experience, reported a definite de
crease in the frequency of leakage
with stapled anastomoses. The
overall rate of leakage with hand
made anastomoses was 8%. In over
500 patients with stapled sutures,
the rate was 2%. This low incidence
of fistula is acquired at the expense
of a higher frequency of anastomot
ic stricture, presumably because of
the persistence of a mucosal gap
after esophagogastric apposition
and a resultant delay in healing.

Palliation: Surgery or
Intubation?
The selection of a means for
palliation in esophageal cancer is
difficult. There is no simple method
that will restore swallowing and
prevent pulmonary and nutritional
complications.
Conlan21 offered patients with
mediastinal infiltration and a medio
cre general status a total gastric
bypass. The death rate was 11.4%.
Most patients died of respiratory
complications, sepsis resulting from
an anastomotic fistula or complica
tions related to the excluded esoph
agus. Of the 78 patients, 69 left the
hospital and 53% were followed up;
43% survived 6 months and 21% 1
year. None lived for more than 18
months. Comparable series in North
America do not contain such pa
tient numbers and show a higher
operative death rate — in the range
of 35% to 40%.22 Wong and col
leagues23 reported on 142 Kirschner operations in which a Rouxen-Y anastomosis is added to de
compress the distal esophagus.
From an initial death rate of 41.5%
they now obtain good palliation
with a death rate of 9%. The mean
survival is 5 months. Manned24 pub
lished a series of 54 substernal
gastric bypasses with three deaths.
The main advantage of the total
gastric bypass is the technical sim
418

plicity of the operation and the
improved quality of life for these
patients. The obvious disadvantage
is the postoperative morbidity and
mortality. Angorn and Haffejee25
compared pulsion intubation with
retrosternal gastric bypass in 106
patients who had unresectable tu
mour. Successful swallowing was
restored in both groups. The post
operative pulmonary complications
were comparable in both groups.
The hospital stay for the bypass
group was three times that of the
intubation group and the death
rates were identical. Consequently,
these authors prefer intubation.
Palliative intubation has been
used since the early 1930s. Long
tubes like the Mousseau-Barbin
and the Celestin have a distal exten
sion to pull the tube into position
through the tumour. They are usu
ally fixed in place with a nonabsorb
able suture, anchoring the tube to
the stomach. Push-through tubes
have been developed to be placed
transorally with the esophagoscope
following dilatation of the strictured
area over a guide wire. Cusumano
and colleagues26 reported on 693
patients with inoperable esophageal
carcinoma who underwent intuba
tion at the University of Padua; 334
had a surgical pull-through proce
dure and 359 an endoscopic pushthrough. They described a learning
curve in applying the method and
reducing morbidity and mortality.
The most frequent complications
for both types of tubes were perfo
ration (2% to 4%), prosthesis migra
tion (3% to 13%) and gastrointesti
nal hemorrhage (2.4% to 0.8%).
The death rate was 7.5% for the
pull-through intubation and 2.8%
for the push-through. In their insti
tution, 70% of all inoperable eso
phageal cancers are now treated by
intubation, preferably using the
push-through method.
Girardet and colleagues27 and
Postlethwait12 reviewed the compli
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cations and mortality of palliative
esophageal intubation. In over
2000 patients they found a death
rate of 26.5% for pull-through
tubes and 14.1% when the prosthe
sis was installed endoscopically.
Complications occurred in 30% of
pull-through tubes and in 28% of
push-through intubations. Perfora
tions were seen in 4% of all intuba
tions and tube migration in 9.9%;
bleeding was seen in 2.8% of all
cases and was managed conserva
tively in most. Other complications
included tube obstruction (8.6%),
fistula formation (9.6%), aspiration
pneumonia (17.2%) and wound in
fection (25.8%).
When esophageal carcinoma is in
an advanced state, intubation seems
to be the quickest and simplest
method of restoring a reasonable
ability to swallow.
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5. Choices in Treating Carcinoma of the
Esophagus
David B. Skinner, MD, FACS*
A number of treatment regimens are now available for patients with esophageal
carcinoma. They include several surgical procedures, chemotherapy and
radiotherapy programs, either separate or combined, laser treatments, intubation
and other palliative methods. Some of these programs are rigorous and are intended
to be curative, others are purely palliative. Thus, each patient needs to be assessed
by careful staging to select the most appropriate treatment. Analysis demonstrates
that the factors principally and independently influencing prognosis are the depth of
malignant penetration through the esophageal wall and the number of involved
lymph nodes in addition to distal metastases. Modern staging techniques should be
used to identify these prognostic factors preoperatively and at surgery before final
decisions about treatment are made.

De nombreux traitements s’offrent maintenant aux patients souffrant de cancer de
l’oesophage. On compte plusieurs techniques chirurgicales, des programmes de
chimiotherapie et de radiotherapie separes ou associes, des traitements au laser,
l’intubation ainsi que d’autres methodes palliatives. Certains de ces programmes
sont rigoureux et sont a visee curative, alors que d’autres sont purement palliatifs.
En consequence, le stade clinique de chaque patient doit etre etabli avec soin afin de
choisir le traitement le plus approprie. L’analyse demontre que les facteurs qui
influencent principalement et independamment le pronostic sont la profondeur
d’envahissement de la paroi oesophagienne et le nombre de ganglions lymphatiques
atteints, en plus des metastases distales. Les techniques modernes de classement du
stade clinique doivent etre utilisees afin d’identifier ces facteurs pronostiques avant
et a l’operation, avant qu’une decision finale soit prise quant au traitement.

ecent advances in surgical
techniques, radiotherapy, chemotherapy, intubation and laser

R

treatments, among others, have
widely extended the range of therapy available for patients suffering

from esophageal carcinoma. Dys
phagia, the most common present
ing symptom, is a late development,
indicating incurable disease in most
cases. However, methods for early
detection, especially cytologic meth
ods, are identifying some patients
with local or regional disease who
can be cured. When a localized
tumour favourable for cure is iden
tified, surgical techniques employ
ing en-bloc removal of an envelope
of normal tissue surrounding the
tumour are indicated to increase the
chances for complete extirpation.1
Similarly, radiotherapy for poten
tially curable esophageal cancer
often involves a different dosage
and plan of delivery from that for
patients requiring palliative radio
therapy.2 On the other hand, surgi
cal bypasses, intubation and laser
resections to maintain a lumen are
purely palliative and do not prolong
life or offer any prospects of long
term cure. Patients who present
without obvious metastases should
undergo careful staging of the dis
ease before deciding whether treat
ment should be for cure or pallia
tion.
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Factors Determining Prognosis
Our earlier studies34 indicated
that only the depth of esophageal
wall penetration and the presence
and number of lymph-node metasta
ses, in addition to systemic metasta
ses, independently influenced the
prognosis of esophageal squamous

TREATING ESOPHAGEAL CARCINOMA

cell carcinoma or adenocarcinoma.
From a multivariate analysis, tu
mour size, degree of differentiation,
cell type and location at varying
levels in the esophagus did not
independently influence survival.
These findings, also reported from
other centres,5 have recently been
included in the international staging
system for esophageal cancer.6 In
this respect, staging for esophageal
carcinoma is similar to that of the
modified Dukes’ system for staging
colonic cancer, with the emphasis
placed entirely on depth of wall
penetration and lymph-node metastases.7

Survival
Patients with carcinoma limited
to the mucosa or submucosa and
with uninvolved lymph nodes have
an 80% chance of surviving 2 years
after an en-bloc surgical resection
and an approximately 55% chance
of surviving 5 years.4 Those with
tumour limited to the mucosa or
submucosa and one to four positive
regional lymph nodes have a better
than 60% 2-year survival and ap
proximately 30% are alive at 5
years. If lymph nodes are free of
cancer but the tumour has penetrat
ed the esophageal muscle, more
than half are alive at 2 years and
approximately 20% at 5 years after
an attempted curative resection.
However, if lymph nodes are in
volved and the tumour has pene
trated the esophageal wall, less
than 10% will be alive at 2 years in
spite of en-bloc resection. These
differences in prognosis are suffi
ciently great that careful staging
must be done before the effects of
preoperative or postoperative adju
vant chemotherapy or radiotherapy
can be accurately assessed. For pa
tients in the most favourable cate
gory, the prognosis of curative sur
gery alone is sufficiently good in

our experience, and those of oth
ers,8 that neoadjuvant or postopera
tive therapy is unlikely to be de
monstrably beneficial. In such
cases, the risk of chemotherapy or
radiotherapy should be avoided.

Staging
Because of the importance of
staging in treatment selection,
much research has been done to
determine appropriate techniques
for staging. The value of chest and
abdominal computed tomography,
bone scanning, gallium scanning
and liver-spleen scanning in addi
tion to the evaluation of symptoms
and physical findings has been as
sessed for systemic metastases.
Computed tomography is by far the
most useful single test; it is excel
lent for detecting lung, liver and
adrenal metastases as well as re
mote enlarged lymph nodes. Galli
um scanning is occasionally positive
for remote metastases if the primary
tumour has a strong uptake. In
approximately 5% of patients, the
bone scan detects an unsuspected
bony metastasis in a patient who
otherwise appears curable.
For wall penetration, endoscopic
ultrasonography is currently under
evaluation and shows great promise
of being the most sensitive for
defining the depth of tumour. If the
outlines of the tumour mass are
irregular or blurred on the comput
ed tomogram and the interpretation
is wall penetration, computed to
mography has proved to detect
more than 90% of cases of full
thickness wall penetration.4 If inter
pretation of wall penetration is re
stricted to the observation that pe
riesophageal fat lines are obliterated
or the tumour appears to engulf
adjacent structures such as the aor
ta, the value and sensitivity of the
computed tomogram is much more
limited. In advanced cases, gallium

scanning, showing intense uptake
at the primary tumour location,
barium swallow axis views or azy
gos venography also confirm full
thickness wall penetration, but
these studies are less sensitive than
computed tomography and are
deemed unnecessary.
For lymph-node metastases only,
the detection of nodes larger than 2
cm by computed tomography or
other techniques allows the predic
tion of nodal metastases. Unfortu
nately, at least 50% of patients who
prove to have positive lymph nodes
after surgical resection do not have
glands large enough to be detected
preoperatively.

Current Treatment
Our current preoperative evalua
tion of patients who have esopha
geal carcinoma includes computed
tomography of the chest and abdo
men, barium swallow evaluation of
the upper digestive tract, endoscopy
with biopsy and bone scanning, in
addition to cardiopulmonary evalua
tion. Additional studies or biopsies
are determined by these initial find
ings. During the evaluation, nutri
tional therapy is provided as indicat
ed by the degree of weight loss and
level of serum albumin. Among pa
tients presenting with established
dysphagia as the principal symp
tom, about 40% are found to have
definite evidence of systemic metas
tases, full-thickness esophageal wall
penetration or remote, enlarged
lymph nodes, and they are not
considered candidates for curative
therapy. In these cases, the thera
peutic decision is based solely upon
the extent of the patient’s symp
toms and the most appropriate way
of providing relief. Often this con
sists of a standard esophagectomy
or esophagectomy without thora
cotomy if the tumour location and
size are such that palliative radia-
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tion, intubation or laser therapy are
unlikely to provide relief. Of the
remaining 60% of patients with dys
phagia who are potentially curable
based on preoperative evaluation,
another 10% to 15% are found to
have more advanced disease at the

time of surgical staging; they un
dergo a palliative resection. The
techniques of en-bloc esophagecto
my are reserved for those patients
who appear to have localized dis
ease both preoperatively and at the
time of surgical exploration.
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Arterial Reconstruction to the Foot
Vessels: Is It Worth the Trouble?
Raymond Labbe, MD, FRCSC; Yvan Douville, MD, FRCSC; Henri-Paul Noel, MD, FRCSC
Between 1974 and 1988, 32 patients with severe rest pain and ischemic ulcerations
of lower extremities underwent 34 arterial reconstructions to the foot vessels, using,
in the majority of cases, the in-situ vein technique. There were 10 early graft
failures, resulting in the loss of five extremities. The indication for surgery,
presence of diabetes and type of bypass were not predictive of early thrombosis.
Five-year primary and secondary patency rates were 52.8% and 62.6%, with a foot
salvage rate of 74%. Although a number of these long bypass grafts fail early
because of the severity of tibial disease, this procedure appears to be durable in a
selected group of patients.

De 1974 a 1988, 34 reconstructions arterielles au niveau du pied ont ete effectuees
chez 32 patients presentant de la douleur de repos severe ou des ulcerations
ischemiques, en utilisant dans la majorite des cas la technique du pontage veineux in
situ. II y a eu 10 thromboses precoces de greffons, resultant en cinq amputations.
L’indication pour la chirurgie, la presence de diabete et le type de pontage n’ont pas
ete predictif d’une thrombose precoce. Les permeabilites primaire et secondaire a 5
ans ont ete de 52.8% et 62.6%, avec un taux de sauvetage du pied de 74%. Bien
qu’un certain nombre de ces pontages longs soit perdu precocement en raison de la
severite de l’atteinte tibiale, il semble que ce soit une procedure durable avec un
effect benefique a long terme dans un groupe selectionne de patients.

leolar arteries, concluded that pro
cedures to the ankle and foot are
effective and durable, and should be
performed with autogenous vein.
Others4-6 have promoted the use of
distal vein bypasses for limb sal
vage.
In an attempt to evaluate our
results with arterial reconstructions
to the foot vessels and to determine
if such procedures have any long
term benefit, we reviewed our expe
rience with bypasses to the posteri
or tibial artery, distal to the internal
malleolus, to the plantar arch and
to the dorsalis pedis artery, leaving
out grafting to tibial vessels above
the level of the malleoli.

Patient Data and Methods
evere tibial disease remains a
major challenge to vascular
surgeons; in limb-salvage situa
tions, arterial reconstruction to the
foot may be the only alternative,
short of a major amputation.
According to Buchbinder and col
leagues,1 limb salvage has been ap
preciably increased by femoral-foot
bypass using in-situ vein and by
popliteal-foot bypass using re
versed vein.

S

In 1986, Grant2 presented his
experience with distal in-situ vein
grafts, including bypasses to tarsal
and plantar arteries, with a follow
up at 36 months; in his series,
longer grafts with smaller distal
anastomotic sites and outflow beds
did not represent important factors
in late failure.
Recently, Andros and associates,3
reporting in June 1988 an impor
tant series of bypasses to paramal-
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Between January 1974 and June
1988, 32 patients underwent 34
bypasses to the foot because of
atherosclerosis. Two patients had
bilateral procedures at 1- and 3-year
intervals. This group represents 3%
of all infrainguinal bypasses done at
l’Hopital du Saint-Sacrement de
Quebec during the same period.
The mean age of the patients was
64.7 years (range from 40 to 83
years) and 81% were men.
Seventeen patients (53%) had dia
betes and 22 (68.7%) were smokers
or previous smokers. Hyper
lipidemia was documented in only
four patients (12.5%) and 16 had
coronary artery disease or hyperten
sion, or both.
All operations were performed for

ARTERIAL BYPASS TO FOOT

foot salvage; in 18 cases there was
ischemic ulceration and gangrene,
in 13 cases debilitating rest pain
and in 3 cases acute tibial thrombo
sis.
There were 20 femoral to dorsalis
pedis artery bypasses — 18 using
in-situ saphenous vein and 2 using
reversed saphenous vein; 13 bypass
es were femoral to plantar arch or
posterior tibial artery — 12 using
the in-situ technique and 1 a mixed
vein technique; only 1 popliteal to
dorsalis pedis artery bypass was
done, using reversed saphenous
vein.
The mean vein diameter was 5.2
± 0 . 1 2 mm proximally and 3.6 ±
0.07 mm distally (mean ± SEM).
Procedures with in-situ veins
were performed essentially by the
same technique over the years. The
proximal anastomosis is completed
first, then, using arterial inflow to
distend the lumen, retrograde ever
sion of the valves is done, using
Cartier’s valvulotome.7 The arterio
venous fistulas, identified with the
help of the electromagnetic flow
meter, are ligated; we accept a

fully thrombectomized, and second
ary patency was 75.8% at 30 days
and 62.6% at 5 years (Fig. 3). Two
bypasses are still patent 10 and 13
years respectively after the bypass
procedure. The foot salvage rate
was 81.3%o at 30 days and 74% at 5
years (Fig. 4). However, due to the
small number of patients, the stan
dard error is larger than 10% after
2 years.
Because early graft failure is the
major determinant of long-term pat
ency, we focused our attention on
the 10 grafts lost in the early
postoperative period. The indication
for surgery (Table I), the presence
of diabetes (Table II) and the site of
distal anastomosis (Table III) were
not associated with a greater risk of
failure; one graft in each of the last
two groups was thrombectomized
the day after surgery and was still
patent at 6 months and
years
later respectively.
Vein diameter and intraoperative
blood flow (ml/min) through the
bypass, as measured by the flow
meter, were not predictive of paten
cy or failure.
The 10 failures resulted in five
amputations, one performed a few
months after surgery.
Thirty-three of the 34 procedures
were long femorodistal bypasses.

minimal residual flow of fistulas.
The distal anastomosis is then car
ried out. Heparin is used locally or
systemically, according to the sur
geon’s preference, and maintained
in an intravenous infusion for 48 to
72 hours so that the partial throm
boplastin time is slightly elevated.
Only a few patients underwent
pre- or post-bypass angiography
during the operation, but this has
now become routine (Fig. 1).
Follow-up information was ob
tained at 6-month intervals, and
graft patency was assessed by ar
terial Doppler examination. The rec
ommendations of Rutherford and
colleagues8 were followed to calcu
late primary and secondary patency
rates and foot salvage rate, using
life-table analysis. Comparisons be
tween subgroups were analysed by
the x 2 test.

Results
One patient died of massive pul
monary embolism in the early post
operative period. Morbidity was es
sentially related to wound-healing
problems, as reported by others.9
The primary patency was 69.8%
at 30 days and 52.8% at 5 years
(Fig. 2). Three grafts were success
100 34
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FIG. 1. Intraoperative arteriogram of
in-situ femoral-dorsalis pedis artery
bypass with visualization of complete
plantar arch.

FIG. 2. Cumulative life-table primary patency rate for 34 femorodistal bypasses.
Number of grafts at risk at beginning of each time interval is shown. Dotted line is
used for standard errors larger than 10%.
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X
Grafts to dorsalis pedis artery did as
well as grafts to the posterior tibial,
with 3-year primary patency rates of
61% and 44% respectively. The pop
liteal dorsalis pedis bypass (the only
short graft in this series) was patent
at 2V‘i years.
Diabetes mellitus was not an ad
verse factor. Surprisingly, diabetic
patients did better than nondiabetic
with respect to primary patency.
Three nondiabetic patients had their
thrombosed graft saved, upgrading
their secondary patency rate to
50.8% at 3 years.
Evaluation of arterial run off was
difficult because of poor preopera

tive angiographic documentation of
tibial and foot vessels in many
cases, mainly because of severe ar
terial disease. Many patients had
their dorsalis pedis or posterior tibi
al artery, or both, explored surgical
ly to confirm the patency or occlu
sion of these vessels before bypass
or amputation.

Discussion
In-situ saphenous vein bypass
has allowed surgeons to reach vas
cular beds as far distal as the
forefoot. Although its superiority to
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FIG. 3. Cumulative life-table secondary patency rate for 34 femorodistal bypasses to
foot. Number of grafts at risk at beginning of each time interval is shown. Dotted
line is used for standard errors larger than 10%.

reversed saphenous vein bypass still
has to be demonstrated,1011 it ap
pears to be an ideal conduit when
severe tibial disease is present and a
more distal revascularization proce
dure is required. Femorodistal by
pass to the foot vessels proved to be
a useful technique in this series; a
5-year primary patency rate of
52.8% is acceptable with respect to
the type of arterial disease and is in
agreement with that reported in the
current literature.3-12 A foot salvage
rate of 81.3% at 30 days reflects the
severity of the disease: five limbs
were lost among the 10 early graft
failures; however, the foot salvage
rate remained at 74% at 5 years,
suggesting that the bypass was a
durable one.
Although shorter bypasses seem
to have better patency to disadvan
taged outflow tracts,13 only one
patient underwent a popliteal to
dorsalis pedis artery bypass in our
series. We have no experience with
the composite sequential bypasses
to the ankle level or more distally,
even though Verta14 indicated good
results.
It is interesting that the presence
of diabetes did not have an adverse
effect on graft patency or limb

i
1
:

i

Table 1. Early Graft Failure: Indication for
Surgery

100 3 4

Indication
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24

Ischemic ulceration +
gangrene
Debilitating rest pain
Acute tibial thrombosis

L
18

16

12

6

6

6

5

60

I
I
|

40

3

No./no. in group
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Table II. Early Graft Failure in Diabetes
No./no. in group
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FIG. 4. Foot salvage rate by life-table analysis. Number of extremities at risk at
beginning of each time interval is shown. Dotted line is used for standard errors
larger than 10%.

Table III. Early Graft Failure According to
Type of Bypass
Bypass type
Femoral-dorsalis pedis
Femoral-distal posterior
tibial

No./no. in group
5/20
5/13

1
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continued from page 402

salvage. This observation has been
reported by others,15' 17 suggesting
that a difference should not be
anticipated between diabetic and
nondiabetic patients in these re
spects.
Early graft failure was seen in 10
cases; two grafts were saved by a
secondary procedure (thrombecto
my), but five extremities were ulti
mately lost. We were not able to
identify the factors associated with
a higher risk of early thrombosis.
However, preoperative angiographic
documentation of distal vascular
beds was not adequate in the major
ity of the patients, and this may
represent a major determinant of
early patency. Emphasis should be
placed on peroperative angiogra
phy, which should be routine dur
ing distal vascular procedures.
Although long distal reconstruc
tion to the foot vessels, using insitu saphenous vein bypass, is tech
nically demanding and carries a
significant risk of early thrombosis,
we believe it is worth doing for limb
salvage; it should be performed
when severe popliteal and tibial dis
ease is present and a vessel is open
in the foot.

1985; 2: 552-557
6. L eather RP, S hah DM, Chanc BB, et al:
Resurrection of the in situ saphenous
vein bypass. 1000 cases later. Ann Surg
1988; 208: 435-442
7. S amuels PB: Evolution of the in situ
bypass. Am J Surg 1987; 154: 248-252

lar surgery, although some are contro
versial. It will be particularly useful for
those preparing for their fellowship ex
aminations in vascular surgery and for
vascular surgeons who require “facts
and figures” for a particular procedure.
We recommend it without hesitation.
Carman M. Iannicello, MD, FRCSC

8. Suggested standards for reports dealing
with lower extremity ischemia. Prepared
by the Ad Hoc Committee on Reporting
Standards, Society for Vascular Surgery/North American Chapter, Interna
tional Society for Cardiovascular Sur
gery. J Vase Surg 1986; 4: 80-94
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9. S chwartz ME, H arrington EB, S chanzer H: Wound complications after in situ
bypass. J Vase Surg 1988; 7: 802-807
10. T aylor LM, P orter JM: Reversed vs in
situ: is either the technique of choice for
lower extremity vein bypass? In Goldstone G: Perspectives in Vascular Sur
gery, vol 1, Quality Med Pub, St. Louis,

1988: 35-55
11. W atelet J, Cheysson E, P oels D, et al:
In situ versus reversed saphenous vein
for femoropopliteal bypass: a prospec
tive randomized study of 100 cases. Am
Vase Surg 1986; 1: 441-452

ROB & SMITH’S OPERATIVE SUR
GERY. Paediatric Surgery. 4th edition.
Edited by Lewis Spitz and H. Homewood Nixon. 703 pp. Illust. Butterworths, Stoneham, Mass., 1988.
$250.00 (US). ISBN 0-407-00666-4.

4. B uchbinder D, P asch AR, Verta MJ, et
al: Ankle bypass: should we go the
distance? Am J Surg 1985; 150: 216219

16. H urley JJ, A uer Al, H ershey FB, e t al:
Distal arterial reconstruction: patency
and limb salvage in diabetics. J Vase
Surg 1987; 5: 796-802

This multiauthored text is the pediatric
section of Rob & Sm ith’s Operative
Surgery series. Pediatric general sur
gery is well covered, but the only
subspecialties included are plastic sur
gery, urology and neurosurgery.
This book tries to bridge the gap
between an atlas and a textbook. There
are 65 contributors and the quality of
each chapter is variable. The introduc
tory chapters, which are theoretical and
basic, may be of value to resident staff.
There is no operative demonstration or
discussion of venous access. The details
in chapters discussing such topics as
hair lip and cleft palate are highly
specialized. The discussion is somewhat
excessive in some chapters, such as
those on empyema thoracis (14 pages)
and inflammatory bowel disease (32
pages), whereas operative descriptions
of meconium ileus and exomphalos, for
example, are controversial and superfi
cial. The 16 pages on Hirschsprung’s
disease represent a more balanced ap
proach, which should have been the
guiding principle for the rest of the
text.

5. V eith FJ, Ascer E, Gupta SK, et al:
Tibiotibial vein bypass grafts: a new
operation for limb salvage. J Vase Surg

17. P enn I: Diabetes mellitus and the sur
geon. Curr ProbI Surg 1987; 24: 535603
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Comparison Between Transcutaneous
Oximetry and Ankle-Brachial Pressure
Ratio in Predicting Runoff and Outcome in
Patients W ho Undergo Aortobifemoral Bypass
F. Michael Ameli, MB, ChB, FRCS(Edin), FRCSC, FACS; Moni Stein, BA, MD; John L. Provan, MS,
FRCS, FRCSC, FACS; Loris Aro, RN; Robert Prosser, MA; Eugene L. St. Louis, MD, FRCPC
In a prospective study, transcutaneous oxygen tension and ankle-brachial pressure
index (A B I) were measured pre- and postoperatively in 105 symptomatic patients
who underwent aortobifemoral bypass to compare the ability of these two
measurements to reflect the runoff status, determined by angiography, and to
predict the outcome of surgery.
Postoperatively, ABI better reflected the runoff status. The difference in mean
AB I for good versus poor runoff was 0.17 (p < 0.05). The difference in mean
transcutaneous oxygen tension below the knee for the two runoff categories was
relatively small (6.3 mm Hg, p < 0.05). Post- minus preoperative increases in ABI
reflected the runoff status better than increases in transcutaneous oxygen tension.
For good runoff, the mean ABI increase was 0.25 and for poor runoff it was only
0.14 (p < 0.05).
Runoff and transcutaneous oxygen tension were found to be the best predictors of
symptomatic recurrence. Poor runoff was associated with a relative risk of 2.5 (p =
0.017) and transcutaneous oxygen pressure o f less than 40 mm Hg implied a
relative risk o f 2.3 (p = 0.029) for symptomatic recurrence. The most important
predictor of graft failure was preoperative ABI.
Transcutaneous oxygen tension and the ankle-brachial pressure index appear to
be valuable noninvasive techniques for vascular assessment, offering different
insights and different predictions for management and prognosis of peripheral
vascular disease.

Au cours d’une etude prospective, on a mesure la tension d’oxygene transcutanee et
l ’indice bras-cheville (IBC) chez 105 patients symptomatiques qui subirent un
pontage aortobifemoral, dans le but de comparer l’utilite de ces deux mesures pour
donner un aperfu de la permeabilite vasculaire, telle qu’etablie par angiographie, et
pour predire les resultats de la chirurgie.
L ’lBC postoperatoire s’est avere un meilleur indicateur de la permeabilite. La
difference entre 1’IBC des patients ayant un bon debit et celui des patients qui
avaient un mauvais debit a ete de 0.17 (p < 0.05). La difference pour les deux
categories de patients entre les tensions d’oxygene transcutanees moyennes prises
sous le genou etait relativement faible (6.3 mm Hg, p < 0.05). Par rapport aux
valeurs preoperatoires, l’augmentation de 1’IBC a donne une meilleure idee de la
permeabilite vasculaire que l’augmentation de la tension d’oxygene transcutanee.
Pour un bon debit, l’augmentation de 1’IBC moyen a ete de 0.25 par rapport a
seulement 0.14 pour un mauvais debit (p < 0.05).
Le debit et la tension d’oxygene transcutanee ont ete meilleurs pour predire une
recidive symptomatique. Un mauvais debit a ete associe a un risque relatif 2.5 fois
plus eleve (p = 0.017) et un tension d’oxygene transcutanee inferieure a 40 mm Hg
supposait un risque relatif de 2.3 (p = 0.029) de recidive symptomatique. Le facteur
le plus important pour predire l’echec du pontage a ete 1’IBC preoperatoire.
La tension d’oxygene transcutanee et l’indice bras-cheville apparaissent comme
deux methodes non sanglantes utiles pour evaluer le systeme vasculaire. Elies
offrent des perspectives differentes et contribuent des facteurs previsionnels
differents face au traitement et au pronostic des maladies vasculaires peripheriques.
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oninvasive vascular tests are
playing an increasingly impor
tant role in the diagnosis and man
agement of patients with peripheral
vascular disease. Doppler segmental
limb systolic pressures are widely
accepted as the standard for nonin
vasive evaluation of peripheral vas
cular disease. The ankle-branchial
index (ABI) (the ratio of ankle to
brachial systolic pressure1’2) is most
frequently used to express the ankle
systolic pressure. It can detect dif
ferences between normal limbs, dis
eased viable limbs and nonviable
limbs.2 The technique is reproduci
ble,3-5 and a change in the pressure
ratio of more than 14% usually
indicates disease.6 The ABI reflects
mainly the hemodynamic status in
relatively large vessels. However,
under certain circumstances, it can
be associated with some problems.
For example, older diabetic patients
tend to have calcific medial stenosis
which falsely elevates the ABI.7 In
addition, the pressures in large ves
sels do not necessarily reflect blood
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NONINVASIVE PREDICTORS IN AORTIC SURGERY

flow to ischemic areas of the skin, a
factor that is often more relevant
clinically. Finally, ankle surgery
may interfere with safe postopera
tive pressure measurements.
Transcutaneous oximetry is a de
pendable noninvasive technique for
assessing peripheral oxygen deliv
ery.8 It is gaining popularity in
vascular surgery because of its sen
sitivity in detecting limb vascular
occlusive disease9 and its ability to
reflect different degrees of isch
emia.10'11 It has also been used
successfully to predict the outcome
of arterial reconstruction,12 and of
stump healing after amputation.13-15
Transcutaneous oximetry has been
criticized for being influenced by
many systemic and local factors.1617
The purpose of this study was
twofold — to compare the ability of
ABI and transcutaneous oxygen
tension (Ptc02) to reflect the .runoff
status of vessels determined by an
giography and to evaluate the abili
ty of the two measurements and
runoff to predict symptomatic re
currence and graft failure.

Patients and Methods
Between November 1985 and
January 1988, 105 consecutive pa
tients underwent aortobifemoral by
pass operations and received aor
tobifemoral Dacron grafts. Back
ground information on the patients
T a b le 1. C h a ra c te ris tic s o f 1 0 5 P atie n ts
W h o U n d e rw e n t A o rto b ife m o ra l B ypass
V a ria b le
A ge, y r
S ex
M
F
P re s e n tin g s y m p to m s
C la u d ic a tio n
S eve re is c h e m ia
D ia b e te s
S m o k in g h is to ry
H y p e rte n s io n
Is c h e m ic h e a rt d is e a s e
C a ro tid d ise ase
P re v io u s v a s c u la r s u rg e ry

N o. (% )
6 3 .2 (m e a n)
61 (5 8 .1 )
4 4 (4 1 .9 )
61 (5 8 .1 )
4 4 (4 1 .9 )
1 8 ( 1 7 .1 )
1 0 2 (9 7 .1 )
4 4 (4 1 .9 )
3 7 (3 5 .2 )
1 5 ( 1 4 .3 )
2 7 (2 5 .7 )

is presented in Table I. The data
were collected prospectively by one
research assistant.
All patients underwent angiogra
phy preoperatively. Each angiogram
was evaluated and scored according
to the runoff at the distal anasto
mosis. This was done for each limb
separately and according to stan
dards suggested by Rutherford and
colleagues.18 We defined poor run
off as 50% or more occlusion in the
runoff arteries at the site of distal
anastomosis.
Of the 210 limbs, distal anasto
moses in 128 (61%) were to the
common femoral artery, in 2 (1%) to
the common iliac artery, in 79
(37.5%) to the deep femoral artery
and in 1 (0.5%) to a previous femoropopliteal graft. Thirty-three
(15.7%) limbs were subjected to
extended profundaplasty. Sixty-nine
(65.7%) proximal anastomoses were
end-to-side and 36 (34.3%) were
end-to-end.
Ankle-arm systolic blood-pres
sure ratios (ABI) were measured for
each limb in the resting supine
position pre- and postoperatively.
Ankle and arm systolic pressures
were measured using a sphygmo
manometer and a Doppler ultra
sound velocity detector. Transcuta
neous oxygen tension measure
ments were made using a Contron
Ptc02 monitor (Contron Instru
ments, Everett, Mass.) with Clarke
electrodes at room temperature. All
measurements were done while the
patient lay supine as the electrodes
were placed on the dorsum of the
foot and 10 cm below the knee on
the symptomatically worse leg.
Transcutaneous oxygen tension
measurements were done before
and up to 10 days after operation.
Complete data were missing on
25 (11.9%) limbs because of death
(six patients, 12 limbs), wound in
fection or hematoma (3 limbs) or
early graft thrombosis (10 limbs).
Morbidity and mortality in the first

month postoperatively were consid
ered as complications. Postopera
tively, patients were seen at 1, 3
and 6 months and at 1 and 2 years.
Three (2.9%) were lost to follow
up. Long-term operative outcome
was evaluated from the cumulative
rates of death, amputation, graft
patency and symptomatic recur
rence. For primary patency rates,
the first occlusion postoperatively,
in spite of future interventions, was
considered as graft failure. Symp
tomatic recurrence was defined as
any symptoms related to vascular
occlusive disease that occurred dur
ing follow-up.
Two statistical packages were
used to analyse the data: SAS19 and
BMDP.20 Angiography scores were
divided into poor versus good run
off, and the means of the postopera
tive ABI and Ptc02 measurements
according to the runoff status were
calculated. We compared these two
means using a comparison meth
od.21 We further calculated the
means for the difference between
postoperative and preoperative
Ptc02 and ABI, according to the
runoff status, and compared them.
In order to compare the prognos
tic power of the diagnostic tests, a
Cox proportional-hazards survival
analysis22 was used. A stepwise se
lection process based on a comput
ed significance probability (maxi
mized partial-likelihood ratio), en
tered or removed variables from the
regression equation. We tested the
independent correlation of the tests
with the time to occurrence of graft
failure, symptoms or death. The
relative risk for each diagnostic test
was expressed as the exponent of
the coefficient of the test in the
hazard equation. The p values re
ported correspond to the impor
tance of the test in predicting in
creased risk for graft failure, symp
tomatic recurrence or death, after
taking into account all the other
significant predictors.
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Results
The operative death rate was
5.7%, amputation rate was 0%,
early patency rate was 94.3% and
early symptomatic relief (by limbs)
was 98%. At 2-year follow-up the
cumulative death rate was 15.5%,
amputation rate 0%, cumulative
patency 92.8% and the cumulative
symptomatic relief dropped to
77.3%.
Postoperative ABI and Ptc02 for
Good Versus Poor R unoff

The difference in mean ABI for
good versus poor runoff was signifi
cant at 0.17 (p < 0.05) (Table II). It
was also significant (p < 0.05) for
Ptc02BK (below the knee) at 6.3
mm Hg but not for Ptc02DF (dor
sum of foot).
Differences Between Postoperative
and Preoperative Ptc02 and ABI

Neither Ptc02 measures demon
strated a significant difference in
the mean increases for the two
runoff categories (Table II), but ABI
showed a significantly (p < 0.05)
higher mean increase for good ver
sus poor runoff of 0.11.
Predictors o f Symptomatic
Recurrence and Graft Failure

(Tables III and IV)
A stepwise regression analysis se
lected three variables as independ
ent and additive predictors of symp
tomatic recurrence during the fol
low-up period: runoff, the preoper
ative Ptco2BK and postoperative
Ptco2DF. The presence of poor run
off had a predictive value superior
to that of the other significant
variables (relative risk, 2.5; 95%
confidence interval, range from 1.2
to 5.4). A preoperative Ptc 02BK
score of less than 40 mm Hg was
associated with a relative risk for
symptomatic recurrence of 2.3 (95%
430

confidence interval, range from 1.1
to 4.9). Postoperative Ptc02DF also
made a significant, independent
contribution in the regression mod
el, but we could not find an abso
lute level that would be associated
with a substantial relative risk (>
1). Variables like postoperative
Ptc02BK, preoperative Ptc02DF and
preoperative and postoperative ABI
were not significant predictors of
symptomatic recurrence.
The most significant predictor of
graft failure was preoperative ABI.
An index of less than 0.4 was
associated with a relative risk for
graft failure of 6.1 (95% confidence
interval, range from 1.6 to 23.6).
Postoperative ABI of less than 0.5
was associated with a relative risk
of 3.2 (95% confidence interval,
range from 0.9 to 11.8). Poor run
off was associated with a relative
risk of 3.0 (95% confidence interval,
range from 0.9 to 9.7). The contri
butions of the last two variables to

the regression model were close to
but not quite statistically significant
at the p = 0.05 level.
Runoff, ABI and Ptc02 were not
significant predictors of short- or
long-term death rates.

Discussion
Ankle-brachial index and trans
cutaneous oximetry are two noninvasive vascular measurements that
evaluate physiological entities
which are interdependent but not
identical. Transcutaneous oxygen
tension is a measure of peripheral
oxygen delivery which is partially
dependent on the hemodynamics in
larger arteries. Clinically, the severi
ty of ischemia is best correlated
with the amount of oxygen supply
to the tissue, which is best estimat
ed by Ptc02. Oxygenation is a few
physiological steps ahead of blood
pressure in the actual function of
living tissues. The amount of blood

T a b le II. M e a n P o s to p e ra tiv e M e a s u re m e n ts and In c re a s e s o f A n k le -B ra c h ia l In d e x (A B I) and
T ra n s c u ta n e o u s O xyg e n T e n s io n (P tc o 2) A c c o rd in g to R u n o ff
R unoff
M e a s u re m e n t
P tc o 2BK, m m Hg
P o s to p
In crease
P tc o 2DF, m m Hg
P o s to p
In crease
ABI
P o s to p
In crease

Good

Poor

5 9 .5
1 3 .4 *

5 3 .2
8 .7 *

6 .3 *
4 .7

5 2 .6
1 4 .6 *

4 7 .5
6 .8

5.1
7 .8

0 .7 8
0 .2 5 *

0.61
0 .1 4 *

D iffe re n c e

0 .1 7 *
0 .1 1 *

* p < 0 .0 5 .
B K = b e lo w th e knee, DF = d o rs u m o f fo o t .
T a b le III. P re d ic to rs o f S y m p to m a tic R ecurrence
V a ria b le
R u n o ff
P tc o 2BK preop
P tc o 2DF p o s to p

p v a lu e

R e lative
risk

9 5 % confidence
interval

0 .0 1 7
0 .0 2 9
0 .0 31

2 .5
2 .3
1 .0 3

1 .2 -5 .4
1.1 - 4 . 9
1 .0 -1 .0 5

T a b le IV . P re d ic to rs o f G ra ft Failure
V a ria b le
A B I p re o p
A B I p o s to p
R u n o ff
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p v a lu e

R e lative
risk

9 5 % confidence
interval

0 .0 0 3
0 .0 6
0 .0 7

6.1
3 .2
3 .0

1 .6 -2 3 .6
0 .9 -1 1 .8
0 .9 - 9 .7
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that gets to the skin depends on
arteriolar and capillary function,
which is not always predictable
from blood pressure in large arter
ies. In diabetics, Ptc02 correlates
better with peripheral tissue isch
emia than ABI, which is usually
high due to arterial calcifica
tion.72324 Researchers who tried to
correlate Ptc02 with blood pressure
were usually disappointed to find
far from perfect linear correla
tion.25-26 This again confirms the
concept that Ptc02 and ABI do not
measure the same thing.
The runoff arterial status is a
well-recognized factor in the post
operative prognosis of patients who
undergo aortobifemoral bypass.27-28
We found that postoperative ABI
was significantly different for good
versus poor runoff, and Ptc02BK
also showed a significant difference,
but the actual value (6.3 mm Hg)
was not impressive. We have fur
ther shown that the mean increase
in post- over preoperative ABI was
significantly (p < 0.05) higher for
limbs with good (0.25) versus poor
(0.14) runoff, but Ptc02 increases
did not differ significantly.
Our results agree with those
from the study of Rutherford and
colleagues,28 which showed that in
the majority of limbs with poor
runoff, the ABI increased by less
than 0.2 after aortobifemoral by
pass grafting. The majority of limbs
with good runoff had an ABI in
crease of more than 0.2. The ABI,
therefore, reflects runoff status bet
ter than Ptco2. This is consistent
with the fact that ABI assesses the
hemodynamic status of relatively
large arteries, which is directly re
lated to runoff, whereas Ptc02 mea
surement depends also on smaller
calibre vessels and other local fac
tors that are independent of runoff.
The excellent ability of ABI to
reflect runoff status gives it an
important role in the postoperative
follow-up. It can be used to evaluate

distal progression of disease or dis
tal acute occlusions and to deter
mine the success of procedures like
thrombectomy, endarterectomy and
angioplasty.
Using the Cox regression analy
sis, we were able to demonstrate the
predictive validity of runoff, Ptc02
and ABI on the outcome of surgery.
Using death rate as the dependent
variable, ABI, Ptc02 and runoff
showed no significant predictive
ability.
Transcutaneous oxygen tension
and runoff were significant predic
tors of symptomatic recurrence.
Limbs with poor runoff had a rela
tive risk of 2.5 for symptomatic
recurrence. The cut-off point cho
sen for preoperative Ptc02BK as a
predictor of symptomatic recur
rence was 40 mm Hg. Limbs with
lower scores ran a relative risk of
2.3. Ankle-brachial index and the
other Ptc02 measurements (except
for postoperative Ptc02DF) were not
significantly associated with symp
tomatic recurrence.
Symptomatic recurrence does not
necessarily mean recurrence of
symptoms identical to or worse
than those in the preoperative peri
od. Any symptoms related to vascu
lar disease were included in this
category. The symptom could be
caused by distal progression of the
disease, disease in the graft itself or
other hemodynamic factors. This
concept of symptomatic recurrence
adds valuable information for the
management of patients and does
not necessarily overlap with graft
failure, amputation or death rate.
For example, graft failure was quite
low at 2-year follow-up (7.2%),
whereas symptomatic recurrence
was much higher (22.7%).
Other studies28-31 have also
shown an important association be
tween poor runoff and persistent
symptoms after aortobifemoral by
pass. The occurrence of persistent
symptoms in patients with poor

runoff ranged from 20% to 57%.
Preoperative ABI was the best
predictor of graft failure with a
relative risk of 6.1 for patients with
scores of less than 0.4. However, it
should be mentioned that 86% of all
graft occlusions occurred early, and
the postoperative ABI was not al
ways measured before these early
occlusions. Therefore, the predic
tive significance of postoperative
ABI might have been much higher.
It is of interest that the preopera
tive ABI was a better predictor of
graft occlusion than runoff. Trans
cutaneous oxygen tension was not
a significant predictor of graft oc
clusion. Other studies27-28 also docu
mented a significant association be
tween poor runoff and graft failure
in patients who underwent aor
tobifemoral bypass.

Conclusions
We have shown that the postop
erative ABI was better associated
with the runoff status, determined
by preoperative angiography, than
Ptc02. Ankle-brachial index in
creases were also better associated
with the runoff status than Ptc02
increases. Transcutaneous oxygen
tension and runoff were significant
predictors of symptomatic recur
rence, while ABI was a significant
predictor of graft failure. Both
Ptc02 and ABI are valuable noninvasive vascular measurements that
offer different insights with differ
ent predictions regarding manage
ment and prognosis of vascular dis
ease.
We thank United States Catheters and
Instruments International (USCI) for
their support of this study.
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The authors note in their preface
that some o f the contributors received
short notice before submitting their
contributions. Twenty-three chapters,
including those on liver resection, duo
denal atresia, malrotations and hypos
padias, have no references at all. The
only reference in the chapter on hy
dronephrosis is the original Anderson
and Hynes article o f 1949; alternative
reconstructive procedures are not men
tioned. In some instances the content
may not be in logical order. For exam
ple, the treatment o f inguinal hernias is
hundreds o f pages displaced from the
management o f undescended testicles.
The book is well bound; unfortunate
ly one 4-page leaf in the review copy
was missing. The artwork is clear. The
size and weight o f the book indicate
that it is intended for library use rather
than transportation.
It is not clear from the content
whether the book is supposed to be a
textbook or an atlas, nor is it apparent
to which type o f physician the book is
directed. Of the 87 chapters, I found 20
that would be satisfactory and useful
for a general surgeon and only 29 that
would be o f use to a resident. Most of
the textbook is obviously aimed at the
specialist pediatric surgeon, but the
lack of detail in the descriptions of
some of the operative procedures, such
as anorectal malformations, and the
lack o f discussion o f other procedures,
such as diaphragmatic hernia, make
this book o f doubtful use to a welltrained pediatric surgeon.
When compared with other pediatric
surgical texts, this book cannot be
highly recommended. Its major use will
be as a resource atlas in a pediatric
hospital library. The combination of
some subjects being dealt with clearly
and completely and others superficially,
detracts from the appeal o f this exter
nally attractive textbook.

Steven Rubin, MD, FRCSC
Children's Hospital o f Eastern Ontario,
401 Smyth Rd.,
Ottawa, Ont.
K1H 8L1
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In vitro studies indicate that the bacterial action of CLAFORAN (cefotaxime sodium)
a semi synthetic cephalosporin antibiotic, results from inhibition of cell wall
synthesis.
Indications and Clinical Uses
Treatm ent: CLAFORAN (cefotaxime sodium) may be indicated for the treatment
of infections caused by susceptible strains of the designated micro-organisms
in the diseases listed below.
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Streptococcus pneumoniae (formerly Diplococcus pneumoniae), other streptococci
(excluding enterocci, e.g. S. faecalis), Straphylococcus aureus (penicillinase and
non penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract infe c tio n s: caused by Escherichia coli, unspecified Klebsiella
species (including K pneumoniae), Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated gonor
rhea caused by N. gonorrhoeae including penicillin resistant strains.
B acte re m ia /S e p tice m ia : caused by Escherichia coli, unspecified Klebsiella
strains and Serratia marcescens.
Skin in fe c tio n s: caused by Staphylococcus aureus (penicillinase and non
penicillinase producing, S. epidermidis, Group A streptococci, Escherichia coli,
Proteus mirabilis and indole positive Proteus.
Intra-abdominal infections: caused by Escherichia coli, and unspecified Kleb
siella species.
Gynecological infections: including pelvic inflammatory disease, endometritis
and pelvic cellulitis caused by E. coli, Group A streptococci and Staphylococcus
epidermidis, anaerobic bacteria including unspecified Peptococcus and Peptostieptococcus strains and some strains of Bacteroides fragilis In several cases, although
clinical cures were achieved, bacteriological follow up was not available.
Clinical experience with CLAFORAN in anaerobic infections is limited. CLAFORAN
has been used with some success in wound and intra-abdominal infections against
some strains of unidentified Bacteroides and anaerobic cocci.
CLAFORAN has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulo
cytopenic patients, results of therapy with CLAFORAN have not been impressive.
CLAFORAN should not be considered in the treatment of enterococcal infections,
i.e. Streptococcus faecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order
to isolate and identify the causative organisms and to determine their suscep
tibilities to CLAFORAN. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re-evaluated once these results
become available.
Prophylactic U se: The administration of CLAFORAN perioperatively (preoperative
ly, intraoperatively and postoperatively) may reduce the incidence of certain infec
tions in patients undergoing elective surgical procedures (e.g. abdominal or vaginal
hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified
as contaminated or potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased
risk of infection, intraoperative (after clamping the umbilical cord) and postoperative
use of CLAFORAN may also reduce the incidence of certain postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage
and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation
by mechanical cleansing as well as with a non absorbable antibiotic (eg. neomycin)
is recommended.
If there are signs of infection, specimens for culture should be obtained for iden
tification of the causative organism so that appropriate therapy may be instituted.
Contraindications
CLAFORAN is contraindicated in patients who have shown hypersensitivity to
cefotaxime sodium, the cephalosporin or the penicillin groups of antibiotics.
Warnings
Before therapy with CLAFORAN is instituted, it must be carefully determined whether
the patient has had previous hypersensitivity reactions to cefotaxime,
cephalosporins, penicillins or other drugs CLAFORAN should be given with caution
to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including
CLAFORAN should be administered with caution to any patient who has
demonstrated some form of allergy, particularly to drugs. If an allergic reaction
to CLAFORAN occurs, the drug should be discontinued and the patient treated
with the usual agents (e.g. epinephrine, antihistamine, pressor-amines or
corticosteroids).
Pseudomembranous colitis has been reported with the use of cephalosporins
(and other broad spectrum antibiotics); therefore, it is important to consider its
diagnosis in patients who develop diarrhea during the administration of CLAFORAN.
This colitis can range from mild to life-threatening in severity
Treatment with broad spectrum antibiotics, such as CLAFORAN, alters the nor
mal flora of the colon and may permit overgrowth of Clostridium difficile or other
Clostridia. It has been established that a toxin produced by Clostridium difficile
is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of CLAFORAN and replace
ment with a suitable specific antibiotic. Moderate to severe cases should be manag
ed with fluid, electrolyte and protein supplementation as indicated. When the colitis
is not relieved by discontinuance of CLAFORAN administration or when it is severe,
an antibiotic specifically effective in antibiotic-associated pseudomembranous colitis
(e.g. vancomycin) or other suitable therapy may be indicated. Other possible causes
of colitis should also be considered (see Adverse Reactions).
Precautions
CLAFORAN (cefotaxime sodium) should be prescribed with caution in individuals
with a history of lower gastrointestinal disease particularly colitis.
The safety of CLAFORAN in pregnancy has not been established. Consequently,
use of the drug in pregnant women requires that the likely benefit from the drug
be weighed against the possible risk to the mother and fetus.
Use of CLAFORAN in women of child bearing potential requires that the anticipated
benefits be weighed against the possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be
exercised when the drug is administered to nursing mothers.
Prolonged use of CLAFORAN may result in the overgrowth of nonsusceptible
organisms. Constant evaluation of the patient's condition is essential. If super

infection occurs, therapy should be discontinued and appropriate measures taken.
Although CLAFORAN rarely produces alterations in kidney function, evaluation
of renal status is recommended, especially in severely ill patients receiving high
doses.
Patients with markedly impaired renal function should be placed on the special
dosage schedule recommended under Dosage and Administration, because nor
mal dosage in these individuals is likely to produce excessive and prolonged serum
antibiotic concentrations.
Positive direct Coomb's test is known to develop in individuals during treatment
with the cephalosporin group of antibiotics, including cefotaxime sodium.
In laboratory tests a false positive reaction to glucose may occur with reducing
substances but not with the use of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
Hypersensitivity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflam
mation with intravenous administration. Pain, induration and tenderness after in
tramuscular injection. G astrointestinal (1.7%): Colitis, diarrhea, nausea and
vomiting. Symptoms of pseudomembranous colitis can appear during or after
CLAFORAN treatment. H em ic and Lym phatic System (< 1 % ): Mild, reversi
ble leukopenia, granulocytopenia and thrombocytopenia have been reported. Some
patients developed positive direct Coomb’s test during treatment with CLAFORAN.
Genitourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient
elevations in SGOT, SGPT, serum LDH and serum alkaline phosphatase levels
have been reported. Kidney ( < 1%); Increased serum creatinine and BUN have
occasionally been observed. Central Nervous System (0.2%); Headache.
Symptoms and Treatment ot Overdosage
Since no case of overdosage has been reported to date with CLAFORAN, no
specific information on symptoms or treatment is available. Treatment of over
dosage should be symptomatic.
Dosage and Administration
CLAFORAN (cefotaxime sodium) may be administered intramuscularly or in
travenously after reconstitution (see Table with recommended mode of reconstitution
according to route of administration).

large muscle such as the upper outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a blood vessel.
Intravenous: The intravenous route is preferable for patients with bacteremia,
bacterial septicemia, or other severe or life-threatening infections, or for patients
who may be poor risks because of lowered resistance resulting from such
debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure,
or malignancy, particularly if shock is present or impending.
For bolus administration a solution containing 1 or 2 g of CLAFORAN can be
injected over a period of 3 to 5 minutes. Using an infusion system, it may also
be given over a longer period of time through the tubing system by which the
patient may be receiving other intravenous solutions. Butterfly* or scalp vein type
needles are preferred for this type of infusion. However, during infusion of the
solution containing CLAFORAN, it is advisable to discontinue temporarily the ad
ministration of other solutions at the same site.
Reg'd TM of Abbott Laboratories.
Reconstitution
For Intramuscular U s e : CLAFORAN should be reconstituted with Sterile Water
for Injection or Bacteriostatic Water for Injection in accordance with the volumes
recommended in the following table.
Reconstitution Table

Intramuscular

Guidelines for Dosage of CLAFORAN (cefotaxime sodium)

Type of Infection
Uncomplicated
Gonorrhea
Uncomplicated
infections
Moderately
severe to severe
infections
Very severe
infections (e.g.
septicemia)
Life-threatening
infections

Daily Dose
(g)

Frequency and Route

1

1 g IM (single dose)

2

1 g every 12 hours
IM or IV
12 g every
8 hours IM or IV

3-6

6-8

up to 12

2 g every
6-8 hours IV
2g every
4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated
surgery, recommended doses are as follows.
(a) 1g IM or IV administered ’/2 to 1V2 hours prior to the initial surgical incision
to ensure that adequate antibiotic levels are present in the serum and tissues
at the start of surgery
(b) 1 g IM or IV administered 1V2 to 2 hours following the first dose; for lengthy
operative procedures, additional intraoperative doses may be administered, if
necessary, at appropriate intervals (IV 2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1g is administered IV as soon as the umbilical cord is clamped.
The second and third doses should be given as 1 g IM or IV at 6 and 12 hours
after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates:
0-1 week of age
50 mg / kg IV q 12 h
1-4 weeks of age
50 m g/kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg,
the recommended daily dose is 50 to 100 mg / kg IM or IV of body weight divid
ed into 4 to 6 equal doses, or up to 180 m g/kg/day for severe infections.
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of CLAFORAN should be continued for a minimum of 48 to 72
hours after the patient defervesces or after evidence of bacterial eradication has
been obtained; a minimum of 10 days of treatment is recommended for infec
tions caused by Group A beta-hemolytic streptococci in order to guard against
the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical
appraisal is necessary during therapy of chronic urinary tract infections and may
be required for several months after therapy has been completed; persistent in
fections may require prolonged treatment. Doses less than those recommended
should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m*
the dose of CLAFORAN should be halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on
sex, weight, and age of the patient) may be used to convert these values into
creatinine clearance.
M ales: Weight (kg) x (140 - age) Females: 0.85 x above value
72 x serum creatinine
Administration
Intramuscular: CLAFORAN should be injected well within the body of a relatively

Approximate
Available
Vol. (mL)

Approx. Average
Concentration
(mg/mL)

2
3
5

2.2
3.4
6.0

230
300
330

500 mg vial
1 g vial
2 g vial

‘ shake to dissolve.
For direct intravenous injection (bolus) a n d /o r continuous intravenous
in fu s io n : 500 mg, 1 and 2 g vials should be reconstituted with at least 10 mL
of Sterile Water for Injection. Reconstituted solution may be further diluted with
50 to 1000 mL of the fluids recommended for IV infusion.
Reconstitution Table

Dosage
Adults
The dosage of CLAFORAN should be determined by susceptibility of the causative
organisms, severity of the infection and condition of the patient.

Volume to be
Added to
Vial (mL)‘

Intravenous
500 mg vial 10
1 g vial
2 g vial

Volume to be
Added to
Vial (mL)*

Approximate
Available
Vol. (mL)

Approx. Average
Concentration
(mg/mL)

10.2
10
10

50
10.4
11.0

95
180

‘ shake to dissolve.
Solutions fo r IV In fu s io n : CLAFORAN is compatible with the following infu
sion fluids:
- Sterile Water for Injection
- 0.9% NaCI injection
- 5% dextrose injection
- 0.9% NaCI and 5% dextrose injection
- 0.45% NaCI and 5% dextrose injection
- 0.2% NaCI and 5% dextrose injection
- Sodium Lactate injection
- 5% dextrose and 0.15% KCI injection
- Plasma-Lyte 56 Electrolyte Solution in 5% dextrose injection
- Ringer’s injection
- Lactated Ringer's solution
- Lactated Ringer's with 5% dextrose injection
CLAFORAN is also compatible with lignocaine 1%.
A solution of 1 g of CLAFORAN in 14 mL of Sterile Water for Injection is isotonic.
Stability of Solution
S to ra g e : Solutions of CLAFORAN range from light yellow to amber, depending
on concentration and the diluent used. The solutions tend to darken depending
on storage conditions and should be protected from elevated temperatures and
excessive light.
“ Reg'd TM of Baxter-Travenol Laboratories.
CLAFORAN reconstituted in the original vial as described under Reconstitution
maintains satisfactory potency for 24 hours at room temperature (25°C) and for
48 hours under refrigeration (0-5°C). Only freshly prepared reconstituted solu
tions may be further diluted with 50 to 1000 mL of the recommended infusion
fluids in Viaflex" intravenous bags. Such solutions maintain satisfactory poten
cy for 24 hours at room temperature (25°C) and for 72 hours under refrigeration
(0-5°C). Any unused solutions should be discarded.
CLAFORAN reconstituted with 1% lignocaine maintains satisfactory potency for
up to 24 hours at room temperature and 48 hours under refrigeration (reference
to lignocaine restrictions is advisable).
CLAFORAN solutions exhibit maximum stability in the pH 5-7 range.
Special In s tru ctio n s: Parenteral drug products should be inspected visually
for particulate matter and discoloration prior to administration. Solutions of
CLAFORAN range from light yellow to amber, depending on concentration and
diluent used. The dry powder as well as solutions tend to darken, depending
on storage conditions.
Inco m patibilities: Solutions of CLAFORAN must not be admixed with
aminoglycoside solutions. If CLAFORAN and aminoglycosides are to be ad
ministered to the same patient, they must be administered separately and not
as a mixed injection.
Solutions of CLAFORAN should not be prepared with diluents having a pH above
7.5 such as Sodium Bicarbonate Injection.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder,
in vials containing 500 mg, 1.0 and 2.0 g of cefotaxime sodium (expressed as
acid on a dry basis).
S tora ge: CLAFORAN in the dry state should be stored at room temperature,
protected from light and heat.
Product monograph available on request
Reference
Jones R.N. et a l.: Antibiotic Prophylaxis of 1036 Patients Undergoing Elective
Surgical Procedures. The American Journal of Surgery, 1987; 153 : 341-346.
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Expanded Polytetrafluoroethylene
Prostheses as Secondary Blood Access
Sites for Hemodialysis: Pathological
Findings in 29 Excised Grafts
Sheny Canizales, MD; Jamal Charara, PhD; Francis Gill, BSc;
Robert Guidoin, PhD; Paul-Emile Roy, MD; Philippe Bonnaud, MD;
Gilles Laroche, MD, FRCSC; Michel Batt, MD; Paul Roy, MD;
Michel Marois, MD; Allan Downs, MD, FRCSC; Carlo Picetti, MD; Serge Contard, MD
The popularity of expanded polytetrafluoroethylene (PTFE) arteriovenous fistulas
for hemodialysis access is increasing. The low infection rate, low thrombogenicity
and low body reactivity make it an important blood access for patients on routine
hemodialysis.
The authors examined 29 PTFE graft fistulas surgically excised from patients on
hemodialysis for one or more of the following complications: infection 7, 2 with
associated hemorrhage; thrombosis 9; aneurysm 11, 3 with associated thrombosis;
stenosis 5, 3 with associated thrombosis; hemorrhage 4 and arterial steal 2. The
explanted prostheses were reinforced Gore-tex in 20, Gore-tex thin wall in 1, Impra
I in 4, Impra II in 3 and Vitagraft in 1.
It was also noted that the implants failed in the short term mainly because of
infection, in the medium term mainly because of thrombosis and stenosis, and in the
long term usually because of aneurysm.

La popularite du teflon microporeux (PTFE) comme derivation arterio-veineuse
pour l’hemodialyse est maintenant tres repandue. Sa resistance a l’infection, sa
faible thrombogenicite et l’absence d’antigenicite permettent de considerer ce
materiau comme une alternative de choix pour permettre Faeces iteratif au sang
chez les patients traites pour hemodialyse chronique.
Les auteurs ont obtenu 29 specimens en PTFE preleves lors de l’exerese
chirurgicale. L’ablation avait ete requise pour corriger les defaillances suivantes: 7
infections dont 2 avec hemorragie; 9 thromboses; 11 formations anevrysmales dont
3 avec thrombose; 5 stenoses dont 3 avec thrombose; 4 hemorragies et 2
hemo-detournements. Les protheses explantees sont: 20 reinforced Gore-tex, 1
Gore-tex thin wall, 4 Impra I, 3 Impra II et 1 Vitagraft.
Les interventions chirurgicales a court terme furent necessaires suite a l’apparition d’infections, a moyen terme suite aux stenoses et aux thromboses, et a long
terme principalement suite aux formations anevrysmales.

From the Biomaterials Unit, Hopital St-Frangois d ’Assise, and Department o f Surgery and
Department o f Pathology, Universite Laval, Quebec, PQ
Supported by grants from the Medical Research Council o f Canada and the Hopital St-Franfois
d ’Assise
Accepted for publication Dec. 20, 1988
Reprint requests to: Dr. Robert Guidoin, Biomateriaux F l-3 0 4 , H opital St-Franfois d ’Assise, 10,
de I ’Espinay, Quebec, PQ G IL 3L5

he increased longevity o f pa
tients with end-stage renal fail
ure through long-term hemodialysis
has resulted in a need for alterna
tive means o f circulatory access.
Repeated and routine access to the
circulation was initially permitted
by
the
external
arteriovenous
shunt1 and the radial-cephalic fistu
la,2 which is technically simple to
construct, is well accepted by most
patients and is associated with
minimal complications and the best
long-term patency o f all available
methods o f angioaccess.34 Howev
er, the increasing number o f pa
tients whose vessels are inadequate
following evolutive complications
has promoted a search for second
ary procedures.5 These have includ
ed saphenous vein autografts to the
arm, biological grafts such as the
bovine carotid artery heterograft
and the m odified human umbilical
cord vein gra ft, and synthetic grafts
such ?s D acron and expanded
PTFE.
The use o f saphenous vein has
not pnved as rewarding in these
circumstances as for peripheral vas
cular reconstruction.6 Also, it is
preferable t o preserve the vein in
case it is needed for peripheral
arterial s u rg e ry or aortocoronary
bypass g ra ftin g . The hom ologous
vein is m o r e appealing because it is

T
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highly resistant to infection and is
easy to puncture. The results, how
ever, are often erratic, harvesting
from a cadaver is very demanding
and quality control of stripped veins
is questionable.78
Although chemically processed
bovine heterografts have been used
successfully by some inves
tigators,9-11 their use has frequently
been associated with complications
such as thrombosis, aneurysms,
lipid uptake and infection.12-15
The umbilical vein has seen limit
ed use,1617 and sufficient data are
not available to draw conclusions.
Whereas experience with Dacron
graft for hemodialysis access has
been scanty,18 expanded PTFE has
been successfully employed as an
arteriovenous fistula. It appears to
be a more valuable alternative. Ad
vantages are that it is easy to use
and can occasionally survive local

ized infections.19-28 Blood access is
highly demanding since the grafts
are challenged by needle punctures
two to three times a week. It is,
therefore, not surprising that the
prosthetic material sometimes fails
and patients have to be reoperated
upon because of complications.
In this study we report our re
sults with 29 PTFE grafts, used for
vascular access, collected from 27
patients at reoperation.

Patients and Methods
The 29 arterial grafts were surgi
cally excised at seven different cen
tres in Canada (three), Italy (one)
and France (three) from 27 patients
(10 men and 17 women) whose
mean age at implantation was 46
years (range from 25 to 72 years).
The average duration of implanta

tion was 23.6 months (range from
0.4 to 75.8 months). The most
frequent complications requiring re
moval of the graft were aneurysmal
dilatation 11 (38%), thrombosis 9
(31%) and infection 7 (24%). Steno
sis 5 (17.2%), hemorrhage 4
(13.8%) and arterial steal 2 (6.9%)
were less frequent (Table I).
Of the 29 expanded PTFE prostheses, 20 were reinforced Gore-tex,
1 was Gore-tex thin wall, 4 were
Impra I, 3 Impra II and 1 a Vitagraft.
The morphologic and pathologic
characteristics and the structural
changes of the prostheses were in
vestigated according to the follow
ing protocol.29 After excision, ideal
ly, the grafts were opened longitu
dinally, carefully rinsed with hepari
nized saline, fixed in a buffered
solution of 1.5% glutaraldehyde and
shipped immediately to the Bi-

Table I. Clinical Data of Patients Who Had Polytetrafluoroethylene Prostheses
Case
no.

Sex

Age at
implantation,
yr

01
02*
03t
04
05
06
07
08
09
10
11f
12
13
14
15
16
17
18*
19
20
21

M
F
M
F
F
F
F
F
F
F
M
M
M
M
F
F
F
F
M
F
F

25
46
46
61
43
53
47
30
62
60
48
26
30
26
60
62
51
54
43
40
36

1983
1982
1980
1982
1984
1983
1980
1982
1978
1982
1977
1979
1979
1985

22
23
24
25
26
27
28
29

M
F
M
F
M
F
M
F

44
38
66
40
25
52
52
72

1985
1985
1987
1987
1982
1985
1986
1987

Year of
implantation Prosthesis
1977
1982
1981
1982

Gore-tex
Gore-tex
Impra I
Gore-tex
Gore-tex
Gore-tex
Gore-tex
Gore-tex
Gore-tex
Impra I
Impra I
Impra II
Impra II
Impra I
Impra II
Gore-tex
Gore-tex
Gore-tex
Gore-tex
Gore-tex
Gore-tex
thin wall
Gore-tex
Gore-tex
Gore-tex
Vitagraft
Gore-tex
Gore-tex
Gore-tex
Gore-tex

*, f = same patient.
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Location
Right thigh
Right forearm
Right arm
Left forearm
Right thigh
Left arm
Left forearm
Left arm
Left forearm
Right forearm
Left forearm
Left forearm
Forearm
Right forearm
Right arm
Right forearm
Left arm
Left arm
Left forearm
Left arm
Right arm
Left arm
Right arm
Right forearm
Right forearm
Left arm

Configuration

Duration ot
implantation,
mo

Complications

Loop
Loop
Straight
Straight
Straight

48.3
1.3
9.9
12.0
2.5
34.9
8.9
23.1
41.2
6.4
14.9
9.2
29.7
20.0
57.4
8.9
75.8
66.0
69.6
0.4

Infection
Aneurysm
Thrombosis
Thrombosis, false aneurysm
Stenosis, thrombosis
Infection
Thrombosis, aneurysm
Thrombosis
Stenosis
Stenosis
Hemorrhage, infection
Aneurysm
Hemorrhage
Aneurysm
Hemorrhage, infection
Aneurysm
Infection
Aneurysm
Thrombosis, aneurysm
Aneurysm
Thrombosis

Straight
Straight
Straight
Loop
Loop
Straight
Loop
Straight

2.9
7.0
2.0
0.5
59.4
25.1
17.9
3.4

Thrombosis
Infection
Arterial steal
Hemorrhage, infection, aneurysm
False aneurysm
Stenosis
Thrombosis, stenosis
Arterial steal

Loop
Straight
Straight
Loop
Straight
Straight
Loop
Straight
Straight
Straight
Loop
Loop
Straight
Straight

PTFE P R O S T t;sE S FOR HEMODIALYSIS

omaterials Laboratory at the Hopital St-Franqois d’Assise in Quebec
City. The prostheses were examined
macroscopically and photographed.
Representative areas of the internal
and external capsules were selected
for pathological investigation. Each
area was divided into two subspeci
mens. One was post-fixed in a Perfix solution, dehydrated with
ethanol and clarified with toluene
before embedding in paraffin. Sec
tions, 4 jxm thick, were stained in
the following order: Weigert’s, Mas
son’s trichrome, Brenn and Brown,
and Dhal stains for viewing by light
microscopy. The second part was
post-fixed in carboxyhydrazide and
osmium tetroxide for examination
by scanning electron microscopy.
Dehydration was obtained by im
mersing the specimens in a series of
solutions of ethanol of graded con
centration, culminating in absolute
ethanol. The specimens were dried
by the critical point method using
liquid carbon dioxide as the transfer
medium. Specimens were then goldpalladium coated and examined in a
JSM 35CF microscope (Jeol Inc.,

Peabody, Mass.) at 15 to 20 kV
accelerating voltage.
The tissues adhering to the re
maining parts of the prostheses
were removed by boiling in a 5%
sodium bicarbonate solution for 5
minutes; they were then cooled
slowly for 24 hours with magnetic
agitation. The prosthesis was then
immersed at least twice in a diluted
commercial bleach solution at room
temperature for 2 hours each time.
Again the specimens were examined
macroscopically and photographed.
Representative specimens from the
intact, the anastomotic and the
punctured regions were also pre
pared for scanning electron micros
copy to evaluate iatrogenic damage
to the graft.
The external capsules of the explanted prostheses were classified
as follows: 1 — no encapsulation, 2
— a thin fibrous coating, 3 — an
intermediate fibrous coating and 4
— a thick fibrous coating. The fatty
external deposits were graded from
1 to 4: 1 — no deposits, 2 — light
deposits, 3 — intermediate deposits
and 4 — abundant deposits.

FIG. 1. Evolutive complications of polytetrafluoroethylene (PTFE) fistulas after
different durations of implantation.

Resus
Mamcopic Observations
Th tim e of explantation for individus c a s e s is shown in Fig. 1. It
show t h a t thromboses and aneu-

FIG. 2. Aneurysmal dilatation of rein
forced Gore-tex graft implanted as
forearm loop for 75.8 months; external
view shows extreme dilatation result
ing from repeated puncturing in limit
ed areas.

FIG. 3. Thrombosed reinforced Goretex graft implanted as forearm loop
fistula for 8.9 months. Lack of external
encapsulation left repeated puncture
area clearly visible in absence of any
healing.
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rysmal formations (Fig. 2) may
occur at any time, but infections
and hemorrhages are observed
within the first 2 years of implanta
tion.
The main cause of aneurysmal
dilatation is repeated punctures of
the same area (Fig. 3). The needle
injures the prosthesis wall, severing
the graft fibres and weakening the
wall; this is followed by leakage of
blood and formation of the aneu
rysm. Therefore, only the develop
ment of fibrous tissue around and
inside the graft wall could maintain
its patency as an impervious blood
conduit (Fig. 4).
The degrees of encapsulation and
external fatty deposits in the cap
sule of the explanted grafts are
presented in Table II. These data
clearly demonstrate that both thick
ening of the capsule and progres
sive incorporation of fatty deposits
increased with the time of implanta
tion.
Histologic Findings

Histologic examination demon-

FIG. 4. Segments of reinforced Goretex graft implanted as straight fistula
in arm for 34.9 months. Graft was
excised because of aneurysmal forma
tion and occlusion due to excessive
banding to ensure hemostasis. Holes
in middle are result of repeated punc
tures in same area, as illustrated in
view of specimen after tissue diges
tion, indicating that integrity of graft
wall was only maintained by fibrous
tissue.
436

strated that 9 of the 29 prostheses
were dilated by dehiscence of the
synthetic structure. In addition,
areas of repeated puncture were
observed (Fig. 5). In some cases,
the luminal surface opposed to the
puncture holes was probably
scratched by the needle (Fig. 6).
When the needle goes deeply
through the graft, it may provoke
scratching and irregularities along
the opposite luminal surface. The
mechanical stability of the wall
graft did not seem to be altered
much by this procedure. The needle
punctures affected severely the
structure of the reinforced Gore-tex
graft, especially its outer wrap,
which was frequently detached.
Nevertheless, the healing process of
a puncture hole showed connective
tissue penetrating the hole and
seemed to be in continuity with the
partially vascularized fibrous con
nective tissues of the outer capsule
of the graft.
In the non-dilated prostheses, we
noted some parietal thrombosis and
in one of these cases the prosthesis
was severely infected. Moreover, se
verely infected areas were detected
in three non-thrombosed grafts.
Some grafts, however, were excised
because of infection without evi
dence of bacteremic colonization.
External encapsulation was ob
served in 15 cases but we could not
establish a clear relation between
the rate of collagen within this
external capsule and the patency
period (Fig. 7).
In three cases we noted the pres
ence of foreign-body reactions asso
ciated with the intense production

of collagen. It seems that this kind
of reaction could contribute to the
formation of the external capsule.
Bacteremic colonization was also
noted within the graft interstices.
Tissue proliferation into the graft
interstices was also observed. In
some cases this layer was detached
during the patent period of the
graft. However, in one case the
proliferation became thicker as it
reached the external capsule and
tended to behave like an atheroscle
rotic injury.
Finally, low amounts of choles
terol and lipid deposits were found
on the luminal surfaces of many
grafts (Fig. 8).

Discussion
Polytetrafluoroethylene is manu
factured in the form of powder
which is mixed with a lubricant to
produce a paste of extruded Teflon
and then shaped into a tube at
room temperature. Expanded PTFE
is processed by mechanical stretch
ing of the plain tube of extruded
Teflon, which results in an ultra
structure of solid PTFE nodes inter
connected by fine fibrils of PTFE. It
is further stabilized by sintering at
high temperature. Node size and
shape and fibril length can be con
trolled by changing the components
of the process. The speed at which
the expanded tube is cooled after
sintering controls its physical prop
erties.30
The technique of expanding
PTFE was ultimately refined and
applied to the development of many

Table II. D egrees o f E n c a p s u la tio n and F a tty D e p o s its V e rs u s P a te n cy P erio d
Encapsulation
degree
1
2
3
4
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-

N one
T h in
In te rm e d ia te
T h ic k

Fatty deposits
in the capsule
(range 1 - 4)

Duration of
im plantation, mo

1.5
1.9
1.9
3 .3

1.9
7 .8
2 6 .4
3 2 .9
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models of PTFE prostheses (Goretex, Impra, Vitagraft). However, the
strength testing of the earlier Goretex and Impra models revealed that
circumferential strength was inade
quate, leading to aneurysmal dila
tions. Gore-tex has had a thin film
consisting of expanding PTFE ap
plied to its outer surface, whereas
the Impra graft has had its radial
strength enhanced by an increase in
wall thickness.31 Although PTFE
has become the material of choice
for synthetic graft for dialysis ac
cess, with cumulative patency rates
exceeding those of most other

grafts,2132 this material is still not
perfect.
The most common problem in
our series was aneurysm formation,
caused by needle injury which
breaks down the wall of the pros
thesis. The resultant leakage of
blood forms a perigraft hematoma,
which becomes organized and leads
to the formation of an aneu
rysm.1433 Moreover, after a certain
period of time, and depending on
the size of the puncture hole and
the number of punctures in a given
area, the integrity and impervious
ness of the prosthetic material relies

only on fibrous tissue. The wall of
the resulting blood conduit is there
fore unable to withstand blood pres
sure and results in predictable aneu
rysmal formation. Nevertheless, this
is quite reasonable if one considers
that during a 6-year period at three
hemodialysis sessions a week with
two needle punctures each time, the
graft will be punctured over 1800
times. A better understanding of
the failure mechanism of this graft
under nosocomial fragmentation of
the wall by needle puncture is re
quired to extend the duration of
access.

FIG. 5. Scanning electron micrograph of reinforced Gore-tex
graft, after tissue digestion, implanted as forearm loop fistula
for 8.9 months, illustrates disruption of prosthetic wall
(original magnificat:on X 20).

FIG. 6. Scanning electron micrograph of Impra I graft, after
tissue digestion, implanted as forearm fistula for 41.2 months.
Needle points are evident (original magnification X 20).

FIG. 7. Optical micrograph of reinforced Gore-tex graft
implanted as forearm loop fistula for 8.9 months. External
capsule is as thick as graft wall. Intense collagen proliferation
is evident within this capsule (Weigert’s stain, original
magnification X 200).

FIG. 8. Scanning electron micrograph showing lipid uptake
on luminal surface of Vitagraft implanted as loop fistula for
0.5 months (original magnification X 1000).
CJS, VOL. 32, NO. 6, NOVEMBER 1989
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Needle puncture for hemodialysis
is very demanding for the vascular
access. The role of the nurses and
the patient in maintaining a patent
access is extremely important.1924
For example, the recommended
angle of insertion of 45° is impor
tant to minimize the risk of false
aneurysm or separation of the outer
layer.34 Separation may occur if the
angle of insertion is too acute. This
separation can sometimes be useful.
During the insertion of the needle
at an acute angle, it slides between
the prosthetic wall and the outer
layer. When the needle is removed,
the outer layer may act as a flap
covering the hole and provide faster
hemostasis. The procedure is clear
ly to be avoided as a general prac
tice because it impairs the mechani
cal integrity of the graft, but we
believe that this principle could be
applied in the design of a special
ized prosthesis for vascular access.
Moreover, rotation of the needle
after insertion is also recommended
to prevent scratching of the luminal
surface opposite the puncture site.34
Polytetrafluoroethylene is a difficult
material to puncture because of its
high resistance to penetration, and
this, combined with the free motion
after the tip of the needle has
penetrated the wall, makes scratch
ing hard to avoid. Even if this
scratching does not impair the me
chanical stability of the wall, it
increases the thrombogenicity of
the surface. However, the risk of
aneurysm formation can be reduced
by avoiding repeated punctures in
the same area.33
The evolutive complications of
the grafts are well distributed over
time. Thrombosis, however, may
occur at any time during the paten
cy period. It has been noted that
the primary cause of thrombosis is
mishandling of the fistula by dialy
sis personnel.35 Hemostatic banding
or unintentional obstruction of the
graft by the sleeping patient may
438

also cause thrombosis. A concerted
effort at communication between
physician and technician has dimin
ished preventable mishaps.24
Although PTFE grafts have
shown good resistance to infection
in experimental situations, they are
at risk from infection both by con
tamination during the initial opera
tion and by subsequent inoculation
of bacteria during the needle punc
ture for dialysis. Therefore, infec
tion could likely affect the graft at
any time during the implantation
period. However, in our report in
fection developed mainly in the first
year of dialysis treatment. The low
incidence of infection after 1 year is
explained by the fact that a wellincorporated graft is not as suscep
tible to bacteremic challenge as a
freshly-implanted one.36 Some bac
teria can form a biofilm, which can
adhere to smooth surfaces.37 This
phenomenon may explain why the
nonincorporated graft is more sus
ceptible to infection. We believe,
therefore, that the graft should be
allowed to mature for at least 15
days after insertion so that incorpo
ration can take place.
Stenosis is one of the common
causes of prosthetic failure, occur
ring primarily near the venous anas
tomosis. Possible mechanisms in
clude the development of venous
fibrous intimal hyperplasia of the
vein just proximal to the anastomo
sis, probably secondary to turbu
lence and high-flow localized in
growth from the anastomosis it
self.26 Diffuse areas of stenosis may
also develop within the graft, pre
sumably because organized laminal
clot accumulates at frequently used
puncture sites.38 However, this
complication seems to be independ
ent of the choice of material.39 It
has been noted in bovine grafts40
and it is found in PTFE grafts.32 We
found that stenosis can occur 1
year after the insertion, unlike
other reports33 in which stenosis
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seemed to occur at any time.
The low amount of lipid and
cholesterol is easily explained by
the fact that these patients do not
always suffer from advanced athero
sclerosis unlike patients who re
quire peripheral vascular surgery.

Conclusions
Our results suggest that the ex
panded PTFE prosthesis is the sub
stitute of choice among currently
available prostheses. Nevertheless,
PTFE is still not the ideal substi
tute. The complications leading to
failure of the vascular access site
are primarily aneurysm formation
and thrombosis. The most obvious
advantage of this expanded PTFE is
its ability to resist infection and to
withstand repeated needle puncture.
We are indebted to operating-room
technicians and hospital attendants
charged with the collection and the
expedition of the specimens. The tech
nical assistance of S. Bourassa, M.
Corriveau, R. Couture, K. Horth and N.
Massicotte was greatly appreciated. We
are indebted to Impra Inc., W.L. Gore
and Associates and Fournitures Hospitalieres for their collaboration. Meet
ings of the French and Quebec groups
were, in part, supported by the
Echanges France-Quebec.

References
1. Q uinton W, Dillard D, S cribner BH:

Cannulation of blood vessels for pro
longed hemodialysis. Trans Am Soc
Artif Intern Organs 1960; 6: 104-113
2. Brescia MJ, Cimino JE, Appel K, et al:
C hronic hem odialysis using venipunc
tu re and a surgically created arteriove
nous fistula. N Engl J Med 1966; 275:

1089-1092
3. P alder SB, Kirkman RL, W hittemore
AD, et al: Vascular access for hemodial
ysis. Patency rates and results of revi
sion. Ann Surg 1985; 202: 235-239
4. Kherlakian CM, Roedersheimer LR, Arbauch JJ, et al: Comparison of autoge
nous fistula versus expanded polytetra-

PTFE PROSTHESES FOR HEMODIALYSIS

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

fluoroethylene graft fistula for angioaccess in hemodialysis. Am J Surg 1986;
152: 238-243
L indenauer SM, W illiams R: Dacron
velour arteriovenous fistula for hemodi
alysis access. Ann Surg 1981; 193: 4348
Haimov M, B urrows L, S chanzer H, et
al: Experience with arterial substitutes
in the construction of vascular access
for hemodialysis. J Cardiovasc Surg (To
rino) 1980; 21: 149-154
Guidoin R, Roy PE, Bonnaud P, et al:
[Stripped veins for secondary vascular
access in hemodialysis. Pathologic study
of the grafts after surgical excision.] J
Mai Vase 1985; 10: 331-342
Bonnaud P: L’homogreffe saphene conservee en hemodialyse: dix annees d’experiences (a propos de 310 cas). In
Mery JP, Cay JL (eds): Les abords
vasculaires hemodialyses, Gambro
MGEN, Paris, 1982: 9-37
H aimov M, J acobson JH ii : Experience
with the modified bovine arterial hetero
graft in peripheral vascular reconstruc
tion and vascular access for hemodial
ysis. Ann Surg 1974; 180: 291-295
S terling WA, T aylor HL, D iethelm
AG: Vascular access for hemodialysis by
bovine graft arteriovenous fistulas. Surg
Gynecol Obstet 1975; 141: 69-72
H aimov M, B urrows L, Baez A, et al:
Alternatives for vascular access for he
modialysis: experience with autogenous
saphenous vein autografts and bovine
heterografts. Surgery 1974; 75: 447452
Coenen L, D ecreane P, J amar R, et al:
Bovine graft and polytetrafluorethylene
prosthesis as an access to circulation for
haemodialysis. Acta ChirBelg 1983: 83:
6-11
Doyle DL, F ry PD: Polytetrafluoroethylene and bovine grafts for vascular
access in patients on long-term hemodi
alysis. Can J Surg 1982; 25: 379-382
Merickel JH, A nderson RC, Knutson
R, et al: Bovine carotid artery shunts in
vascular access surgery. Complications
in the chronic hemodialysis patient.
Arch Surg 1974; 109: 245-250
Garvin PJ, Codd JE: Aggressive ap
proach to late thrombosis of bovine
heterografts. Ann Surg 1979; 190:

743-745
16. R ubio PA, F arrell EM: Human umbili
cal vein graft angio access in chronic
hemodialysis: a preliminary report. Dial
ysis Transplantation 1979; 8: 211-212
17. B aur CM, P orter JM, F letcher WS:
Human umbilical cord vein allograft
arteriovenous fistula for chemotherapy
access. Am J Surg 1979; 138: 238-240
18. Burdick JF, S cott W, Cosimi AB: Expe
rience with dacron graft arteriovenous
fistulas for dialysis access. Ann Surg
1978; 187: 262-266
19. Anderson CB, E theredce EE, S icard
GA: One hundred polytetrafluoroethylene vascular access grafts. Dialysis
Transplantation 1980; 9: 237-238
20. H umphries AL jr , N esbit RR jr , Caruana RJ, et al: Thirty-six recommendations
for vascular access operations: lessons
learned from our first thousand opera
tions. Am Surg 1981; 47: 145-151
21. S abanayacam P, S chwartz AB, S oricelli RR, et al: Experience with one hun
dred reinforced expanded PTFE grafts
for angioaccess in hemodialysis. Trans
Am Soc A rtif Intern Organs 1980; 26:
582-583
22. B aker LD jr , J ohnson JM, Goldfarb D:
Expanded polytetrafluoroethylene
(PTFE) subcutaneous arteriovenous
conduit: an improved vascular access for
chronic hemodialysis. Trans Am Soc
A rtif Intern Organs 1976; 22: 382-387
23. B hat DJ, T ellis VA, K ohlberg WI, et
al: Management of sepsis involving ex
panded polytetrafluoroethylene grafts
for hemodialysis access. Surgery 1980;
87: 445-450
24. Giacchino JL, Geis WP, B uckingham
JM, et al: Vascular access: long-term
results, new techniques. Arch Surg
1979; 114: 403-409
25. Gross GF, H ayes JF: PTFE g raft a rte

28. S eccia M, B uccianti P, Chiarugi M, et
al: The PTFE grafts as alternative blood
access in the surgical management of
long-term haemodialysis. Life Support
Syst 1984; 2: 63-69
29. F ormichi MJ, G uidoin RG, J ausseran
JM, et al: Expanded PTFE prostheses as

30.

31.

32.

33.

34.

35.

36.

37.

38.

riovenous fistulae for hem odialysis ac
cess. Am Surg 1979; 45: 748-749
26. J enkins AM, Buist TA, Glover SD:

Medium-term follow-up of forty autoge
nous vein and forty polytetrafluoroe
thylene (Gore-Tex) grafts for vascular
access. Surgery 1980; 88: 667-672
27. K ester RC: Reinforced expanded poly
tetrafluoroethylene (Gore-Tex) grafts for
haemodialysis. Biomater Med Devices
Artif Organs 1978; 6: 3 3 1 -3 4 0

39.

40.

arterial substitutes in humans: late
pathological findings in 73 excised
grafts. Ann Vase Surg 1988; 2: 1 4 -2 7
Cannon JA: The expanded reinforced
polytetrafluoroethylene prosthetic vas
cular graft. In W right CB (ed): Vascular
Grafting, Clinical Applications and Tech
niques, Wright-PSG. Boston, 1983: 3142
S elman SH, R hodes RS, A nderson JM,
et al: Atheromatous changes in expand
ed polytetrafluoroethylene grafts. Sur
gery 1980; 87: 630-637
T ellis VA, Kohlberg WI, B hat DJ, et
al: Expanded polytetrafluoroethylene
graft fistula for chronic hemodialysis.
Ann Surg 1979; 189: 101-105
Munda R, F irst MR, A lexander JW, et
al: Polytetrafluoroethylene graft survival
in hemodialysis. JAMA 1983; 249: 219—
222
W.L. Gore and Associates, Inc.: Techni
cal Considerations Concerning Punctur
ing in the Goretex Vascular Graft for
Hemodialysis, Elkton, Md, 1980
F ranklin C: Early clinical experience
with a new PTFE graft in the A-V fistula
position. Adv Ther 1984; 1: 110-114
W ilson SE, O wens ML (eds): Vascular
Access Surgery, Year Bk Med, Chicago,
1980: 185-203
Gault MH, C osterton JW, P aul MD, et
al: Staphylococcal epidermidis infection
of a hemodialysis button-graft complex
controlled by vancomycin for 11
months. Nephron 1987; 45: 126-128
T ilney NL, K irkman RL, W hittemore
AD, et al: Vascular access for dialysis
and cancer chemotherapy. Adv Surg
1986; 19: 221-270
Morgan AP, Dammin GJ, L azarus JM:
Failure modes in secondary vascular
access for hemodialysis. ASAIO J 1978;
1: 44-52
Mohaideen AH, Mendivil J, A vram MM,
et al: Arterio-venous access utilizing
modified bovine arterial grafts for hemo
dialysis. Ann Surg 1977; 186: 643-650

CJS, VOL. 32, NO. 6, N O VEM BER 1989

439

^PRIMAXIN®
(imipenem and cilastatin sodium
for injection)
Antibiotic

•
•
•
•
•
•

Morganella morganii
Neisseria
Proteus (indole positive and indole negative
strains)
Providencia
Pseudomonas aeruginosa
Serratia marcescens

Gram-positive Anaerobes

CNS adverse experiences such as myoclonic
activity, confusional states, or seizures have
been reported with PRIMAXIN® especially when
recommended dosages based on renal function
and body weight were exceeded. These expe
riences have occurred most commonly in patients
with CNS disorders (e.g., brain lesions or
history of seizures) and/or who have compro
mised renal function. However, there were rare
reports in which there was no recognized or
documented underlying CNS disorder. Close
adherence to recommended dosage schedules
is urged, especially in patients with known
factors that predispose to seizures.

•
•
•

Clostridium (excluding C. difficile)
Peptococcus
Peptostreptoccus

Gram-negative Anaerobes

•
•

Bacteroides fragilis
Bacteroides (non-fragilis)

CONTRAINDICATIONS
PRIMAXIN® (imipenem and cilastatin sodium for
injection) is contraindicated in patients who have
shown hypersensitivity to either component of this
product.

ACTION

WARNINGS

Imipenem exerts a bactericidal action by inhibiting
cell wall synthesis in aerobic and anaerobic gram
positive and gram-negative bacteria.

PRIMAXIN® (imipenem and cilastatin sodium for
in je c tio n ) SHOULD BE ADMINISTERED WITH
CAUTION TO ANY PATIENT WHO HAS DEMONS
TRATED SOME FORM OF ALLERGY, PARTICULARLY
TO STRUCTURALLY-RELATED DRUGS. IF AN
ALLERGIC REACTION TO PRIMAXIN® OCCURS,
DISCONTINUE THE DRUG. SERIOUS HYPER
S E N S IT IV IT Y R EACTIONS MAY REQUIRE
E PIN E P H R IN E AND OTHER EMERGENCY
MEASURES.

P R IM A X IN ® c o n s is ts o f tw o c o m p o n e n ts :
(1) im ipenem , a derivative of thienam ycin, a
carbapenem antibiotic; and (2) cilastatin sodium, a
specific inhibitor of dehydropeptidase-l a renal
enzym e w h ic h m etabolizes and in a c tiv a te s
imipenem. Cilastatin blocks the metabolism of
imipenem in the kidney, so that concom itant
administration of imipenem and cilastatin allows
antibacterial levels of imipenem to be attained in the
urine.
Inhibition of cell-wall synthesis is achieved in gram
negative bacteria by the binding of imipenem to
penicillin binding proteins (PBPs). In the case of
E s c h e r ic h ia c o li and s e le c te d s tra in s o f
Pseudomonas aeruginosa, imipenem has been
shown to have highest affinity for PBP-2, PBP-1a
and PBP-1 b, with lower activity against PBP-3. The
preferential binding of imipenem on PBP-2 and
PBP-1 b leads to direct conversion of the individual
cell to a spheroplast resulting in rapid lysis and cell
death without filament formation. When imipenem
is removed prio r to complete killing of gram
negative species, the remaining viable cells show a
measurable lag, termed a "post-antibiotic effect”
(PAE), prior to resumption of new growth.

INDICATIONS AND CLINICAL USE
PRIMAXIN® (imipenem and cilastatin sodium for
injection) may be indicated in the treatment of
serious infections when caused by sensitive strains
of bacteria. Where considered necessary, therapy
may be initiated on the basis of clinical judgment
before results of sensitivity testings are available.
Continuation of therapy should be reevaluated on
the basis of bacteriological findings and of the
patient's clinical condition.
Imipenem is active in vitro against a wide range of
gram -positive and gram-negative aerobic and
anaerobic bacteria, including most strains which
are beta-lactam ase producing. Patients have
responded while under treatment with PRIMAXIN®
for single or mixed infections of the following body
systems, when they were associated with a number
of pathogenic species and strains of the genera
listed:
1.
2.
3.
4.
5.
6.

Lower Respiratory Tract Infections
Urinary Tract Infections
Intra-Abdominal Infections
Gynecological Infections
Septicemia
E n d o ca rd itis caused by S taphylococcus
aureus
7. Bone and Joint Infections
8. Skin Structure Infections

Gram-positive Aerobes

•
•
•
•

Listeria monocytogenes
Nocardia asteroides
S taphylococcus (excluding many strains
which are methicillin resistant)
Streptococcus (excluding S. taecium)

Gram-negative Aerobes

•
•
•
•
•
•
•

Acinetobacter
Citrobacter
Enterobacter
Escherichia coli
Haemophilus influenzae
Haemophilus parainlluenzae
Klebsiella

emesis, inappetence, body weight loss, diarrhea
and death) at doses equivalent to the average
human dose in pregnant rabbits and cynomolgus
monkeys that is not seen in non-pregnant animals in
these or other species. Inother studies, PRIMAXIN®
was well tolerated in equivalent or higher doses (up
to 11 times the average human dose) in pregnant
rats and mice (see REPRODUCTION STUDIES
under TOXICOLOGY in the complete monograph).
Nursing Mothers

It is not known whether PRIMAXIN® is excreted in
milk. If the use of PRIMAXIN® is deemed essential,
the patient should stop nursing.
Pediatric Use

Efficacy and tolerability in infants under the age of
3 months have not yet been established; therefore,
PRIMAXIN® is not recommended in the pediatric
age group below the age of 3 months.
Drug Interactions

Concomitant administration of PRIMAXIN® and
probenecid results in only minimal increases in
plasma levels of imipenem and plasma half-life. It is
not recommended that probenecid be given with
PRIMAXIN®.
PRIMAXIN® should not be mixed with or physically
added to other antibiotics. PRIMAXIN® has been
administered concomitantly with some antibiotics,
such as aminoglycosides.
There is no evidence to suggest that association of
PRIMAXIN® with any other beta-lactam antibiotics
has any therapeutic advantage.

Pseudomembranous colitis

ADVERSE REACTIONS

Pseudomembranous colitis has been reported with
the use of PRIMAXIN®. Therefore it is important to
consider this diagnosis in patients who develop
diarrhea during or after therapy. This colitis may
range from mild to life threatening in severity.

PRIMAXIN® (imipenem and cilastatin sodium for
injection) is generally well tolerated. The following
adverse reactions were reported on 1,723 patients
treated in clinical trials Many of these patients were
severely ill and had multiple background diseases
and physiological impairments, making it difficult to
determ ine causal relationship of adverse ex
periences to therapy with PRIMAXIN®.

M ild cases of pseudomembranous co litis may
respond to drug discontinuance alone. In more
s e v e re cases, m a n a g e m e n t m ay in c lu d e
sig m o id o s c o p y , a p p ro p ria te b a c te rio lo g ic a l
studies, fluid, electrolyte and protein supple
mentation, and the use of a drug such as oral
vancomycin, as indicated. Other causes of colitis
should also be considered.

Local Adverse Reactions

Adverse local clinical reactions that were reported
as possibly, probably or definitely related to therapy
with PRIMAXIN® were:

PRECAUTIONS
General

Prolonged use o f PRIMAXIN® (imipenem and
cilastatin sodium fo r injection) may result in
overgrow th of resistant organism s. Repeated
evaluation of the patient's condition is essential. If
superinfection occurs during therapy, appropriate
measures should be taken.
CNS adverse experiences such as m yoclonic
activity, confusional states, or seizures have been
reported with PRIMAXIN® especially when recom
mended dosages based on renal function and body
weight were exceeded. These experiences have
occurred most commonly in patients with CNS
disorders (e.g., brain lesions or history of seizures)
and/or who have compromised renal function.
However, there were rare reports in which there was
no recognized or documented underlying CNS
disorder. Close adherence to recommended dosage
schedules is urged especially in patients with
known factors that predispose to seizures (see
D O S AG E AND A D M IN IS T R A T IO N ). A n ti
convulsant therapy should be continued in patients
with a known seizure disorder. If focal tremors,
myoclonus, or seizures occur, patients should be
evaluated neurologically and placed on an ti
convulsant therapy if not already instituted. If CNS
symptoms continue, the dosage of PRIMAXIN®
should be decreased or discontinued.
Use in Patients with Impaired Renal Function

Dosage in patients with impaired renal function is
based on the severity of infection but the maximum
daily dose varies with the degree of renal functional
im p a irm e n t (see DOSAGE AND A D M IN IS 
TR A TIO N - Dosage in P atients w ith Renal
Insufficiency).
Use in Pregnancy

The use of PRIMAXIN® in pregnant women has not
been studied, therefore, PRIMAXIN® should be
used during pregnancy only if clearly needed. Use
of this drug in women of childbearing potential
requires that the anticipated benefits be weighed
against possible hazards.
Reproduction studies with bolus I.V. doses suggest
an apparent intolerance to PRIMAXIN® (including

Incidence (%)

Phlebitis/thrombophlebitis
Infused vein pain
Vein induration
Infused vein infection

1.7
0.6
0.2
0.1

Systemic Adverse Reactions

Adverse clinical reactions that were reported as
po ssib ly, probab ly, or d e fin ite ly related to
PRIMAXIN® were:
Incidence (%)
Gastrointestinal

nausea
diarrhea
vomiting
tongue papillar hypertrophy
pseudomembranous colitis
(see WARNINGS)
hemorrhagic colitis
gastroenteritis
abdominal pain
glossitis
heartburn
pharyngeal pain
increased salivation

2.0
1.7
1.6
0.2
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

CNS

fever
dizziness
seizures
(see PRECAUTIONS)
somnolence
confusion
myoclonus
vertigo
headache
encephalopathy
paresthesia

0.4
0.3
0.2
0.2
0.2
0.1
0.1
0.1
<0.1
<0.1

Special Senses

transient hearing loss in
patients with impaired hearing
tinnitus

<0.1
<0.1

Respiratory

dyspnea
hyperventilation
thoracic spine pain

0.1
<0.1
<0.1

The maximum daily dose should not exceed 4 g or
50 mg/kg, which ever is less.

Cardiovascular
hypotension
palpitations
tachycardia

0.4
0.1
<0.1

Dosage in Elderly Patients

<0.1
<0.1

The recommended dosage of PRIMAXIN® in elderly
patients with normal renal function is the same as
given for adults above. Renal status of elderly
patients may not be accurately portrayed by
measurement of BUN or creatinine alone. Deter
mination of creatinine clearance is suggested to
provide guidance for dosing in such patients.

Renal
oliguria/anuria
polyuria
Skin
rash
pruritus
urticaria
skin texture changes
candidiasis
erythema multiforme
facial edema
flushing
cyanosis
hyperhidrosis
pruritus vulvae

0.9
0.3
0.2
0.1
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Body as a whole
polyarthralgia
asthenia/weakness

<0.1
<0.1

Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug
relationship, that were reported during clinical trials
were:
Hepatic: Increased SGPT, SGOT, alkaline phospha
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs
test, decreased WBC and neutrophils, increased
WBC, increased platelets, decreased platelets,
decreased hemoglobin and hematocrit, increased
monocytes, abnormal prothrombin time, increased
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, increased
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red
blood cells, urine white blood cells, urine casts,
urine bilirubin, and urine urobilinogen.

TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN® (imipenem and cilastatin sodium for
injection) is cleared by hemodialysis.

DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN®
(imipenem and cilastatin sodium fo r injection)
represent the quantity of imipenem to be ad
ministered by I.V. infusion only. An equivalent
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN® should be determined
by the severity of the infection, renal function, body
weight, the antibiotic susceptibility of the causative
organism(s) and the condition of the patient. Doses
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN®
in clinical trials for infections of the various body
systems ranged from 6 to 10 days except for
endocarditis and bone and joint infections for which
the median duration of treatment was 4 weeks.
Dosage in Adults

Dosage in Patients with Renal Insufficiency
P a tie n ts w ith c r e a tin in e c le a r a n c e s o f
< 5 m L/m in/1.73 m2 « 0 .0 8 mL/s/1.73 m ') should
not receive PRIMAXIN® unless hemodialysis is
instituted w ithin 48 hours. Both imipenem and
cilastatin are cleared from the circulation during
h e m o d ia ly s is . The p a tie n t sh o u ld re c e iv e
PRIMAXIN® after hemodialysis and at 12 hour
intervals timed from the end of that hemodialysis
session. Dialysis patients, especially those with
background CNS disease, should be carefully
m o n ito re d ; fo r p a tie n ts on h e m o d ia ly s is ,
PRIMAXIN® is recommended only when the benefit
outw eighs the potential risk of seizures (see
PRECAUTIONS). Currently, there are inadequate
data to recommend the use of PRIMAXIN® in
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN®
IN RELATION TO RENAL FUNCTION

RENAL
FUNCTION
Mild
impairment

Moderate
impairment

CREATININE
CLEARANCE
mL/mln/1.73 m*
(mL/s/1.73 m2)

MAXIMUM
TOTAL
DAILY
DOSAGE

(g)

DOSAGE
INTERVAL
(h)

31-70
(0.52-1.17)

0.5

6 -8

1.5-2

21-30
(0.35 - 0.50)

0.5

8-12

1-1.5

0.25 - 0.5

12

0.5-1.0**

DOSE

(g)

RECONSTITUTION
Contents of the vials must be suspended and
transferred to 100 mL of an appropriate infusion
solution.
A suggested procedure is to transfer approximately
10 mL from the 100 mL of the appropriate infusion
solution to the vial (see list of diluents under
COMPATIBILITY AND STABILITY). Shake well.
Return the resulting 10 mL of suspension to the
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to
ensure complete transfer of the contents of the vial
to the infusion solution.
CAUTION: CONTENTS OF VIA LS NOT FOR
DIRECT INFUSION.

COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection
5% or 10% Dextrose Injection
5% Dextrose Inje ction w ith 0.02% sodium
bicarbonate solution
5% Dextrose and 0.9% S odium C h lo rid e
Injection
5% Dextrose Injection with 0.225% or 0.45%
saline solution
NORMOSOL-M in D5-W
5% Dextrose Injection with 0.15% potassium
chloride solution
Mannitol 2.5%, 5% and 10%
Reconstituted solutions

Severe*
impairment

0-20
(0-0.33)

P atients w ith c re a tin in e clea ra n ce o f 6 to
20 mL/min/1.73 m2 (0.1 - 0.3 mL/s/1.73 m2) should
be treated with 250 mg (or 3.5 mg/kg whichever is
lower) every 12 hours for most pathogens. When
the 500 mg dose is used in these patients, there may
be an increased risk of seizures.
*x The highest dose is only recom m ended fo r
infections due to less susceptible organism s
primarily some strains of Ps. aeruginosa.

When only the serum creatinine level is available,
the following formula (based on sex, weight, and
age of the patient) may be used to convert this value
into creatinine clearance (mL/min). The serum
creatinine should represent a steady state of renal
function.
Males:

Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)

Females:

0.85 x above value.

When using the International System of units (SI),
the estimated creatinine clearance (mL/s) in males
can be calculated as follows:
(lean body weight, kg) x (140 - age, years) x 1.4736
(72) x (serum creatinine concentration, /rm ol/L)

The recommended daily dose is 1 to 2 g adminis
tered in equally divided doses every 6 to 8 hours
(see Table 1).

Each reconstituted 250 mg or 500 mg dose should
be given by intravenous infusion over twenty to
th irty minutes. Each 1000 mg dose should be
infused over 40 to 60 minutes. In patients who
develop nausea during the infusion, the rate of
infusion may be slowed.

and in females the estimated creatinine clearance
(mL/s) is:

Solutions of PRIMAXIN® range from colourless to
yellow. Variations of colour within this range do not
affect the potency of the product.
PRIMAXIN®, as supplied in vials and reconstituted
as above maintains satisfactory potency for four
hours at room temperature and for 24 hours under
refrigeration (4°C). PRIMAXIN® has been found to
be stable in 0.9% Sodium Chloride Injection for
10 hours at room temperature and 48 hours under
refrigeration.

DOSAGE FORMS
AVAILABILITY
PRIMAXIN® is supplied as a sterile powder mixture
in vials containing im ipenem anhydro us and
cilastatin sodium as follows:
3514 Ca - 250 mg imipenem equivalent and 250 mg
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature
below 30° C.

FULL PRODUCT MONOGRAPH
AVAILABLE ON REQUEST
(318-b,1,89)
®Trademark Merck & Co., Inc./
Merck Frosst Canada Inc., R.U.

MSP

2164

MERCK
C A N AD A

(lean body weight, kg) x (140 - age, years) x 1.2526
TABLE 1

(72) x (serum creatinine concentration, /tm ol/L)

ADULT DOSAGE OF PRIMAXIN®
I.V. Administration
Severity
of infection

Dose
(mg of imipenem)

Dosage
Interval

Daily
Dose

250 mg

6h

1.0 g

PRIMAXIN® is cleared by hemodialysis. After each
dialysis session the dosage schedule should be
restarted.
Dosage in Infants and Children

Mild
Moderate

500 mg

8h

1.5 g

Severe (fully
susceptible)

500 mg

6h

2.0 g

1000 mg
1000 mg

8h
6h

3.0 g
4.0 g

Severe* infections
due to less
susceptible
organisms
or life threatening
conditions

x Primarily some strains of Ps. aeruginosa.

The recom m ended to ta l d a ily d o sa g e o f
PRIMAXIN® in children and infants 3 months of age
and older is 60 to 100 mg/kg of body weight divided
into 4 equal doses given at six hour intervals. The
higher dosages should be used fo r infants and
young children. The total daily dosage should not
exceed 2 grams. Clinical data are insufficient to
recommend an optimum dose for infants and
children with impaired renal function.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.
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P.O. BOX 1005, POINTE-CLAIRE
DORVAL, QUEBEC H9R 4P8
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Concomitant Vascular Procedures in
Conjunction With Myocardial
Revascularization: All or None? A Report
of a Case
Fredrick B.Y. Hoy, MD; Anthony Brody, MD; Robert C. Gomez, MD
Patients with coronary artery atherosclerosis usually have concomitant peripheral
vascular lesions. The authors describe the case of a 65-year-old woman who had
multiple symptomatic lesions: severe stenosis of the left main coronary artery and
the carotid arteries, a large abdominal aortic aneurysm and bilateral renal artery
occlusion. To manage these and to avoid myocardial infarction and cerebrovascular
accident at operation, concomitant procedures were performed as follows: coronary
artery bypass grafting, aneurysm resection, carotid endarterectomy and
revascularization of the larger kidney. Although the patient’s hospital stay was
prolonged, there was no major morbidity and her recovery was good. She returned
to a normal life-style, requiring only hemodialysis on an outpatient basis.
Les patients souffrant d'atherosderose coronaire ont habituellement des lesions
vasculaires peripheriques concomitantes. Les auteurs decrivent le cas d’une femme
de 65 ans qui presentait de multiples lesions symptomatiques: une importante
stenose du tronc coronarien gauche et des carotides, un gros anevrisme de l’aorte
abdominale et une occlusion bilaterale des arteres renales. Afin de traiter ces lesions
tout en evitant l'infarctus du myocarde ou un accident cerebrovasculaire durant
l’operation, les interventions concomitantes suivantes ont ete pratiquees: pontage
aortocoronarien, resection d’anevrisme, endarterectomie carotidienne et revasculari
zation du rein le plus gros. Bien que la patiente ait eu une hospitalisation
prolongee, il n ’y eut pas de morbidite importante et son retablissement fut
satisfaisant. Elle put retourner a une vie normale, n’ayant besoin que d’une
hemodialyse en externe.

um erous reports have outlined
the management of patients
who have coronary artery disease
and significant peripheral vascular
lesions, including extracranial ca
rotid stenoses, abdominal aortic an

N

eurysms, aortoiliac occlusive dis
ease and renal artery stenoses. We
describe a case in which the patient
had multiple, serious, symptomatic
lesions requiring concomitant re
pair.
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Case Report
A 65-year-old woman was admit
ted for management of refractory
hypertension, increasing renal in
sufficiency and congestive heart
failure. She had been hypertensive
for 30 years and was unresponsive
to oral antihypertensive agents. She
had also been complaining of short
ness of breath on exertion for 5
years. She had a history of angina
pectoris, paroxysmal nocturnal dys
pnea, orthopnea, swelling of her
ankles, and had had previous ad
missions for congestive heart fail
ure. She also had experienced four
episodes of right amaurosis fugax.
She weighed 104.5 kg and had a
blood pressure of 200/130 mm Hg.
Many drugs, including Zaroxolyn,
Catapres, Lasix, Procardia, Capot
en, Nipride, Aldactone and Labetalol had been used alone or in combi
nation without effectively control
ling her blood pressure. Her serum
creatinine level was 389 /umol/L
and blood urea nitrogen was 22.8
m m ol/L urea.
Aortography demonstrated a
9-cm, fusiform, infrarenal, abdomi
nal aortic aneurysm and occluded
renal arteries, which demonstrated
distal reconstitution (Fig. 1). Both
kidneys were small. Renal scanning
confirmed the small size of the
kidneys, especially the left. There

CONCOMITANT REVASCULARIZATION: ALL OR NONE?

was decreased function bilaterally.
Renal vein renin levels were
markedly elevated in both renal
veins.
Because of her history of angina,
coronary angiography was also per
formed. This revealed 80% stenosis
of the left main coronary artery.
The right coronary artery had no
marked stenosis. 2D echocardiogra
phy revealed left ventricular hyper
trophy with good contractility.
Noninvasive carotid studies per
formed because of her symptoms of
amaurosis fugax, suggested an oc
clusion of the left common carotid
artery and a hemodynamically sig
nificant right carotid lesion. Carotid
angiography confirmed the occlu
sion of the left common carotid
artery. In addition, there was a 75%
ulcerated stenosis at the origin of
the right internal carotid artery and
an occluded right external carotid
artery.
Following these investigations,
her serum creatinine level rose fur
ther to 645 ^trnol/L and her blood
urea nitrogen to 30.7 mmol/L
urea. Hemodialysis was started. In
view of her refractory hypertension,

FIG. 1. Abdominal aortogram shows
large aortic aneurysm and occluded
renal arteries with distal reconstitu
tion.

we believed that the major threat to
this woman’s life was her large
abdominal aortic aneurysm. Howev
er, because of the severe stenosis of
her left main coronary artery and
angina, she was considered to be at
high risk for a myocardial infarction
during cross-clamping of the aorta.
Furthermore, because of her history
of amaurosis fugax, she would be at
serious risk for a cerebrovascular
accident at the time of cardiopulmo
nary bypass. After a nephrology
consultation, it was decided that if
the patient remained stable during
surgery, an attempt should be made
to revascularize the larger right
kidney in the hope of preserving
renal function and allowing easier
control of blood pressure.
The laparotomy was made in the
midline from the sternal notch to
the pubis. The patient was found to
have a large thin-walled abdominal
aortic aneurysm arising below the
left renal vein. The larger right
kidney measured 6 cm in greatest
length.
The right carotid artery was ex
posed and when the patient was
heparinized it was opened. A heavi
ly calcified, stenotic, ulcerated
plaque was endarterectomized from
the right common and internal ca
rotid arteries. The right common
carotid artery was closed, but the
neck incision was left open and
cardiopulmonary bypass instituted.
Saphenous vein grafts were then
placed to the left anterior descend
ing and circumflex coronary arter
ies. The patient was weaned from
cardiopulmonary bypass, but the
cannulas were left in place.
The abdominal aortic aneurysm
was then resected. It was 10 cm in
diameter, thin-walled and had no
intraluminal clot. A preclotted knit
ted Dacron tube was used to replace
the abdominal aorta. Blood in the
pericardial and peritoneal cavities
was returned to the heart-lung ma
chine and retransfused. A saphe

nous vein graft was then placed
from the aortic graft to the right
renal artery. The cannulas were
then removed from the heart. The
heparin effect was reversed with
intravenously administered prot
amine sulfate. Hemostasis was se
cured and all incisions were closed.
Postoperatively, the patient re
mained stable with respect to her
cardiac, respiratory and central ner
vous systems. She continued to
require hemodialysis and her post
operative stay was prolonged by her
reluctance to ambulate and her in
ability to sustain adequate enteral
nutrition. Permanent vascular ac
cess for dialysis was established 29
days postoperatively. At the time of
discharge, 55 days after the opera
tion, she was fully ambulatory. Her
blood pressure was 120/70 mm Hg
on Vasotec (Frosst, Dorval, PQ)
only. She weighed approximately
91 kg.
At her 6-month follow-up, she
was fully active. She required out
patient hemodialysis three times
weekly. Her blood pressure was well
controlled on one oral antihyperten
sive agent.

Comment
Because atherosclerosis is a gen
eralized disease process, patients
with coronary artery disease would
be expected to have significant con
comitant peripheral vascular le
sions.12 In addition, myocardial in
farction is the leading cause of early
and late death after carotid endar
terectomy23 or abdominal aortic an
eurysm repair.45
Our patient had multiple prob
lems: (a) angina upon minimal exer
tion due to severe left main coro
nary artery stenosis, (b) transient
ischemic attacks due to severe ca
rotid lesions, (c) a large blood-filled
abdominal aortic aneurysm and (d)
uncontrolled hypertension and renal
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failure resulting from bilateral renal
artery occlusions.
Reis and Hannah6 and others57-9
have advocated combined coronary
artery bypass and abdominal aneu
rysm resection in patients with
symptomatic coronary artery dis
ease and large or tender aneurysms.
The incidence of cerebrovascular
accident in those who have symp
tomatic extracranial carotid lesions
and undergo coronary artery by
pass has been reported in the range
of 10%.10 Accordingly, in this group
of patients, combined coronary by
pass and carotid endarterectomy
has been recommended.10-12
It was our opinion that the most
immediate threat to our patient was
her large abdominal aneurysm, but
in view of her symptomatic severe
coronary artery disease she was also

at high risk of myocardial infarction
and thus would require concomitant
coronary artery bypass and aneu
rysm resection. Having made that
decision, we further believed that a
cerebrovascular accident was highly
likely at the time of cardiopulmo
nary bypass because of her carotid
artery anatomy and symptoms. Ac
cordingly, concomitant coronary ar
tery bypass, carotid endarterectomy
and abdominal aneurysmectomy
were planned. In addition, if the
procedure was progressing well, an
attempt would be made to revas
cularize the larger kidney to pre
serve remaining renal function and
make refractory hypertension more
amenable to medical therapy. De
spite a prolonged postoperative hos
pital stay, there was no major mor
bidity from the combined proce

Item 222
Most patients with a superficial femoral artery occlusion have limited
disease; reconstitution of the popliteal artery above or below the knee
joint is demonstrated on arteriography. These patients usually complain
of intermittent claudication without rest pain or tissue loss (ulcer or
gangrene). Operation for claudication is usually reserved for patients
whose symptoms are disabling and who have participated in exercise
conditioning and stopped smoking.
When the occlusive disease extends below the popliteal artery, the
patency rate after bypass is lower. When infrapopliteal bypass is
required, the primary indication for operation should be threatened limb
loss. Clinical criteria of threatened limb loss include gangrene, an
ischemic ulcer, cyanotic toes, and ischemic rest pain. Disabling intermit
tent claudication is not limb threatening and should be managed by
infrapopliteal bypass only in selected patients, after nonoperative
therapy has failed.

0
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Giant Fibroepithelial Polyps of the
Female Urethra: Two Case Reports and
Review of the Literature
Susan Dian Goldberg, MD, FRCSC;* Linda Sugar, MD, FRCPCt
Fibroepithelial polyps are one of the less common obstructive lesions of the female
urethra. The authors describe two cases of giant fibroepithelial polyps in paraplegic
women. Both patients had a history of long-term indwelling catheterization to
manage neurogenic bladder. The chronic irritation caused by the catheters was
thought to be responsible for the development of the polyps. Resection is required
in these cases to relieve the urethral obstruction and eliminate the possibility of
malignant disease.

Les polypes fibro-epitheliaux represented l’une des causes les moins frequentes
d’obstruction de l’uretre chez la femme. Les auteurs decrivent deux cas de polypes
fibro-epitheliaux geants chez des femmes paraplegiques. Les deux patientes
presentaient une longue histoire de catheterisme a demeure pour cause de vessie
neurogene. On croit que l’irritation chronique causee par le catheter est a l’origine
du developpement des polypes. Dans ces cas, la resection est necessaire pour
soulager l’obstruction et eliminer la possibility d’une maladie maligne.

we describe two
I ncasesthisof paper
giant fibroepithelial pol

Case Reports

yps, seen in two paraplegic women
as obstructive mass lesions. In both
instances, the patient’s neurogenic
bladder was managed by placement
of an indwelling urethral catheter.
Chronic irritation secondary to the
indwelling catheter was thought to
be the main cause of the lesions in
both cases.

Case 1

The large polypoid lesions made
repeated catheter changes increas
ingly difficult. Cystoscopy was per
formed to elucidate the nature of
the lesions. It revealed minimally
inflamed bladder mucosa, a normal
bladder neck, and two, white,
fleshy, polypoid lesions, 0.7 and
0.75 mm in diameter, distal to the
urinary sphincter (Fig. 1). Excisional biopsy of the lesions demonstrat
ed that they were composed of
nonkeratinizing squamous epitheli
um overlying an inflamed fibrovascular stroma (Fig. 2).

A 65-year-old woman had two
large white polypoid lesions pro
truding from the urethral meatus.
Paraplegic as a result of a motor
vehicle accident, she had had an
indwelling catheter to manage her
neurogenic bladder for 10 years.

From the *Department o f Surgery and f Department o f Pathology, University o f Toronto,
Toronto, Ont.
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FIG. 1. Case 1. Close-up of urethral
meatus demonstrating polyp.
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FIG. 2. Case 1. Histologic detail of polyp. Nonkeratinizing squamous epithelium
overlies mildly inflamed stroma (hematoxylin and eosin, original magnification X
100 ) .

Case 2
On routine physical examination,
a 36-year-old paraplegic woman was
noted to have a large white polyp
oid urethral lesion. Her neurogenic
bladder had been treated with an
indwelling catheter 7 years after
injury in a motor vehicle accident.
Cystoscopy, performed to define the
nature of the lesion, revealed a
minimally inflamed, heavily trabeculated bladder with a single, large,
white, polypoid lesion distal to the
bladder neck, obstructing the uri
nary outlet (Fig. 3). Excisional biop
sy revealed a polyp, 8 mm in diame
ter, consisting of nonkeratinizing
squamous epithelium overlying a
mildly inflamed fibrovascular core.

Discussion
The female urethra is a fibromuscular tube 3 to 5 cm in length and
lined by stratified transitional epi
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thelium, originating from the uri
nary bladder proximally and squa
mous epithelium of vulvar origin
distally.1 Although urethral carun
cles are the most common protuber
ant lesion of the female urethra,
less common lesions presenting as
urethral masses include hemangi
omas, varices, mucosal prolapse,
meatal tags, condylomas, papillo
mas, periurethral cysts, adenomas,
carcinomas and fibroepithelial pol
yps.1
Presenting signs and symptoms
include pain, dysuria, hematuria,
bloody discharge, itching and inter
mittent urinary obstruction.
In a review1 of 394 cases of
urethral tumours, clinically inter
preted as caruncles, 376 lesions
were classified as urethral carun
cles. Seven lesions were categorized
as benign urethral papillomas asso
ciated with chronic inflammatory
changes, and nine lesions were
found on pathological evaluation to
be malignant. Six of the malignant
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FIG. 3. Case 2. Urethral meatus with
view of fibroepithelial polyp.

lesions were categorized as squa
mous cell carcinomas, the remain
ing three cases represented Bowen’s
disease. The average age at presen
tation in those who had a malignant
lesion was 55 years.1
Both our patients had a history
of long-term indwelling catheteriza
tion to manage neurogenic bladder.
The associated chronic irritation
was thought to be responsible for
the development of inflammatory
polyps at the urethral meatus. Re
sultant overgrowth of squamous
epithelium led to the development
of the large white fleshy lesions
seen protruding from the urethral
opening. Resection of the lesions
is advised to rule out malignant
disease and to relieve the obstruc
tion caused by the lesions.
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Surgical Wound Infections: a 63 -Month
Survey in a Developmental Institution
R. Lampard, MD, MSc, MBA
Michener Centre, a developmental institution of 1200 residents, instituted a
nosocomial infection control program in October 1983, which included surgical
wound monitoring.
Of the 336 clean and clean-contaminated operations performed in the next 63
months, there were 15 wound infections attributable to the surgeon; another 7
occurred which were directly attributable to the patient’s postoperative behaviour.
Six of the seven occurred in severely retarded patients. The wound infection rate
dropped during the surveillance period from 23% to 4.1% or less.
Careful preselection of patients for elective surgery and studious attention to
postoperative nursing care are necessary to achieve these rates or to reduce them
further, particularly amongst severely retarded patients.

Le Centre Michener, un etablissement voue au developpement de 1200 beneficiaires,
a mis sur pied, en octobre 1983, un programme de controle des infections
nosocomiales qui comprenait la surveillance des infections de plaies.
Sur 336 operations “propres” ou “propres avec contamination” effectuees au
cours des 63 mois qui ont suivi, on a denombre 15 infections de plaies attribuables
au chirurgien; 7 autres etaient directement attribuables au comportement postoperatoire du patient. Six de ces sept sont survenues chez des patients profondement
retardes. Au cours de la periode de surveillance, le taux d’infection de plaie a chute
de 23% a 4.1% ou moins.
Une preselection soigneuse des patients pour la chirurgie non urgente et une
attention serieuse portee aux soins infirmiers postoperatoires sont necessaires si
Ton veut atteindre de tels taux ou les reduire davantage, surtout lorsqu’il s’agit de
patients souffrant d’arrieration mentale profonde.

he study of wound infection
dates back to the mid-1800s
when the basic principles of body
resistance, routes of transmission
and antisepsis were postulated and
confirmed by Pare, Semmelweis and
Lister respectively.12 These princi
ples were not widely accepted until
the 20th century.
With the discovery of the penicil
lins and sulfanilamides in the 1930s
and the general availability of these

T

drugs later, the emphasis was on
treatment rather than prevention of
infection. Nevertheless, studies
shortly after World War II revealed
that 5.7% of hospitalized patients
had nosocomial infections.3
The identification of mutant
strains of Staphylococcus aureus,
which were penicillin resistant, sti
mulated renewed emphasis on the
value of prevention.4
In the 1970s, the Centres for
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Disease Control in Atlanta recom
mended the establishment of infec
tion control committees, and the
hiring of surveillance nurses and
hospital epidemiologists. In 1974,
they initiated a study of the efficacy
of nosocomial infection control to
assess the effectiveness of these
programs.3 It was discovered that
during the period 1970 to 1976,
hospitals with infection control pro
grams reduced their nosocomial in
fection rates by 32%, but those
without such programs showed an
increase of 18%. The value of these
programs was not only demonstrat
ed but reaffirmed.5

Implementation of the Program
The Michener Centre is a provin
cial institution for the mentally re
tarded, having approximately 1200
residents. Although disease rates
there have been identified and cal
culated since the early 1970s, ex
tension of the monitoring program
to include a monthly list of all
nosocomial and postoperative
wound infections was not begun
until 1983, when a part-time infec
tion control nurse was hired. With
the help of the manual Guidelines
for Prevention o f Surgical Wound
Infections6 and provincial infection
control guidelines,7 a customized
infection control manual was drawn
up to help identify, classify, isolate
and prevent infection. Demonstra
tions were given of good hygiene
techniques. Individual cases were
referred to the infection control
nurse, who visited the site to ensure
that aseptic techniques were being
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followed. All antibiotic choices were
analysed against organism sensitivi
ties to ensure that the correct
choice was made or, if necessary,
that the antibiotic chosen was
changed. Any patient with a postop
erative wound infection was exam
ined by the infection control nurse
and the infection was classified in
accordance with the four-stage clas
sification developed by the United
States National Research Council in
1964 (Table I).8

Comments
The wound infection data are
reviewed monthly and any unusual
findings are brought to the atten
tion of the surgeon involved or the
family physician. Otherwise, a sum
mary of wound infection rates for
each surgeon and the cumulative
rates for all surgeons (Table V) are
circulated annually.
The type of surgery performed at
the Michener Centre differs from
that done in normal hospitals.

Table I. US National Research Council Classification of Postoperative Wound Infections8

Results

Class of infection

In the 63 months since the sur
vey started, 336 clean and cleancontaminated and 20 contaminated
and dirty operations have been per
formed. There were 21 infections,
15 in the clean and clean-con
taminated group (Table II). In 98%
of cases the operation was per
formed by surgeons at the nearby
regional hospital; in the remainder,
the patients were referred to teach
ing hospitals 230 km away. All
patients were returned early after
operation to the 26-bed infirmary at
the Michener Centre, thus allowing
7- and 30-day follow-up.
Early in the study, it became
apparent that some wound infec
tions were caused by the patient,
who was disturbed by the operation
and contaminated the wound by
removing the dressings, scratching
and picking at the incision and
sutures, and in other ways interfer
ing with the healing process. These
infections could not be considered
as “surgeon induced”, so they were
excluded from the series (Table III).
There were seven (32%) such cases,
six of them occurring in severely
retarded patients. This represented
2% of all operations (7 of 356).
A drop in postoperative wound
infection rates is usually achieved
within 6 months of the institution
of a surveillance program. At the
448

Michener Centre it took only 3
months for the rate to drop marked
ly from 23% and reach a plateau of
2.8% to 4.7%. The rate then re
mained almost constant for the next
35 months. However, it continues
to be higher than the rate for the
nearby regional hospital (Table IV),
suggesting that the residents of the
Michener Centre may be contribut
ing to this higher rate. Neverthe
less, the difference in the two rates
has decreased from 22.4% in 1983
to 2.5% in 1988.

Clean

Clean-contaminated

Contaminated

Dirty

Description
Nontraumatic
Elective
Primary closure
No entry into gastrointestinal or respiratory tract
No break in sterile technique
Entry into gastrointestinal or respiratory tract
Entry into biliary or urinary tract
Break in sterile technique
Operation performed into or through vaginal mucosa
Surgery performed in presence of acute inflammation
Fresh traumatic wounds
Spillage from gastrointestinal tract
Major break in sterile technique
Presence of pus
Perforated viscus
Old or dirty traumatic wounds

Table II. Postoperative Surgical Wound Infections at Michener Centre,
October 1983 to December 1988
No. of
operations

No. of
infections'

1983 (Oct - Dec)

13

3

1984

84

4

1985

63

2

1986

58

2

1987

69

2

1988

49

2

336

15

201

5

Year

Clean and
clean-contaminated
operations
Contaminated and dirty
operations

Patient’s
functional
levelf
Moderate
Profound
Moderate
Profound
Profound
Profound
Profound
Severe
Severe
Moderate
Severe
Profound
Moderate
Borderline
Severe

'Excluding those attributed to resident behaviour.
tlQ levels of mental functioning were as follows: borderline = 68-85, mild = 52-67, moderate
= 36-51, severe = 20--35, profound = <20.
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SURGICAL WOUND INFECTIONS

Major abdominal surgery and gyne
cologic procedures are less com
mon. Orthopedic and ophthalmo
logic procedures are much more
common.
The excess morbidity caused by
patient interference postoperatively
represented 32% of all postoperative
wound infections (7 of 22 cases).
Table III. Postoperative Wound Infections
Attributed to Resident Behaviour
Year

No. of
patients

1983
1984
1985

0
1
4

Patient’s functional
level
-

Profound
Profound
Severe
Moderate
Profound

0
1
1

1986
1987
1988

for the Michener Centre population
approximate those in general hospi
tals through (a) good patient selec
tion for operation, (b) regular and
repeated use of the same group of
consulting surgeons and (c) care
and treatment by nurses experi
enced in dealing with retarded pa
tients. As emphasized in the study
on the efficacy of nosocomial infec
tion control,3 a program that effec
tively monitors infection control
policies and practices m ust be in
place before these competitive re
sults can be achieved.

However, this represented only 2%
(7 of 356) of all operations. Patients
with severe or profound functional
limitation had more infections than
those with lesser limitation (Table
VI). Patients with a severe or pro
found functional level now undergo
additional assessment by the family
physician about their suitability for
operation. Although the desired
surgical outcome has almost always
been achieved, the additional medi
cal opinion has resulted in several
operations being cancelled or post
poned until surgical indications
were more compelling.

References
Conclusions

Severe
Severe

The most important conclusion
to be drawn from this study is that
postoperative wound infection rates

Table IV. Clean and Clean-Contaminated
Surgical Wound Infection Rates (%) at
Michener Centre and Red Deer Regional
Hospital
Year

Michener
Centre

Red Deer
Regional Hospital

1983
1984
1985
1986
1987
1988

23.1
4.7
3.2
3.4
2.8
4.1

1.69*
1.98'
1.90
1.92
1.77
1.51

1. C ruse PJ: Wound infections. In S immons
RL, Howard RJ (eds): Surgical Infectious

Diseases, ACC, New York, 1982: 429441
2. Luke WP: Surgical infections — the

Table VI. Distribution of Residents by Functional Level, December 1988

Functional
level
Borderline
and mild
Moderate
Severe
Profound
Totals

'Estimated.

Wound infections attributed
to patient interference

Wound infections

No. of
operations

No.

% of all operations

No.

% of all operations

(17.2)
(20.4)
(22.5)
(39.8)

57
69
103
107

1
4
4
6

1.8
5.8
3.9
5.6

0
1
3
3

1.4
2.9
2.8

1180 (99.9)

336

15

4.5

7

2.1

Total

Cumulative
infection rate,
1983 - 1988, %

No. (%)
203
241
266
470

Table V. Cumulative Surgical Infection Summary
Surgeon
(specialty)
1 (Urol)
2 (Opth)
3 (Ortho)
4 (Plastic)
5 (Gen)
6 (Ortho)
7 (Gen)
8 (Gen)
9 (ENT)
10 (Gyn)
11 (Gen)
12 (Gen)
13 (Ortho)
14 (Urol)
15 (Opth)
16 (Ortho)
17 Out of town
Totals

Infections

Cases
83

84

85

86

87

88

Total

83

84

85

86

87

88

0
1
0
0
2
1
0
0
0
1
6
1
0
0
0
1
0

2
14
10
2
10
8
1
0
1
3
11
2
1
1
0
9
9

0
14
3
3
12
10
0
0
0
4
7
2
0
0
0
4
4

2
14
1
0
10
4
2
0
0
3
7
0
1
0
3
10
1

0
19
1
0
9
5
0
2
0
2
15
1
3
0
0
7
5

0
7
4
0
0
4
2
8
0
2
11
0
0
1
2
7
1

4
69
19
5
43
32
5
10
1
15
57
6
5
2
5
38
20

0
0
0
0
0
1
0
0
0
1
1
0
0
0
0
0
0

0
0
0
0
2
0
0
0
0
0
1
0
0
0
0
1
0

0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
1
0
0
0
0
1
0
0
0
0
0
0
0

0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0

0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
0

0
1
1
0
4
1
0
0
0
3
2
0
0
0
0
3
0

0
1.6
6
0
9
3
0
0
0
20
4
0
0
0
0
7.9
0

13

84

63

58

69

49

336

3

4

2

2

2

2

15

4.7
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action of cefoxitin, a cephamycin derived from
cephamycin C, results from the inhibition of
bacterial cell wall synthesis. Evidence suggests
that the methoxy group in the 7a position is
responsible for the resistance of cefoxitin to
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The treatment of the following infections when
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia
spp.)
5 - Lower respiratory tract infections
6 - Bone and Joint in fe c tio n s caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the susceptib ilit y of th e causative o rg a n is m (s ) to
MEFOXIN®. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
Organisms particularly appropriate for therapy
with MEFOXIN® are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci

NOTICES

Gram negative (beta-lactamase producing and
non-producing strains)

Escherichia coli
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species

Abstract Submissions for the 1990
Royal College Meeting
The 1990 Royal College meeting will be
held in Toronto, Ontario, from Sept.
1 4 -1 7 , 1990. In January 1990, the
Annual Meeting Committee will invite
all Fellows and members of participat
ing societies to submit abstracts of
scientific papers for consideration by
the specialty review panels for the 1990
program.
The abstract submission forms will
be distributed to all Fellows as an insert
to the January 1990 Annals. Watch for
your copy.
Please note that the deadline for
receipt of the abstracts, accompanied by
the processing fees will be Mar. 9,
1990.

continued on page 466

450

Anaerobes

Bacteroides fragilis
MEFOXIN® may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas
spp., most strains of enterococci, many strains
of Enterobacter cloacae, and m ethicillinr e s is ta n t s ta p h y lo c o c c i and L is te ria
monocytogenes.
Clinical experience has demonstrated that
MEFOXIN® can be administered to patients who
are also receiving carbenicillin, gentamicin,
tobramycin, or amikacin (see PRECAUTIONS
and ADMINISTRATION).
PROPHYLACTIC USE

MEFOXIN® may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal or
abdominal hysterectomy and abdominal surgery
when there is a significant risk of postoperative
infection or where the occurrence of post
operative infection is considered to be especially
serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)
and postoperative use of MEFOXIN® may
reduce the incidence of surgery related post
operative infections.

©Trademark Merck & Co., Inc./
Merck Frosst Canada Inc., R.U.
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Effective prophylactic use depends on the time
of administration. MEFOXIN® usually should be
given one-half to one hour before the operation.
Prophylactic administration should usually be
stopped within 12 hours. It has been generally
reported that continuing administration of any
antibiotic beyond 24 hours following surgery
increases the possibility of adverse reactions
but, in the majority of surgical procedures, does
not reduce the in cid e n ce o f subsequent
infection.
If signs of postsurgical infection should appear,
specimens for culture should be obtained for
identification of the causative organism(s) so
that appropriate treatment may be instituted.

CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN® is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN®, cepha
losporins, penicillins or otherdrugs. MEFOXIN®
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
of partial cross-allergenicity between cephamycins and the other beta-lactam antibiotics,
penicillins and cephalosporins. Severe reactions
(including anaphylaxis) have been reported
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported
w ith v ir tu a lly a ll a n tib io tic s in c lu d in g
MEFOXIN®. This colitis can range from mild to
life threatening in severity. Antibiotics should
therefore be prescribed with caution in indi
viduals with a history of gastrointestinal disease,
particularly colitis. It is important to consider a
diagnosis of pseudomembranous co litis in
patients who develop diarrhea in association
with antibiotic use. While studies indicate that a
toxin produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form of
allergy, particularly to drugs, should receive
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs,
adm inistration of the drug should be dis
continued. Serious hypersensitivity reactions
may require treatment with epinephrine and
other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced when
MEFOXIN® is administered to patients with
transient or persistent reduction of urinary
output due to renal insufficiency (see DOSAGE
AND ADMINISTRATION) because high and
prolonged serum antibiotic concentrations can
occur from usual doses.
In patients treated with MEFOXIN® a false
positive reaction to glucose in the urine may
occur with Benedict's or Fehling’s solutions but
not with the use of specific glucose oxidase
methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100 pg/mL. Serum
samples from patients treated with MEFOXIN®
should not be analyzed for creatinine if with
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine
may interfere with measurement of urinary 17hydroxy-corticosteroids by the Porter-Silber
reaction, and produce false increases of modest
degree in the levels reported.
Increased nephrotoxicity has been reported
fo llo w in g co n co m ita n t a d m in is tra tio n of
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient's condition is
essential and if super-infection occurs during
therapy, appropriate measures should be taken.
Should an organism become resistant during
antibiotic therapy, another antibiotic should be
substituted.

Use in Pregnancy
The safety of MEFOXIN® in the treatment of
infections during pregnancy has not been
established. If the administration of MEFOXIN®
to pregnant patients is considered necessary, its
use requires that the anticipated benefits be
weighed against possible hazards to the fetus.
Reproductive and teratogenic studies have been
performed in mice and rats and have revealed no
evidence of impaired fertility or harm to the fetus
due to MEFOXIN®.
Nursing Mothers
Cefoxitin is excreted in human milk.
Children
In children 3 months of age or older, higher
doses of MEFOXIN® (100 m g /kg /d a y and
above) have been associated with an increased
incidence of eosinophilia and elevated SGOT.

ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse
reactions rarely required cessation of treatment
and usually have been mild and transient.
Local Reactions
Throm bophlebitis has occurred w ith intra
venous administration. Some degree of pain and
tenderness is usually experienced after intra
muscular injections using water. Induration has
occasionally been reported.
Allergic
M a c u lo p a p u la r rash, u rtic a ria , p ru ritu s ,
eosinophilia, fever and other allergic reactions
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported rarely.
Blood
Eosinophilia, leukopenia, neutropenia, hemo
lytic anemia, and thrombocytopenia and bone
marrow depression have been reported. Some
individuals, particularly those with azotemia,
may develop positive d irect Coombs tests
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase and
jaundice have been reported.
Cardiovascular Function
Hypotension.

Usual Adult Dosage
Type of
Infection

Daily
Dosage

Frequency
and Route

Uncomplicated
forms* of infections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

1 g every 6-8 h
I.V. or i.M.

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing antibiotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

'Including patients in whom bacteremia is absent or
unlikely

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk of
rheum atic fever or g lo m e ru lo n e p h ritis. In
staphylococcal and other infections involving a
collection of pus, surgical drainage should be
carried out where indicated.
Adults with impaired Renal Function
MEFOXIN® may be used in patients w ith
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given. After
a loading dose, the following recommendations
for maintenance dosage may be used as a guide:

RENAL
FUNCTION

CREATININE
CLEARANCE
mL/min

DOSE

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST

50-30

1-2 g

every 8-12 h

FREQ UEN CY

MSP

In patients undergoing hem odialysis, the
loading dose of 1 - 2 g should be given after each
hemodialysis, and the maintenance dose should
be given as indicated in the Table above.

Moderate
impairment

29-10

1-2 g

every 12-24 h

Severe
impairment

9-5

0.5-1 g

every 12-24 h

Essentially
no function

<5

0.5-1 g

every 24-48 h

C A N AD A
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TREATMENT OF OVERDOSE

MEFOXIN® may be administered intravenously
or intramuscularly as required. (See complete
m o n o g ra p h on A D M IN IS T R A T IO N and
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients
with bacteremia, bacterial septicemia, or other
severe or life-threatening infections, or for
patients who may be poor risks because of
lowered resistance resulting from such debili
tating conditions as m alnu tritio n , trauma,
surgery, diabetes, heart failure, or malignancy,
particularly if shock is present or impending.
TREATMENT DOSAGE
Adults
The usual a d u lt dosage is 1 g o r 2 g of
MEFOXIN® every 6 to 8 hours. Dosage and
route of administration should be determined by
severity of infection, s u s c e p tib ility of the
causative organisms, and co ndition of the
patient. The usual adult dosages are shown in
the Table below.

MEFOXIN® is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN® in the dry state should be stored
below 30°C. The d ry m ate ria l as w e ll as
solutions tends to darken, depending on storage
conditions; product potency, however, is not
adversely affected.

1127a

Mild
impairment

DOSAGE AND ADMINISTRATION

AVAILABILITY

(332-a,4,89)
MAINTENANCE DOSAGE OF
MEFOXIN® IN ADULTS
WITH REDUCED RENAL FUNCTION

Renal Function
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure has
been reported rarely. The role of MEFOXIN® in
changes in renal function tests is difficult to
assess, since factors predisposing to prerenal
azotemia or to impaired renal function have
often been present.

Other than general supportive treatment, no
specific antidote is known. MEFOXIN® can be
eliminated by dialysis in patients with renal
insufficiency.

A t p re se n t th e re is in s u ffic ie n t data to
recommend a specific dosage for children with
impaired renal function. However, if the adminis
tration of MEFOXIN® is deemed to be essential
the dosage should be modified consistent with
the recommendations fo r adults (see Table
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN® is recommended as follows:
Vaginal or abdom inal hysterectom y and
abdominal surgery
2 g adm inistered in tra m u scu la rly or in tra 
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and th ird 2 g doses should be
administered at 2-6 h o u r intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord has
been clamped. The second and third 2 g doses
should be given intravenously or intram us
cularly four hours and eight hours after the first
dose.

|

P.O. BOX 1005, POINTE-CLAIRE
DORVAL, QUEBEC H9R 4P8

Neonates (Including Premature Infants), Infants
and Children (See WARNINGS for Neonates
under ADM INISTRATIO N in the com plete
monograph.)
Premature Infants
with Body Weights
Above 1500 g

20-40 mg/kg every 12 h I.V.

Neonates

01 week of age 20-40 mg/kg every 12 h I.V.
20-40 mg/kg every 8 h I.V.
1- 4 weeks of age
Infants

1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

Children

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

In severe infections, the total daily dosage in
infants and children may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN® is not recommended for the therapy
of meningitis. If meningitis is suspected, an
appropriate antibiotic should be used.
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Effect of Hypothermia and Cardioplegia
on Intramyocardial Voltage and Myocardial
Oxygen Consumption
R.W. Landymore, MD, FRCSC; A.E. Marble, PhD, PEng
Intramyocardial voltage and myocardial oxygen consumption were measured in the
fibrillating heart between the temperatures of 37°C and 25°C and in the arrested
heart after infusion of potassium cardioplegic solution in 10 adult mongrel dogs.
Electrical activity from the myocardium was recorded using specially designed
plunge electrodes, and intramyocardial voltage was monitored by an in-line
voltmeter. Myocardial oxygen consumption gradually decreased from 5.8 ± 0.6 ml
0 2/m in at 37°C to 2.3 ± 0.5 ml 0 2/m in at 25°C. In contrast, hypothermia did not
cause a similar decrease in intramyocardial voltage which remained within a range of
1.8 ± 0.5 mV to 2.4 ± 0.5 mV between the temperatures of 37°C and 25°C. The
infusion of potassium cardioplegic solution resulted in a dramatic decrease in
voltage to 43 ± 5
and myocardial oxygen consumption fell to 0.5 ± 0.3 ml
0 2/m in. Our data demonstrated that the mean voltage of the fibrillating heart
remains constant between the temperatures 37°C and 25°C and myocardial oxygen
consumption decreases with hypothermia, which suggests that voltage does not
correlate with the level of myocardial oxygen consumption. Myocardial oxygen
consumption and intramyocardial voltage, however, decrease dramatically when
cardioplegia is instituted.

Chez 10 chiens batards adultes, on a mesure le voltage intramyocardique et la
consommation d’oxygene du myocarde sur le coeur en fibrillation maintenu a des
temperatures de 37°C et de 25°C et sur le coeur a l’arret apres perfusion d’une
solution cardioplegique de potassium. L’activite electrique du myocarde a ete
enregistree a l’aide d’electrodes de conception speciale, et le voltage intramyocardi
que a ete monitorise a l’aide d’un voltmetre en ligne. La consommation myocardique
d’oxygene a baisse progressivement de 5.8 ± 0.6 ml d’0 2/m in a 37°C jusqu’a 2.3 ±
0.5 ml d’0 2/m in a 25°C. Par opposition, l’hypothermie n ’a pas cause une baisse
similaire du voltage intramyocardique, lequel est demeure dans l’intervalle de 1.8 ±
0.5 mV a 2.4 ± 0.5 mV entre les temperatures de 37°C et de 25°C. La perfusion
d’une solution cardioplegique de potassium a entraine une baisse spectaculaire du
voltage de 43 ± 5 g \ , et la consommation myocardique d’oxygene a chute de 0.5 ±
0.3 ml d’0 2/m in. Ces resultats demontrent que le voltage moyen du coeur en
fibrillation demeure constant entre 37°C et 25°C et que la consommation d’oxygene
du myocarde s’abaisse dans des conditions d’hypothermie; ceci indique que le
voltage n’est pas relie au niveau de consommation d’oxygene du myocarde. La
consommation myocardique d’oxygene et le voltage intramyocardique baissent
toutefois de fafon spectaculaire quand une cardioplegie est mise en route.

From the M aritime Heart Center, Victoria General Hospital, Halifax, NS

I

nduction of myocardial arrest
with cold potassium cardioplegic
solution decreases myocardial ener
gy requirements by lowering myo
cardial temperature and preventing
electromechanical activity. Al
though cardioplegia initiates a rapid
electromechanical arrest, smallamplitude electrical potentials may
be recorded from the myocardium,
using specially designed plunge
electrodes, within 10 to 15 minutes
after the infusion of potassium car
dioplegic solution when there is no
visual mechanical activity and when
the electrocardiogram is isoelec
tric.1-2 These small-amplitude elec
trical potentials have a fundamental
frequency of 3.0 Hz and may persist
for more than 30 minutes before
electromechanical activity resumes.1
Although the importance of smallamplitude electrical activity during
cardioplegic arrest is uncertain, pre
liminary investigations in our labo
ratory suggest that such activity is
associated with impaired functional
recovery of the myocardium after
90 minutes of ischemia.3 To estab
lish the relationship between in
tramyocardial voltage and myocar
dial metabolism we designed a
study to measure oxygen consump
tion (a) in the fibrillating heart
between the temperatures of 37°C
and 25°C, (b) during small-ampli
tude electrical activity and (c) in the
cardioplegic-arrested heart.

Supported by Medical Research Council o f Canada grant no. R1524369-760
Accepted fo r publication Apr. 25, 1989
Reprint requests to: Dr. R. W. Landymore, Rm. 3065, R. C. Dickson Centre, Victoria General
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Materials and Methods
Ten, adult, mongrel dogs, weigh-

MYOCARDIAL METABOLISM DURING CARDIAC OPERATIONS

ing between 21 to 25 kg, were
sedated with 1 ml of Innovar. Anes
thesia was induced and maintained
with Somnutol. Ventilation was pro
vided with a Bird Mark 7 (Bird
Corp., Palm Springs, Calif.) pres
sure-regulated ventilator.
The left femoral artery was cannulated with a no. 14F USCI arteri
al cannula (C.R. Bard Inc., Billerica,
Mass.) for cardiopulmonary bypass,
and venous return was provided
with two 34 USCI cannulas. The
cava were snared and the left ventri
cle was vented. Cardiopulmonary
bypass was established with a Med
tronic impellar pump (model
1835-00U) driven by a Medtronic
circulatory assist console (model
1810) that would deliver nonpulsatile flow at a rate of 2.5
L/m in-m r2 (Medtronic Inc., Circu
latory Systems Division, Roseville,
Miss.).
The right atrium was opened
while the dog was on bypass and a
no. 12F USCI catheter was inserted
into the coronary sinus and brought
out directly through the wall of the
atrium for measurement of coro
nary sinus flow. A snare was passed
externally around the coronary

sinus to prevent migration of the
catheter and to ensure that the
effluent from the catheter repd on
chart paper with specially con
structed plunge electrodes. The
thermistor probes were calibrated
before each experiment with a mer
cury thermometer.
Oxygen saturation was monitored
continuously with two Oxy-Sat me
ters (SM-0100; Bentley Laborato
ries, Irvine, Calif.). Oxygen sensing
equipment was positioned in the
arterial circuit and also placed in
line with the coronary sinus drain
age. Myocardial oxygen consump
tion (MV02) was measured at twodegree intervals between the tem
peratures of 37°C and 25°C and
was calculated from measurements
of oxygen saturation, coronary
sinus flow (CSF) and hemoglobin
(Hb) according to the following for
mula: MV02 (ml/min) = (% arterial
saturation — % venous saturation)
X Hb X 1.34 X CSF (ml/min).
d on
chart paper with specially con
structed plunge electrodes. The
thermistor probes were calibrated
before each experiment with a mer
cury thermometer.
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Oxygen saturation was monitored
continuously with two Oxy-Sat me
ters (SM-0100; Bentley Laborato
ries, Irvine, Calif.). Oxygen sensing
equipment was positioned in the
arterial circuit and also placed in
line with the coronary sinus drain
age. Myocardial oxygen consump
tion (MV02) was measured at twodegree intervals between the tem
peratures of 37°C and 25°C and
was calculated from measurements
of oxygen saturation, coronary
sinus flow (CSF) and hemoglobin
(Hb) according to the following for
mula: MV02 (ml/min) = (% arterial
saturation — % venous saturation)
X Hb X 1.34 X CSF (ml/min).
Myocardial temperature was then
increased to 30 °C and cardiac ar
rest was initiated by infusing potas
sium cardioplegic solution directly
into the oxygenator.4 Crystalloid
cardioplegic solution containing 25
m mol/L of potassium3 was infused
directly into the oxygenator until
complete cardiac arrest was ob
tained. Cardiac arrest was defined
by the absence of visual mechanical
activity and loss of electrical activity
on the surface electrocardiogram
and from the plunge electrodes.
Intramyocardial voltage and myo
cardial oxygen consumption were
measured in the arrested heart and
were monitored continuously until
gross electromechanical activity re
sumed.
The results are reported as the
arithmetic mean ± the standard
error of the mean.

5
4

<
o

Results

3
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FIG. 1. Mean intramyocardial voltage and myocardial oxygen consumption (MV02)
during hypothermia and cardioplegic arrest. ± = standard error of mean.

Intramyocardial voltage and myo
cardial oxygen consumption are il
lustrated in Fig. 1. Intramyocardial
voltage during ventricular fibrilla
tion varied between 1.8 ± 0.5 mV
and 2.4 ± 0.5 mV between the
temperatures of 37°C and 25°C.
The mean intramyocardial voltage
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did not decrease as the core temper
ature was lowered. In contrast,
myocardial oxygen consumption
gradually decreased from 5.8 ± 0.6
ml 0 2/m in at 37°C to 2.3 ± 0.5 ml
0 2/m in at 25°C. The infusion of
cardioplegic solution resulted in a
dramatic decrease in both the intramyocardial voltage and myocar
dial oxygen consumption. Voltage
recorded in the arrested heart mea
sured 43 ± 5 mV and myocardial
oxygen consumption decreased to
0.5 ± 0.3 ml 0 2/m in. Intramyocardial voltage and myocardial oxygen
consumption remained low until the
onset of ventricular fibrillation.
Small-amplitude electrical poten
tials were recorded from the myo
cardium just before the onset of
ventricular fibrillation. However,
the transition from a complete ar
rest to ventricular fibrillation was so
rapid that we could not measure
coronary sinus flow, and, thus,
could not calculate myocardial oxy
gen consumption during the pres
ence of the small-amplitude fibrilla
tion waveforms.

Discussion
Infusion of potassium cardiople
gic solution into the ascending
aorta will initiate a rapid electrome
chanical arrest but may not main
tain a complete electrical arrest.
Independent investigators12 have
recorded small-amplitude electrical
potentials from the myocardium
with specially designed plunge elec
trodes after the infusion of the
cardioplegic solution when the
heart is quiescent and the elec
trocardiogram is isoelectric. Smallamplitude electrical activity origi
nates in the HIS bundle and is
conducted to the ventricles within a
few minutes.5 This activity is char
acterized by the onset of smallamplitude fibrillation waveforms
which have a mean voltage two to
454

three times greater than the cardio
plegic arrest potential, which usual
ly lies between 10 and 40 n V .6
These small-amplitude electrical po
tentials are usually recorded within
5 to 15 minutes after the infusion
of cardioplegic solution and may be
present for more than 30 minutes
before the resumption of electrome
chanical activity.6 Earlier investiga
tions in our laboratory suggested
that the presence of small-ampli
tude electrical activity may be asso
ciated with impaired recovery of
myocardial function after ischemic
arrest.3 To explore further the rela
tion between intramyocardial volt
age and myocardial metabolism we
measured myocardial voltage and
oxygen consumption in the fibrillating heart between the temperatures
of 37°C and 25°C in the cardiople
gic arrested heart and, finally, we
attempted to measure myocardial
oxygen consumption and intramyo
cardial voltage during small-ampli
tude electrical activity.
Our observations indicate that
myocardial oxygen consumption
gradually decreases as the tempera
ture of the fibrillating heart is low
ered from 37°C to 25°C. Because
Buckberg and colleagues7'8 demon
strated that hypothermia decreased
myocardial energy requirements by
lowering myocardial oxygen con
sumption, we expected that moder
ate hypothermia would have similar
effects on the magnitude of the
fibrillation waveforms, since hypo
thermia is known to reduce the
contractile force of the myocardi
um. However, moderate hypo
thermia did not reduce the rtiean
voltage of the fibrillation waveforms
between the temperatures of 25°C
and 37°C, indicating that the volt
age of the fibrillating heart does not
correlate directly with the level of
myocardial oxygen consumption.
Cardiac arrest was initiated by
infusing the cardioplegic solution
into the oxygenator rather than
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into the ascending thoracic aorta.
This was necessary in order to
preserve coronary sinus flow, so
that myocardial oxygen consump
tion could be calculated. Cardio
plegia induced an electrical and me
chanical arrest in all animals. Ven
tricular fibrillation and plunge-elec
trode activity ceased after the car
dioplegic solution was infused and
intramyocardial voltage decreased
from 2.1 mV in the fibrillating heart
at 30°C to 40 jtv. The cessation of
electromechanical activity was asso
ciated with a marked reduction in
myocardial oxygen consumption,
and both voltage and myocardial
oxygen consumption remained low
until the spontaneous onset of ven
tricular fibrillation. Small-amplitude
electrical potentials were recorded
from the plunge electrodes just be
fore ventricular fibrillation resumed
but because the transition between
the arrested state and electrome
chanical activity was so short that
we could not measure coronary
sinus flow and thus calculate myo
cardial oxygen consumption during
small-amplitude electrical activity.
Brandt and associates4 monitored
the electrical status of the myocar
dium during cardioplegic arrest
using an identical experimental
model. They never recorded electri
cal activity from the plunge elec
trodes after the infusion of the
cardioplegic solution, which led
them to conclude that cardioplegia
always initiated and maintained a
complete electrical arrest. Our data
and Brandt’s observations4 comple
ment each other but are in contrast
to numerous earlier investiga
tions,^i-3.5.6,9,io which indicated that
small-amplitude electrical potentials
may be recorded from the myocardi
um within 10 to 15 minutes after
infusion of the cardioplegic solu
tion. Cardiac arrest for these ex
periments1-3'5'6910 was induced by
infusing potassium directly into the
aortic root. Infusion of cardioplegic

MYOCARDIAL METABOLISM DURING CARDIAC OPERATIONS

solution into the clamped ascending
thoracic aorta almost completely
abolishes coronary flow, which pre
vents rapid fluctuations of intracel
lular potassium. The gradual de
cline of intracellular potassium as
sociated with this technique results
in a slow transition between the
arrested myocardium and the onset
of gross electromechanical activity.
Thus, small-amplitude electrical po
tentials may develop and persist for
more than 30 minutes before ven
tricular fibrillation resumes. In con
trast, infusion of cardioplegia into
the oxygenator preserves coronary
flow and presumably causes rapid
washout and decline of intracellular
potassium, leading to the sudden
onset of ventricular excitation.
The metabolic significance of
small-amplitude electrical activity is
not fully understood, although an
earlier investigation3 suggested that
such activity was associated with
postischemic depression of left ven
tricular function. Unfortunately, we
were unable to calculate myocardial
oxygen consumption during smallamplitude electrical activity. Howev
er, we measured the voltage of the
fibrillating heart during hypo
thermia and following the induction
of potassium cardioplegia. Interest
ingly, the mean voltage of the myo
cardium during ventricular fibrilla
tion remained relatively constant as
myocardial temperature was low
ered. Considering that myocardial
oxygen consumption progressively
decreases with hypothermia, one
must assume that voltage does not
correlate directly with the level of
myocardial oxygen consumption.
Therefore, the increase in the rest
ing potential associated with the
onset of small-amplitude activity
may indicate increased myocardial
oxygen consumption but may not
directly reflect the level of myocar
dial metabolism. The significance of
small-amplitude electrical activity
during cardioplegic arrest remains

uncertain, requiring further clarifi
cation to determine its effects on
myocardial metabolism and preser
vation.
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Cefizox
sterile ceftizoxime sodium

THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from in
hibition o f cell-wall synthesis in aerobic and anaerobic gram-positive and gram
negative organisms. In vitro, ceftizoxime shows a strong affinity for penicillin
binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the
infections listed below when caused by susceptible strains of the designated
microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (includ
ing S. pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis;
Escherichia coli; Haemophilus influenzae (including ampicillin-resistant strains);
Staphylococcus aureus (including penicillinase-producing but excluding
methicillin-resistant strains); Serratia sp.; and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis; Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia
marcescens; and Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to
Pseudomonas infections of the urinary tract, a good clinical response accompanied
by bacterial eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus
epidermidis; Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides
sp. (including 8 . fragilis); Peptococcus sp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S.
pneumoniae); Staphylococcus aureus (excluding methicillin-resistant strains);
Escherichia coli; Bacteroides sp. (including 8 . fragilis); Klebsiella sp.; and Serratia
marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding
methicillin-resistant strains); Staphylococcus epidermidis; Escherichia coli;
Klebsiella sp., (including K. pneumoniae); Streptococcus sp. (excluding enterococci
but including Group A 6-hemolytic Streptococcus pyogenes); Proteus mirabilis;
Serratia sp.; Enterobacter sp.; Bacteroides sp. (including 8. fragilis); Peptococcus
sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding
methicillin-resistant strains); Proteus mirabilis; Peptococcus sp.; and Pepto
streptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to
identify the causative organisms and to determine their susceptibilities to ce fti
zoxime. Therapy with CefizoxTM may be initiated before results of the susceptibility
studies are known. However, modification of the treatment may be required once
these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have
shown hypersensitivity to ceftizoxime or other members of the cephalosporin group
of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful
inquiry should be made to determine whether the patient has had previous hyper
sensitivity reactions to cephalosporins, penicillins, or other drugs. CefizoxTM
should be given cautiously to penicillin-sensitive patients. Antibiotics, including
CefizoxTM, should be administered with caution to any patient who has demon
strated some form of allergy, particularly to drugs. If an allergic reaction to Cefi
zoxTM occurs, its administration should be discontinued. Serious acute hyper
sensitivity reactions may require epinephrine and other emergency measures.
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other
antibiotics). Therefore, it is important to consider this diagnosis in patients adm inis
tered CefizoxTM who develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may
permit overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe
cases should be managed with fluid, electrolyte and protein supplementation as
indicated. When the colitis is not relieved by drug discontinuance or when it is
severe, consideration may be given to the administration of oral vancomycin or
other suitable therapy. Other possible causes of colitis should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in
clinical studies. However, there is no other evidence that CefizoxTM (sterile ce fti
zoxime sodium) has produced alterations in renal function. Renal status should be
periodically evaluated, especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible
organisms including species originally sensitive to the drug. Careful observation of
the patient is essential. If superinfection occurs during therapy, appropriate
measures should be taken.
CefizoxTM should be administered with caution to individuals with a history of
gastrointestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine,
patients with impaired renal function (i.e., creatinine clearance <1.32 mL/s or
^7 9 mL/min) should be placed on a special dosage schedule recommended under
DOSAGE AND ADMINISTRATION. Normal dosages in these individuals are likely to
produce excessive serum concentrations of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and
aminoglycosides has caused nephrotoxicity. The effect of administering CefizoxTM
concomitantly with aminoglycosides is not known.
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Pregnancy: The safety of CefizoxTM in pregnancy has not been established. The
use of CefizoxTM jn pregnant women requires that the likely benefit from the drug
be weighed against the possible risk to the mother and fetus. The pharmacokinetics
of CefizoxTM jn pregnant patients has not been investigated. Reproduction studies
performed in rats and rabbits have revealed no evidence of impaired fertility or harm
to the fetus caused by ceftizoxime. Animal reproduction studies, however, are not
always predictive of human response.
Labour and Delivery: The safety and efficacy of CefizoxTM use during labour and
delivery has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations
(less than 4% of serum concentrations at 1 hour after dosing). The clinical signifi
cance of this is unknown; therefore caution should be exercised if CefizoxTM jS to
be administered to a nursing woman.
Infants and Children: The safety of CefizoxTM jn infants less than 6 months of age
has not been established. In children six months of age and older, treatment with
CefizoxTM has been associated with transient elevated levels of eosinophils,
SGOT, SGPT and CPK (creatine phosphokinase). The CPK elevation may be related
to intramuscular administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an agedependent reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse
Incidence
Incidence
Reaction
>1% but < 5 %
<1%
Hypersensitivity:

Rash
Pruritus
Fever

Liver:

Transient elevation of SGOT,
SGPT and alkaline phosphatase

Blood:

Neutropenia
Leukopenia
Thrombocytopenia

Renal:

Transient elevation
of BUN and creatinine

Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test

Local:

Injection site: burning, cellulitis,
phlebitis (with IV administration),
pain, induration, tenderness,
parasthesia

Genitourinary:

Vaginitis

Gastro
intestinal:

Diarrhea, Nausea, Vomiting, Pseudomembranous colitis

No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no
specific information available on symptoms or treatment. In cases of suspected
overdosage, supportive therapy should be instituted according to symptoms. Serum
ceftizoxime levels can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly
or intravenously after reconstitution.
Dosage and route of administration should be determined by the condition of the
patient, severity of the infection and susceptibility of the causative organism(s). The
intravenous route may be preferable for patients with bacterial septicemia, or other
severe or life threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at
least 48 hours after evidence of bacterial eradication has been obtained. For
B-hemolytic streptococcal infections, a minimum of 10 days of treatment is
recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM is 1 to 12 grams admin
istered in equally divided doses every 8 or 12 hours (see Table 1 below).
TABLE 1
Type of Infection
Uncomplicated
Urinary Tract

Daily Dose
(Grams)

Frequency and Route

1

500 mg q12h, IVorIM

Other Sites

2-3

1 g q8h or q12h, IV or IM

Severe or
Refractory

3-6

1 g q8h, IV or IM, to
2g q8horq12h, IV orIM *

Life-Threatening

9-12

3 o r4 g q 8 h IV

*When administering 2 g intramuscularly, the dose should be divided and injected
into different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas
aeruginosa and because many strains are only moderately susceptible to CefizoxTM,
higher dosage may be appropriate when urinary tract infections are caused by
these organisms. Other therapy should be instituted if the response is not prompt.

Adults with Impaired Renal Function: In patients in w hom the cre a tin in e clearance

RECONSTITUTION

is 1.32 m U s (79 mL/min) or less, the dosage of C e fizo xT M m ust be reduced. Fo llo w 
ing an initial loading dose of 500 mg to 1.0 g IM o r IV, the m a in ten an ce dosing
sched ule presented in Table 2 sh o u ld be follow ed in pa tie n ts w ith reduced renal
function.

S T A N D A R D V IA LS (1 G R A M and 2 G R A M S )
For intramuscular Injection: R e c o n stitu te with S te rile W ater for Injection o r B a c 
terio static W ater for Injection.

Reconstitution Table for Standard Vials - I.M. Injection

TABLE 2
Renal
Function

Creatinine
Clearance
mL/s
mL/min

L e ss Severe
Infections

Life-Threatening
Infections

0.83-1.32

50-79

500 mg
q8h

750 mg to 1.5 g
q8h

0.08-0.82
M oderate to
severe im pairm ent

5-49

250 or 500 mg
q12h

500 mg to 1.0 g
q12h

500 mg q48h or
250 mg q24h

500 mg to 1.0g
q48h or 500 mg
q24h

M ild
Impairment

H e m od ia lysis
patients*

00.07

0-4

*ln p atien ts undergoing h em od ialysis no ad ditio na l supp le m e n ta l d osing is
required. DOSING, HOWEVER, SHOULD BE SCHEDULED SO THAT THE PATIENT
RECEIVES THE DOSE AT THE END OF THE DIALYSIS. W hen started 24 hours after
adm inistration of 1 g of CefizoxTM, h em od ialysis h a s been show n to reduce serum
levels by 50%.
W hen o nly the serum creatinine level is available, cre a tinin e cle a ra n ce may be
calcu lated from the follow ing form ulae (for p atien ts 18 years and over only). The
serum creatinin e level should represent renal function at the ste a dy state.

Vial
Size

D iluent to be
A dded to Via l

A pproxim ate
A vailab le
V olum e

A p p ro xim a te
Average
C on ce n tratio n

1 g
2g

3.0 m L
6.0 m L

3.7 m L
7.4 m L

270m g/m L
270m g/m L

Shake w ell until dissolved.

For Intravenous Injection: R e c o n stitu te o nly with Ste rile W ater for Injection.
Reconstitution Table for Standard Vials - I.V. Injection
Vial
Size

D iluent to be
A dded to V ia l

A pproxim ate
A vailab le
V olum e

A p p ro xim ate
Average
C on ce n tratio n

1 g

10 m L
20 m L

10.7 m L
21.4 m L

95 mg/m L
95 mg/mL

2g

Shake w ell until dissolved.

For Intravenous Infusion: R e c o n stitu te as for intravenous injection. Further
dilute the reconstituted s o lu tio n to 50 to 100 m L w ith one of the “ S o lu tio n s for
Intravenous Infusion" (see below).

Males:
C reatin ine Cle a ra n ce

72 x serum creatinine (mg/100 mL)

C reatin ine Cle a ra n ce
(mL/s)

TABLE 4 : Solutions for Intravenous Infusion

W eight (k g )x (140-age)

(mL/min)

W eight (kg) x 140 - age)
~~

49 x serum creatinine ( /xmol/L)

Females: 0.85 of the above values
Infants and Children: The follow ing dosage schedule is recom m ended:
TABLE 3
Age Group
Infants (6 mo-2 yrs.),
and
Children (2-12 yrs.)

Unit Dosage

Frequency and Route

50m g/kg IV orIM

q 6 h o rq 8 h , IV o rIM

The p ed iatric d o sag e should not exceed the m axim um adult d o sa g e for serious
infections.

ADMINISTRATION
Intramuscular: The reconstituted so lution of CefizoxTM sho uld be injected well
w ithin the body of a relatively large m uscle, such a s the gluteus. W hen adm inister
ing 2 g IM doses, the do se should be divided eq ually and then injected into different
large m u scle m asses.

Sodium C h lo rid e Injection
5% or 10% D extrose Injection
5% D extrose and 0.9%, 0.45% o r 0.2% Sodium C h lo rid e Injection
Ringer’s Injection
Lactated R in g er’s Injection
10% Invert S u g a r in Sterile W a te r for Injection
5% Sodium B icarb onate in S te rile W ater for Injection
5% Dextrose in Lactated R in g e r’s Injection O N L Y when reco nstitu ted
4% Sodium B icarb o na te Injection.

w ith

STABILITY OF SOLUTIONS
Storage: A ll reconstitu ted s o lu tio n s and those further diluted sho uld be used
w ithin 24 hours if stored at room tem perature or w ithin 48 hours if refrigerated.
These sto rag e lim its are from th e tim e o f the initial reconstitution.

Incompatibility: CefizoxTM sh o u ld not be added to blood products, protein
hyd rolysates or am ino a cid s . CefizoxTM should not be m ixed together w ith an
a m in og lyco sid e.
DOSAGE FORMS
Availability: CefizoxTM is a v a ila b le a s a sterile pow der in Standard V ia ls o f
1 gram or 2 gram s, con tain in g ce ftizo x im e as sod ium salt.

Storage: CefizoxTM pow der fo r in je ctio n should be stored at room tem perature
(15°-30°C).

Intravenous: Injection (bolus): The reconstituted so lu tio n of CefizoxTM should be
injected slo w ly over 3 to 5 minutes, d irectly or through the tubing system by w hich
the patient is receiving another com p atib le intravenous solution. During adm inistra
tion o f the so lutio n containing CefizoxTM, it is d e sira b le to tem porarily disco ntinue
a d m inistration of the other solution.
Intermittent or co n tin u o u s infusion: The further d iluted reconstitu ted so lution of

CefizoxTM sho uld be adm inistered over a 20 to 30 m inute period.
NOTE: Ce fizo xT M so lu tio n s should not be p h y sica lly m ixed w ith any other drug.
There is a known incom patibility w ith am in og lycosid e a n tib io tics. Therefore, they
should not be p h y sica lly mixed with CefizoxTM so lu tio n s nor ad m inistered at the
sam e site.

2A s indicated in the manufacturer's product m onograph cefoxitin, M erck S harp & Dohme Canada, 1985

PHARMACEUTICAL INFORMATION

3Lou M.A. et a l.: 14th International Congr. Chem other.. Kyoto, Japan, June 1985, pp 2378-2379.

CHEMISTRY

4Neu H.C., Chin N X : The activity and beta-lactam ase stability of cefotetan com pared to other beta-lactam antibio tics
Chemioterapia 1985;4:271-277.

Trade Name: CEFIZO XT M

5Fu K .P . Neu H.C.: Antibacterial activity of ceftizoxim e. a B-lactamase-stable cephalosporin Antim icrob. Agents
Chemother 1980;12:583-590

Proper Name: Ce ftizo xim e Sodium
Chemical Name: Sodium (6R-[6<», 7 B (Z )]]-7 -[[(2 ,3 -d ih y d ro -2 -im in o -4 -th ia z o ly l)
(m e th o x yim in o )a ce tyl]a m in o ]-8 -o xo -5 -th ia -1 -a za b ilcy clo [4 .2 .0 ]
carboxylate

FOOTNOTES
'A s indicated in the manufacturer's product m onograph Cefizox, S m ith Kline & French Canada Ltd . 1988.

o ct-2 -e n e -2 -

Structural Formula:

6Thornsberry C .: Review of in vitro activity of third-generation cephalo sporin s and other newer beta-lactam antibio tics
against clinically im portant bacteria. Am J. M ed 1985;79 (Suppl 2A): 15-20.
7Drulak M.W.. Chow A .W .: Com paritive in vitro activity of ceftizoxim e cefoperazone and cefoxitin against anaerobic
bacteria Antimicrob. Agents Chemother. 1981;20:683-685.
8Aldridge K E et a l : Com parision of the activities of penicillin 6 and new B-lactam antibiotics against clin ical isolates of
Bacteroides species. Antimicrob. Agents Chem other 1984;26(3):410-413.
9Adapted from Parker D.D.: Abstr. Annu. M eet A m . Soc. M icrobiol .Atlanta, GA, M arch 1987, Abstract no. A-107. p. 18
,0Kitzmann R. Cost analysis of the ecom om ic effect of replacem ent of cefoxitin with ceftizoxime. Presented at the 45th
Annual Meeting, A m erican Society of Hospital Pharm acists. San Francisco, California.
"G u astell C. Cost savings realized from in terchanging ceftizoxim e for cefoxitin. A m J Hosp Pharm 1988
Nov;45:2376-2377.
,2W ikler M .A et a l : Efficacy of ceftizoxim e adm inistered twice daily for the treatment of serious infections in hospitalized
patients. Infect. M ed 1986;(Suppl.):9-12.

Molecular Formula: C 13 H i2 N 5 0 s S 2 N a

,3Data on file. S m ith Kline & French Canada Ltd

Molecular Weight: 405.38

,5Richards DM Heel RC. Ceftizoxime: A review of its antibacterial activity, pharm acokin etic properties and therapeutic
use. Drugs 1985:29:281-329.

Description: Ce ftizo xim e Sodium is a w hite to pale yello w cry sta llin e powder.
Composition: CefizoxTM vials con tain ceftizoxim e sod ium (expressed in term s
of free acid). The sodium content o f each gram of C e fizo xT M is approxim ately
60
mg (2.6 m Eq sod ium ion).
S o lu tio n s of CefizoxTM range from colou rle ss to p ale yellow, d epending upon the
diluent and volum e used. The so lutio n should be d isca rd e d if it b e co m es cloudy.
The pH o f freshly reconstituted so lu tio n s usually ranges from 6.0 to 8.0.
A so lutio n of 1 g C efizo xTM in 13 m L Ste rile Water for Injection is isoton ic.

u Sanford J . P : Guid e to Antim icrobial Therapy. W est Bethesda, M D:Antim icrobial Therapy Inc., 1988:50.

,6DiPiro J. May J R Use of cephalosporins with enhanced antianaerobic activity for treatment and prevention of
anaerobic and m ixed infections Clin Pharm 1988 Apr:7:285-302
,7Bellom o S. Antim icrobial activity of cefizoxim e sodium : Com parision with cefoxitin Hosp Formul 1988:23
(Suppl. D): 18-27
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Evaluation of Autotransfusion in Elective
Aortic Reconstruction
Alan M. Graham, MD, FRCSC; Tom Burdon, MD; James F. Symes, MD, FRCSC
A new intraoperative autotransfusion system was prospectively evaluated in 30
major aortic reconstructions. After systemic heparinization of the patient, blood is
collected in a cardiotomy reservoir and immediately reinfused (up to 500 ml/min).
The amount of autotransfused or banked blood necessary to maintain the
hemoglobin at 100 g/L during and for 24 hours after surgery was monitored and
coagulation profiles, renal function and complications were recorded.
The amount of autotransfused blood averaged 1414 ml and the number of packed
red blood cells transfused over 24 hours averaged 1.9 units. Of the 30 patients, 24
required 2 units of homologous blood or less over 24 hours; 8 patients received no
homologous transfusions and another 8 only 1 unit. There was no significant
change postoperatively in serum creatinine or fibrinogen levels or in the
prothrombin and partial thromboplastin times; the platelet count fell from 264 X
109/L preoperatively to 182 X 109/L postoperatively (p < 0.05), but this was not
clinically relevant. The free plasma hemoglobin level rose substantially, but
perioperative urine output was good. There were no complications attributable to
autotransfusion.
The use of the autotransfuser during major vascular surgery provides a safe,
effective means to minimize the loss of clotting factors, preserve blood-bank
resources and eliminate the risk of disease transmission from homologous blood. By
allowing rapid reinfusion when blood loss is excessive, this system can prevent
prolonged hypotension in patients at increased cardiac risk.
Un nouveau systeme d’autotransfusion peroperatoire a ete evalue de maniere
prospective lors de 30 reconstructions aortiques majeures. Apres heparinisation
generate du patient, le sang a ete recuelli dans un reservoir de cardiotomie et
reinjecte immediatement (jusqu’a concurrence de 500 ml/min). Qu’il soit
autotransfuse ou qu’il provienne de la banque de sang, on a surveille la quantite de
sang necessaire pour maintenir Themoglobine a 100 g/L pendant l’operation et
durant les 24 heures suivantes. On a aussi enregistre les profils de coagulation, les
indices de fonction renale et les complications rencontrees.
La quantite moyenne de sang autotransfuse a ete de 1414 ml, a laquelle s’ajouta
1.9 unites d’hematies concentrees pour 24 heures. Des 30 patients, 24 eurent besoin
de 2 unites de sang autologue ou moins, sur 24 heures; 8 patients ne re^urent
aucune transfusion de sang autologue et 8 autres re$urent 1 unite seulement. On
n’a observe aucune modification postoperatoire significative de la creatininemie, des
taux de fibrinogene ou des temps de prothrombine ou de cephaline. Le compte
plaquettaire a chute de 264 X 109/L avant Toperation, a 182 X 109/L apres (p <
0.05), un changement sans importance clinique. Le taux d’hemoglobine plasmatique
libre a augmente de fa?on marquee mais le debit urinaire peroperatoire est demeure
bon. On n’a releve aucune complication attribuable a l’autotransfusion.
L’emploi de ce systeme d’autotransfusion au cours des chirurgies vasculaires
majeures offre un moyen sur et efficace de minimiser la perte des facteurs de
coagulation, reduit la demande sur la banque de sang et elimine le risque de
transmission des maladies venant du sang homologue. En permettant la
retransfusion rapide du sang quand les pertes sont excessives, ce systeme peut
prevenir une hypotension prolongee chez des patients ayant un risque cardiaque
eleve.
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the collection
A utotransfusion,
and reinfusion of a patient’s

own blood, although not a new
concept, has only recently been ap
plied to areas other than open-heart
surgery. Concern with regard to the
transmission of infectious agents in
blood products, however, has rekin
dled an awareness of the possible
dangers of homologous transfusion.
Hepatitis remains the most serious
infection after transfusion. In Cana
da, non A-non B hepatitis contami
nates between 2% and 5% of all
transfusion products, and as many
as 17% in the United States. Human
immunodeficiency virus, which can
result in the fatal acquired immune
deficiency syndrome, is also effec
tively transmitted by transfusion.1
These serious complications have
stimulated the development of new
methods that would minimize or
avoid homologous blood transfu
sion, such as autologous blood
transfusion, intraoperative hemodilution and collection and reinfusion
apparatus.
Reconstruction of the abdominal
aorta for occlusive and aneurysmal
disease may, in complicated cases,
require the transfusion of substan
tial quantities of homologous blood.

From the Department o f Surgery, Royal
Victoria Hospital, M cGill University, 687
Fine Ave. W, Montreal, PQ H3A 1A1
Accepted fo r publication Apr. 6, 1989
Reprint requests to: Dr. Alan M. Graham,
Ste. S10.01, Royal Victoria Hospital, 687
Pine Ave. W, Montreal, PQ H3A 1A1

AUTOTRANSFUSION IN AORTIC SURGERY

Since many of these procedures
require urgent or emergency sur
gery, autologous blood collection is
not possible. Furthermore, nor
movolemic hemodilution is not pos
sible in many patients who undergo
aortic surgery because of their con
comitant cardiac disease.
With these considerations in
mind we have developed and used
an autotransfusion system. It is
similar to a system used at the
University Health Center of Pitts
burgh.2 Thirty consecutive patients
who underwent aortic reconstruc
tion were assessed.

Methods
Over a 6-month period, 30 pa
tients scheduled to undergo elective
aortic surgery were studied. Includ
ed were 16 patients who had aneu
rysmal disease of the aorta and iliac
arteries, 11 who had aortoiliac oc
clusive disease, 1 who had an ili
T a b le 1.

Procedures Carried Out in 30 Patients
No. patients

Aneurysmal disease
Aortic aneurysm repair infrarenal
Aortic and iliac artery
aneurysm repair
Aortobifemoral bypass
(aneurysmal and
occlusive disease)
Aortoiliac aneurysm with
bilateral renal artery
bypass
Occlusive disease
Aortobifemoral bypass graft
+
extended profundaplasty
single renal artery bypass
bilateral common femoral
aneurysms
nephrectomy
Miscellaneous
Thoracoabdominal aneurysm
repair with reimplantation
of celiac, superior
mesenteric and renal
arteries
Coarctation (adult) repair
lleofemoral pseudoaneurysm
repair

7
6

2

1

5
3
2
1

1
1
1

ofemoral pseudoaneurysm, 1 who
had adult coarctation of the thorac
ic aorta and 1 who had thoracoab
dominal aneurysm with reimplanta
tion of the celiac, superior mesen
teric and both renal arteries (Table
I).

For all patients, intraoperative
blood loss, the quantity of blood
autotransfused and the requirement
for homologous transfusion of
blood products to maintain a hemo
globin at 100 g /L were document
ed. In addition, pre- and postopera
tive renal function, perioperative
urine output, pre- and postoperative
coagulation profile (prothrombin
and partial thromboplastin times,
platelet and fibrinogen levels), free
plasma hemoglobin level and surgi
cal outcome were assessed. The
preoperative cardiac status of all
patients according to the New York
Heart Association classification was
noted; 19 were in class I and 11 in
class II (3 patients in the latter class
underwent aortocoronary bypass
before aortic surgery).
The autotransfusion system (Fig.
1) was used only while the patient
was heparinized. The anticoagulat
ed blood is collected in a cardiotomy reservoir that contains a mi
croaggregate filter. A one-quarter
inch line is connected to the reser

voir, inserted in an occlusive roller
pump and attached to a heat ex
changer. The blood is filtered
through a 105 lira filter screen,
which is proximal to the heatexchanger outlet. A 20 /um blood
transfusion filter is inserted distal to
the heat-exchanger outlet.
The blood can be either recir
culated to the cardiotomy reservoir
through an extension line or re
turned to the patient through a
large-bore intravenous line. Blood
temperature is monitored with a
temperature probe within the heat
exchanger. The temperature is kept
constant at 37 °C with a water
source. A pressure-monitoring de
vice is also attached to the heat
exchanger. Blood aspiration at the
field depends on wall suction regu
lated in the range of 50 to 75 mm
Hg. The system is primed with 200
ml of heparinized saline before aspi
ration of blood.

Results
There were two postoperative
deaths, one from a myocardial in
farction on postoperative day 6 and
one from a cerebrovascular accident
on postoperative day 5. There were
no complications associated with
the autotransfusion system and no
patient had major hemorrhagic
morbidity.
The mean time the autotransfus
er was used was 108 minutes
(range from 45 to 220 minutes) and
the volume of blood autotransfused
averaged 1414 ml (range from 200
to 4100 ml).
The total blood-bank requirement
for the 30 patients was 54 units of
packed cells, 4 units of fresh-frozen
plasma and 20 units of platelets
(Table II). The average number of
packed cells transfused to maintain
a hemoglobin of 100 g /L during
operation and within the first 24
hours postoperatively was 1.9
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units, the requirements ranging
from no transfusion in eight pa
tients and only 1 unit in another
eight to 7 units in two patients. The
last two patients were unusual and
presented difficult problems. One
was an elderly man who had chron
ic disseminated intravascular coagu
lation and a large, heavily calcified
abdominal aneurysm. The other was
a middle-aged woman who had a
thoracoabdominal aneurysm involv
ing all major intra-abdominal ves
sels; it was associated with a large
intraoperative blood loss because of
heavy calcification of the aortic wall
at the anastomotic sites.
Of the 30 patients, 24 (80%)
required 2 units or less of packed
red cells (Table III). Excluding three
patients who required large transfu
sions, the total number of homolo
gous units given to maintain a
hemoglobin of 100 g /L was only
35 for 27 patients. This is an
arbitrary figure; had we decided on
a hemoglobin level of 80 g /L as
others have,3 73% of patients would
have required no homologous
blood.
The major complication of auto
transfusion has been suggested to
be hemolysis, with its resultant
renal dysfunction. We monitored
renal function closely by measuring
serial serum creatinine levels. The
mean serum creatinine level preoperatively was 132.6 /tmol/L (range
from 70.7 to 229.8 #tmol/L). The
level just before discharge from
hospital was 123.8 / j. n 10I/L (range
from 61.9 to 256.4 /imol/L) (Table
III). Hourly urine output in the
Amount of Packed Red Cell
Transfusions Needed to Maintain
Hemoglobin Level at 10 g/L

initial 24 hours after operation av
eraged 1.57 m l/kg. No patient was
oliguric, but some had received
mannitol and lasix intraoperatively,
which may have had an effect on
the outputs.
There was no significant change
in the prothrombin time (11.0/11.4
s preoperatively versus 11.3/11.5 s
24 hours postoperatively), the par
tial thromboplastin time (31.7/32.0
preoperatively versus 32.2/31.7 s)
and the fibrinogen levels (3.47 g/L
versus 3.22 g/L). However, the
patient who had chronic DIC preop
eratively in association with an aor
tic aneurysm4 had a rise in the
fibrinogen level from a preoperative
level of 0.88 g/L to 1.76 g/L 48
hours after aneurysmectomy. Free
plasma hemoglobin was measured
in a number of patients, and al
though urinary function was unal
tered the free plasma hemoglobin
levels were elevated from a mean (±
SD) preoperative value of 56 ± 19
g /L to 117 ± 31 g/L (p < 0.01,
paired f-test).
The number of platelets de
creased in the first 24 hours post
operatively to 182 X 109/L from
264 X 109/L preoperatively. Al
though this change is numerically
significant (p < 0.05), it was not
clinically relevant.

Discussion
The vascular surgeon’s patients
have often undergone previous vas
cular procedures and require reop
eration due to progression of ath

T a b le II.
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No. units

N o. p a tie n ts

0
1
2
3
5
7

8
8
6
5
1
2

T a b le III.

Laboratory Data Before and After Autotransfusion

M e a s u re m e n t

Creatinine, ^m ol/L
Fibrinogen, g/L
Prothrombin time, s
Partial thromboplastin time, s
Platelets, X 109/L
Hemoglobin, g/L
*p < 0.05 by Student's paired f-test.
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erosclerosis and graft failure. Inher
ent in these procedures is the fre
quent need for homologous blood
transfusion. Further, availability of
compatible blood is sometimes lim
ited due to previous isoimmuniza
tion. Demands on homologous
donor blood have increased as the
number of complex surgical proce
dures has escalated. Transmission
of infectious disease is now of para
mount interest to the general pub
lic. Other adverse effects include
isoimmunization, hypocalcemia, aci
dosis and hypothermia. All of these
issues have forced the surgical com
munity to become more aware of
the need to use autologous blood
whenever possible.
Autotransfusion has been used
successfully without complication
in many centres.5-7 In fact, Cutler3
reported that 76% of patients who
underwent elective aortofemoral
grafting avoided intraoperative ho
mologous blood transfusion. He
used hemodilution to a hematocrit
of 25% in patients at low cardiac
risk and to 30% in higher risk
patients, in association with auto
transfusion. By comparison, 26% of
our patients received no transfu
sions, and an equal percentage re
ceived only 1 unit of packed cells
without the aid of hemodilution;
73% would not have required any
transfusion had we accepted a he
matocrit of 25%. Landow8 recently
reviewed perioperative hemodilution
and suggested that healthy patients
from 2 to 60 years of age could
undergo hemodilution to 25%, and
that patients with diabetes, claudiP re o p e ra tiv e

P ostoperative

132.6
3.47
11.0/11.4
31.7/32.0
264
134

123.8
3.22
11.3/11.5
32.2/31.7
182*
114
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cation or heart disease should not
undergo hemodilution at all. Our
patients generally belonged to the
last two groups.
At present, there are simple and
complex systems available for auto
transfusion. The Solcotrans system
(Solco Basle Inc., Rockland, Mass.)
is a simple system composed of
plastic reservoirs containing prede
termined amounts of citrate-phos
phate-dextrose (CPD); the reser
voirs are connected to suctioning
devices, allowing collection of blood
from the operative field. When the
container is full, it is passed from
the operative field to the anesthetist
who infuses the fluid by gravity or
pressure.
Both Sorenson (Sorenson Re
search, Division of Abbott Labora
tories, Salt Lake City, Utah) and
Thoratec9 systems are disposable
suction and collection devices. Ci
trate-phosphate-dextrose, as the an
ticoagulant, and blood are mixed at
the tip of disposable atraumatic
aspiration wands, blood is collected
in disposable plastic containers
which may have external pressure
applied to accelerate reinfusion. It is
difficult in these systems to regu
late the ratio of CPD to blood and
therefore good control of an
ticoagulation is difficult.
Cell washing autotransfusion sys
tems are presently available for clin
ical use. In these, the blood is
aspirated, plasma and red cells are
separated, the red cells are washed
and resuspended and are then rein
fused by gravity. These systems are
more complex and costly but have
been widely used.10'11 Rapid reinfu
sion during the period of highvolume blood loss, as can occur
during aneurysmectomy, is not pos
sible with these systems and there
fore hypotension may occur with its
attendant cardiac risk.
The Bentley autotransfusion de
vice was popularized by Klebanoff
in 1979.12 It is essentially a modi

fied cardiotomy reservoir used with
a roller pump, allowing blood to be
reinfused under pressure. The Bent
ley system has been associated with
a risk of air embolism from the
device. The problem in most of the
reports was that the autotransfu
sion system was not appropriately
attended.1314 Most transfusion de
vices now rely on gravity or exter
nal compression on collapsible con
tainers for reinfusion. The disadvan
tage of this is the inability to auto
transfuse rapidly and thereby avoid
hypotension.
Our device is relatively inexpen
sive and has the capacity to warm
shed blood and to provide rapid
reinfusion. Our device, although de
pendent on a skilled technician, can
deliver scavenged blood at a rate of
up to 500 ml/min. This has proven
invaluable in situations of complex
aortic reconstructions when rapid
volume loss has occurred. The sur
geon can proceed more effectively,
with less haste, knowing that blood
lost is being immediately returned
and that the hemodynamics are sta
ble.
The possible physiologic compli
cations of autotransfusion such as
microemboli, sepsis, free hemoglo
bin and nephrotoxicity resulting
from hemolysis and with coagulopa
thy have been reviewed by Jacobs
and Hsieh.15 Although the clinician
must be aware of these, few prob
lems have been documented with
the autotransfusion systems in use
today.16 Of the measurements we
made, the only significant change
was in the number of platelets (264
X 109/L to 182 X 109/L) and in
the free plasma hemoglobin. The
decrease in platelets appeared to
have no identifiable clinical rele
vance. The rise in free plasma he
moglobin is also of little concern if
the patient’s urine output is suf
ficient to avoid tubular damage.
Our system is particularly advan
tageous to the patients at high

cardiovascular risk, who may have
cardiac disease in addition to their
vascular problems and tolerate peri
ods of hypotension and hypoxia
poorly. The ability of the system to
reinfuse large volumes of warm
blood quickly minimizes the cardio
vascular complications.

Conclusions
The autotransfusion system we
used requires a trained attendant
but has proven to be a safe and
effective means of maintaining a
stable hemodynamic situation in pa
tients who undergo aortic recon
struction even when there is large
volume blood loss. It is particularly
suitable for high-risk patients who
would tolerate volume loss poorly.
Further, the adverse effects of
transfusion of homologous blood
such as the transmission of infec
tious disease, isoimmunization, hy
pocalcemia, acidosis and hypo
thermia can be minimized with the
autotransfusion of shed blood. Up
to 73% of patients could undergo
aortic surgery without the transfu
sion of homologous blood.
We thank F. Burdon, J. Carbonneau
and J.G. Robitaille for the service of the
autotransfuser and M. Grant for help in
preparing the manuscript.
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TECHNIQUES OF PERCUTANEOUS
GASTROSTOMY. Edited by Jeffrey L.
Ponsky. 127 pp. Illust. Igaku-Shoin
Medical Publishers, Inc., New York;
W.B. Saunders Company Canada Lim
ited, Toronto, 1988. $71.50. ISBN
0-89640-139-1.

Since Ponsky’s initial description in
1981, the use of percutaneous endo
scopic gastrostomy has increased great
ly. This text, a collection of 14 brief
chapters, begins with a discussion of
historical perspectives and indications
for gastrostomy. This is followed by a
brief description of the various surgical
gastrostomies, then three chapters de
tailing the different techniques of per
cutaneous endoscopic gastrostomy (the
“pull”, “push” and “introducer” meth
ods).
One chapter details the use of percu
taneous endoscopic gastrostomy in chil
dren, in whom this technique was ini
tially developed. There are chapters on
percutaneous placement of jejunostomies and complications of percutaneous
gastrostomy. In one chapter the nurse’s
role is discussed, and in another the
three techniques of percutaneous endo
scopic gastrostomy placement are com
pared. A cryptic chapter deals with the
technical aspects of tube feeding and
the liquid diets.
There is considerable overlap of in
formation and illustrations in these
chapters. There are a number of typo
graphic errors. Furthermore, the radi
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ologic technique of percutaneous gas
trostomy without endoscopy, which is
also being used widely, is never men
tioned.
This book gives a good coverage of
the percutaneous gastrostomy methods
and will be valuable to surgeon-endo
scopists, residents and gastroenterolo
gists who are just becoming familiar
with this technique. However, the book
is brief, relatively expensive and does
not provide enough new information for
those who have had experience with
this technique as it developed.
Mervyn Deitel, MD, FRCSC
Professor o f Surgery,
Professor o f Nutritional Sciences,
University o f Toronto,
St. Joseph's Health Centre,
Toronto, Ont.

ANORECTAL MALFORMATIONS IN
CHILDREN: UPDATE 1988. Edited by
F. Douglas Stephens and E. Durham
Smith. 604 pp. Illust. Alan R. Liss,
Inc., New York, 1988. $150.00 (US).
ISBN 0-8451-1070-5.

This book has everything you ever
wanted to know about anorectal malfor
mations, and more! It is currently the
definitive textbook on this subject. 1
cannot imagine any pediatric surgeon
being without it or not using it as a
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reference text on this multifaceted, diffi
cult congenital pediatric problem. This
anomaly first appears in the newborn
and is usually a problem for life. It is a
problem that also hangs around the
pediatric surgeon’s neck like the pro
verbial albatross. However, in this text,
we have all the up-to-date theories,
investigations, operations and results,
pro and con, to bring clarity to a
perplexing scene.
The book is aptly dedicated “to all
parents, doctors, nurses, and others
who work to improve the quality of life
for people born with anorectal anoma
lies”. Contributions (the editors state)
were received either as complete chap
ters or as parts of chapters, or were
incorporated into the text of chapters
by the author-collators. The contribu
tors include most of the members of the
1984 Wingspread Workshop, which
was attended by internationally recog
nized authorities in the field. In such a
multiauthored book, all the different
opinions are expressed, and the reader
is then left to accept or reject such
views.
This text is of interest only to work
ers in this field and, for them, the book
is a must!
Sigmund H. Ein, MD, FRCSC, FAAP,
FACS
Division o f General Surgery,
Hospital for Sick Children,
Toronto, Ont.
M5C 1X8
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Internal Carotid Artery Aneurysm and
Marfan’s Syndrome
David A. Latter, MD, FRCSC;* Michael A. Ricci, MD;* R.D.C. Forbes, MD, FRCPC;t
Alan M. Graham, MD, FRCSC*
Aneurysms of the extracranial carotid artery are most commonly caused by
atherosclerosis or trauma but may also have unusual causes, such as Marfan’s
syndrome. Although aneurysmal changes in the extracranial carotid vessels usually
are due to extension of aortic dissection into the carotid system, isolated aneurysms
may occasionally complicate Marfan’s syndrome. The authors report a case of
Marfan’s syndrome in which the patient, a 45-year-old woman, presented with an
asymptomatic mass in the right side of the neck at the level of the carotid
bifurcation. An isolated internal carotid artery aneurysm was identified. The
aneurysm was resected using an interposition vein graft over an outlying shunt.
Histologic examination confirmed the typical cystic medial necrosis with loss of
elastic fibres and an increase of mucoid material in the media. The patient’s recovery
was smooth and at 2-year follow-up there were no signs of recurrent aneurysm
formation.

Les anevrismes de l’artere carotide externe sont le plus souvent causes par
l’atherosclerose ou un traumatisme, mais ils peuvent aussi avoir une cause
inhabituelle comme le syndrome de Marfan. Bien que l’anevrisme de la carotide
externe soit generalement du a l’extension d’une dissection aortique dans le systeme
carotidien, des anevrismes isoles peuvent occasionnellement venir compliquer le
syndrome de Marfan. Les auteurs decrivent un cas de syndrome de Marfan au cours
duquel la patiente, agee de 45 ans, a presente du cote droit du cou, une masse
asymptomatique, au niveau de la bifurcation carotidienne. Un anevrisme isole de la
carotide interne fut identifie. L’anevrisme fut reseque par interposition d’une greffe
veineuse sur une derivation peripherique. L’examen histologique confirma la
necrose kystique typique de la media, avec perte des fibres elastiques et une
augmentation du material muqueux dans la media. La guerison de la patient fut sans
accroc et, a l’examen de controle apres 2 ans, il n’y avait aucun signe de recidive
d’anevrisme.

arfan’s syndrome is an inherit
ed autosomal dominant disor
der of connective tissue. It affects
up to 60 people per million popula
tion.1 It is characterized by defec
tive collagen synthesis leading to
ocular, skeletal and cardiovascular

M

abnormalities. Ocular manifesta
tions include subluxation of the
lens in 50% to 80% of patients.
Skeletal abnormalities are those of
dolichostenomelia (increased limb
length compared with the trunk),
arachnodactyly, joint laxity, scolio

From the departm ent o f Surgery and fDepartment o f Pathology, Royal Victoria Hospital,
McGill University, Montreal, PQ
Accepted for publication Mar. 16. 1989
Reprint requests to: Dr. A.M. Graham, Ste. S8.45, Royal Victoria Hospital, 687 Pine Ave. W,
Montreal, PQ H3A 1A1

sis and high arched palates.1’2 Car
diovascular abnormalities are the
most important since they are the
cause of death in 90% to 100% of
patients with Marfan’s syndrome.3-5
These abnormalities include mitral
and aortic valvular disease, fusiform
ascending aortic aneurysm and aor
tic dissection.3 Although a compre
hensive review3 of Marfan’s syn
drome and its cardiovascular conse
quences failed to discover a single
case of carotid artery aneurysm in
169 patients, isolated carotid aneu
rysms are a rare but recognized
complication.6-7 We describe one
such case in this article.

Case Report

A 45-year-old woman was re
ferred to our vascular service when
a painless swelling in her right neck
was discovered during a routine
check-up. Definite hemispheric neu
rologic symptoms were absent, but
she did complain of an occasional
“cloud-like” blurring of the visual
field of her right eye which lasted a
few seconds and was likely a symp
tom of lens dislocation. She denied
paresthesia, paralysis or loss of
consciousness. She had mitral valve
prolapse and was taking digoxin
and nadolol for supraventricular ta
chyarrythmias. Her family history
revealed that her mother had suf
fered from Marfan’s syndrome and
died at the age of 45 years because
of rupture of an aortic arch dissec
tion.
She was a tall woman with the
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characteristic marfanoid body habi
tus, long slender digits, a high
arched palate and evidence of bilat
eral lens dislocations. Her pulse rate
and blood pressure were normal.
The vascular system was normal on
examination except for the right
side of the neck where a welldemarcated 2 X 2-cm pulsatile mass
was found. There was no associated
bruit or thrill.
Investigations included abdomi
nal ultrasonography, which was
normal, and aortic arch aortogra
phy (Fig. 1). The aortogram re
vealed a saccular aneurysm, 2.5 cm
in dimension, arising from the right
internal carotid artery at its origin
from the common carotid artery.
The left external carotid artery ap
peared to be slightly dilated but was
not frankly aneurysmal. The aortic
arch appeared normal. Under gener
al anesthesia, the right internal ca
rotid artery was exposed by a longi
tudinal incision along the anterior
border of the sternocleidomastoid
muscle. The common carotid, exter
nal carotid and internal carotid ar
teries distal to the aneurysm were
identified and controlled. Grossly,
there was an aneurysm of the inter
nal carotid artery, 2.5 cm in diame
ter, originating at the bifurcation
and extending for 2.5 cm up the
internal artery (Fig. 2). The com
mon carotid, external carotid and
distal internal carotid vessels were
entirely normal. A segment of sa
phenous vein was harvested, sys
temic heparinization was carried
out, the respective arteries were
clamped and the aneurysm was
opened. An internal Inahara-Pruitt
shunt was inserted into the com
mon and internal carotid arteries
with the saphenous vein reversed
and placed over the distal limb of
the shunt, to re-establish blood flow
to the right hemisphere. The distal
anastomosis was fashioned with
running 6-0 Prolene suture. A por
tion of the proximal anastomosis
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was completed similarly, then the
shunt was removed, the arteries
were re-clamped and the proximal
anastomosis was finished. The total
ischemia time was 7 minutes. The
heparin effect was reversed with
protamine sulfate and the wound
was closed in layers. Postoperatively, the patient became conscious
immediately and had no neurologic
deficits. Her postoperative course
was uncomplicated. A duplex scan
of the surgical site 2 years postop-

eratively revealed a patent graft
with no aneurysmal dilatation.
Histologic sections of the aneu
rysm wall showed extensive cystic
medionecrosis with marked medial
elastic fibre fragmentation and dis
solution (Fig. 3), associated with
striking deposition of amorphous
intercellular ground substance and
the presence of prominent cystic
areas (Fig. 4).

Discussion
Patients with Marfan’s syndrome
usually die at an early age, due to
cardiovascular events in 90% to
100% of patients.3 Fusiform aneu
rysms of the ascending aorta with
subsequent aortic insufficiency and
congestive heart failure, dissecting
aortic arch aneurysms and mitral
valve disease are the usual cardio
vascular abnormalities which lead
to death. Rarely, an isolated aneu
rysm of the carotid artery is discov-

FIG. 1. Arch aortogram shows saccular
aneurysm (arrow) of right internal ca
rotid artery.

FIG. 2. Operative view of right inter
nal carotid aneurysm. Large vessel
loops are around internal carotid ar
tery (left) and common carotid artery
(right); smaller, coloured loops sur
round external carotid and large silk
stitch (arrow) marks superior thyroid
artery.
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FIG. 3. Section of aneurysm site show
ing fragmentation and loss of medial
elastic fibres (elastic-van Gieson’s
stain, original magnification X 250).

CAROTID ANEURYSM AND MARFAN’S SYNDROME

ered in a patient with Marfan’s
syndrome.67 In these patients, ca
rotid artery aneurysms usually are a
result of dissection of the aortic
arch extending into the common
carotid artery. Why fusiform as
cending aortic aneurysms occur in
some patients with Marfan’s syn
drome and aortic dissection occurs
in others, appears to be related to
the status of the aortic media. Rob
erts and Honig3 noted that in pa
tients with a fusiform or saccular
aneurysm of the aortic arch, histo
logic analysis of the wall of the
aorta revealed severe cystic medial
necrosis. Conversely, in patients
with aortic arch dissection, there is
minimal or no evidence of cystic
medial necrosis. This coincides with
the pathologic features demonstrat
ed in our patient. The saccular
aneurysm was isolated to the proxi
mal internal carotid artery and had
severe cystic medial degeneration.
Simple, true, dissecting aneu
rysms are not prone to thromboem
bolic complications and can be
treated medically with anticoagula

tion, allowing the port of re-entry to
heal with a minimal risk of
stroke.8-9 Saccular or fusiform aneu
rysms of the carotid artery, howev
er, have an increased risk of throm
bus formation and subsequent em
bolization. The incidence of stroke
in patients with these aneurysms,
regardless of the cause, approaches
50%.9 It is because of this high
stroke rate that surgical treatment
has evolved.
Surgery of carotid artery aneu
rysms dates back to 1808 when Sir
Astley Cooper first successfully
treated a carotid artery aneurysm by
ligation.10 Since then, surgical
treatment has matured greatly with
a marked improvement in results.
Basic principles of carotid artery
surgery must be applied to carotid
aneurysm repair and a special effort
made to minimize handling of the
aneurysm to avoid embolization.
Adequate proximal and distal con
trol is necessary, and cerebral pro
tection must be assured. Autoge
nous vein is the material of choice
for the interposition graft. Because

of the more extensive tissue dissec
tion with a carotid aneurysm, local
anesthesia is not advocated. The
best method to monitor cerebral
ischemia under general anesthesia
is continuous electroencephalographic monitoring with subse
quent selective shunting.6 If this is
not possible, then a carotid shunt
should be used routinely.11
A useful technique is to place the
vein graft over the distal end of the
shunt before shunt placement. This
allows the surgeon to do the distal
anastomosis and part of the proxi
mal anastomosis with an in-lying
shunt. The shunt can then be re
moved to allow completion of the
proximal anastomosis with minimal
ischemia time. This technique al
lows the surgeon to work with
good cerebral protection and at a
relaxed pace to assure technical
perfection.
Carotid artery aneurysms can be
complex and their treatment must
be individualized,12 but by adhering
to basic principles and using the
expanded knowledge gained from
cases like this one, we will be able
to treat these serious problems with
a morbidity and mortality similar to
that of elective carotid endarterecto
my.
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NOTICES
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International Conference on
Gallstones
An international conference on gall
stones and their management is to be
held in Jerusalem from Feb. 2 5 to Feb
2 8 , 199 0 . The conference will cover
diverse aspects of gallstone disease;
epidemiology, natural history, patho
genesis, biliary imaging, motility and
particularly new therapeutic modalities,
such as shock-wave lithotripsy, direct
dissolution of gallstones, medical disso
lution and endoscopic management.
The role of surgery and the long-term
problems of recurrence and prevention
will also be discussed. The organizing
committee comprises T. Gilat and S.
Bar Meir from Israel, J. Geenan and W.
Hogan from the United States, M. Clas
sen from Germany and H. Dowling from
the United Kingdom. For further infor
mation contact; Gallstone Conference,
Vered Congress, 15 Weizman St., Nes
Ziona 7 0 4 0 0 , Israel; tel: 0 8 -4 0 0 7 7 7 , 8,
9; 4 0 0 5 6 2 ; telex: 3 8 1 3 6 1 VERED IL;
fax: 9 7 2 -8 -4 0 4 1 4 2 .
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Lederle Surgical
Infectious Diseases
Fellowship
Purpose

To support research in the broad area of
surgical infections including critical care,
metabolism, and nutrition as they relate to
the septic surgical patient.
Successful applicants in 1989/90

Lederle congratulates the two recipients of
last year’s fellowship.
Dr. Bill Fragiskos researching under
Dr. M urray Girotti at the Toronto G eneral
Hospital. This project relates to non-specific
host defenses in subjects with anergic
response to skin test antigens.
Dr. Tellado-R odriguez researching under
Dr. N icolas Christou at McGill University.
This project will investigate specific immu
nological changes in patients suffering
from blunt trauma.
These research projects will contribute
to the rapidly growing understanding
o f the com plexities of host defenses in
resisting disease.
Applications are invited for 1990/91

Applications are invited for two fellowships,
carrying a grant of $15,000 for one year
to support a Canadian surgical trainee
working in a Canadian laboratory.
The fellowship, which starts on
July 1st, 1990, is offered by Lederle
Laboratories in co-operation
with the Canadian Association
of General Surgeons.
Inquiries and applications
should be sent to:
Dr. John Duff, Chairman, Projects Committee
of tlie Canadian Suigical Research Fund
Canadian Association of General Surgeons
University of Western Ontario
339 Windennere Rd, Box 5339
London, Ontario N6A 5A5

ORIGINAL ARTICLES

Objective Comparison of Manual
Dexterity in Physicians and Surgeons
D. Squire, MD;* A.A. Giachino, MD, FRCSC;* A.W. Profitt, MD, FRCSC;t C. Heaney, OTJ
Recent interest in the assessment of manual dexterity of surgical residency
applicants prompted an investigation of psychomotor skills in surgeons and
physicians. The Purdue Pegboard and Minnesota Manual Dexterity tests were given
to 57 subjects. Analysis of the data revealed no significant difference in
dexterity between medical and surgical residents, suggesting that medical students
do not select specialty training programs because of the presence or absence of
manual skills. The data also revealed that surgical staffmen performed substantially
worse than those in the other groups on some of the tests, possibly because of an
older average age. The authors conclude from their data that manual dexterity tests
should not be used in assessing candidates for surgical residency training positions.
L’interet recent pour revaluation de la dexterite manuelle des candidats a residence
en chirurgie est a l’origine de cette etude portant sur les aptitudes psychomotrices
des chirurgiens et medecins. Le panneau alveole Purdue et l’epreuve de dexterite
manuelle Minnesota ont ete utilises pour tester 57 sujets. L’analyse des resultats n’a
revele aucune difference d’aptitude entre les residents de medecine et ceux de
chirurgie, ce qui indique que les etudiants ne choisissent pas leur programme de
formation de speciality en fonction de la presence ou de l’absence de dexterite
manuelle. Les donnees revelent egalement que les chirurgiens ont ete sensiblement
pires que les autre groupes dans l’execution de certains tests, possiblement parce
que leur age moyen etait plus eleve. Les auteurs concluent de ces resultats que les
epreuves de dexterite manuelle ne devraient pas etre utilisees pour evaluer les
candidats aux postes de residents en chirurgie.
increasing competition for
W ithresidency
training positions,

selection committees are striving to
identify methods of choosing the
most appropriate candidates. It is
often assumed that a surgeon has

special manual skills and that surgi
cal results are directly related to
manual dexterity. Therefore, as an
adjunct to the usual selection proc
ess, several programs1 have begun
assessing the manual skill of appli
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cants. We question the validity of
this concept, and in this study we
compared the manual dexterity of
physicians and surgeons, including
residents and attending staff. We
attempted to answer the following
questions:
• Is there a difference in manual
dexterity between physicians and
surgeons?
• Is surgical skill primarily de
termined by manual dexterity?
• Do medical students select
specialties according to their skills?
• Is it reasonable to skill-test
surgical residency applicants?

Methods and Study Population
Two standardized tests of hand
function, the Purdue Pegboard Test
(Fig. 1) and the Minnesota Manual
Dexterity Test were used to assess
the subjects. The Purdue Pegboard
consists of four subtests, each
scored separately, plus a fifth de
rived score. Each hand is tested
separately, then both hands togeth
er and finally a simple assembly of
small objects is performed. Each
test has a specific time limit and the
score relates to the number of tasks
performed in that time. The fifth,
derived score is a sum of the first
three (right hand, left hand, both
hands).
The Minnesota Manual Dexterity
Test has two parts: a turning test
(Fig. 2) and a placing test (Fig. 3).
In the turning test, a subject is
timed as he turns two coloured

CJS, VOL. 32, NO. 6, N O V E M B E R 1989

467

SQUIRE, ET AL.

discs and reinserts them into appro
priate holes. In the placing test, the
subject reinserts each disc into its
appropriate hole. Each test is timed
and performed five times. The first
result is discarded as a practice and
the remaining four are summed to
give a cumulative score in seconds.
Twenty-six surgical residents, 18
medical residents, 7 attending sur
geons and 6 attending physicians
participated in the study (Table I).
The ages of the medical and surgi
cal residents were similar while the
surgical staff were slightly older
than the medical staff. The data
were analysed using a one-way anal
ysis of variance, and modified f-tests
where applicable.

Results
Purdue Pegboard

The results of testing the domi
nant hand, the nondominant hand
and both hands together showed
that there was no significant differ
ence between medical and surgical
residents; the surgical staffmen’s
scores were significantly (p < 0.01)
lower than those of the other three
groups. No groups bettered the
average score of 10 000 American
assembly workers2 (Figs. 4 to 6).
When the entire medical group
was compared to the entire surgical
group no significant difference in
scores was noted.
The assembly subtest (Fig. 7)
again showed no difference between
the two groups of residents. Both
the medical and surgical staff had
lower scores but were not signifi
cantly different from each other.

FIG. 2. Minnesota Manual Dexterity Test: turning test.

Minnesota Manual Dexterity Test

The two groups of residents re
ceived nearly identical scores (96%)
on the turning test and the medical
staff excelled with a 99 percentile
468

FIG. 3. Minnesota Manual Dexterity Test: placing test.
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placing test (Fig. 9) gave similar
results to the assembly subtest of
the Purdue Pegboard (Fig. 7). The

result, but the surgical staff per
formed worst of all with a 77
percentile average (Fig. 8). The

residents were grouped around one
mean and did better than the staff
who recorded poorer scores but
were similar to each other.

Table I. Participants
Surgeons

Physicians

No. of subjects
Mean age, yr

Residents

Staff

Residents

Staff

18
28

6
42

26
29

7
46

Discussion
Since its original design, the P u r
due Pegboard has been extensively

NUMBER OF PEQS

RESIDENTS

FIG. 4. Results of Purdue Pegboard Test using dominant
hand. Norm. = average score of 10 000 American assembly
workers.2

STAFF

RESIDENTS

STAFF

NORM.

FIG. 5. Results of Purdue Pegboard Test using nondominant
hand.
NUMBER OF PIECES

!

RESIDENTS

STAFF

RESIDENTS

STAFF
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FIG. 7. Results of Purdue Pegboard, assembly test.
FIG. 6. Results of Purdue Pegboard Test using both hands.
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55555555555555555

R ESID ENTS

FIG. 8. Minnesota Manual Dexterity Test. Results of turning
test.

S TA F F

RESIDENTS

STAFF

FIG. 9. Minnesota Manual Dexterity Test. Results of placing
test.
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investigated and found to measure
“the ability to make rapid con
trolled manipulative movements of
small objects where the fingers are
primarily involved’’.2 In addition,
the assembly subtest measures “the
ability to make skillful controlled
arm-hand movements of large ob
jects” .2
The Minnesota Manual Dexterity
Test was designed to measure na
tive speed capacity of simple but
rapid eye-hand coordination.3 The
hand and wrist are primarily used in
the turning test, and the placing
test assesses large scale movements
involving the elbow and shoulder.
The assembly subtest of the Purdue
Pegboard and the placing test of
the Minnesota Manual Dexterity
Test measure similar capabilities.
Recognizing the validity of these
tests, we now return to the original
four questions.
• Is there a difference in the
manual dexterity of physicians and
surgeons? With the exception of
the turning test of the Minnesota
Manual Dexterity Test, all tests
showed no difference when the en
tire medical group was compared to
the entire surgical group. The rela
tively poor performance of the sur
gical staff on some tests was unex
pected. If this was a valid observa
tion then the concept that manual
dexterity is paramount for success
in surgery is unfounded. The poorer
performance may have been a sam
pling error due to the small number
of the group or related to the
slightly older average age of the
surgical staff.
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• Is surgical skill determined
primarily by manual dexterity?
Since a group with no surgical
skills (physicians) had manual dex
terity ratings equivalent to those of
their surgical colleagues, manual
dexterity is not the primary determi
nant of surgical skills. In 1984,
Schueneman and colleagues1 stud
ied 120 general surgical residents
and attempted to correlate a subjec
tive assessment of operative skills
with various tests of neuropsychologic ability. They concluded
that “pure psychomotor skill is not
the major dimension in distinguish
ing the proficient surgical perfor
mance from the mediocre”.
• Do medical students select
specialties according to their skills?
This does not appear to be the case,
otherwise the two groups of resi
dents would have shown some dif
ference in the test results. For many
years, dental schools used skill tests
in an attempt to correlate manual
dexterity with technical success in
the profession. The chalk carving
test, generally adopted by dental
schools for the assessment of psy
chomotor skills in 1949, has been
abandoned in favour of a paper and
pencil perceptual motor ability test,1
which is at least as good, or better,
a predictor of future technical
grades.45 Debate continues about
the reliability and predictive capaci
ty of these two tests,4-8 and, after
years of use, there is still no clear
conclusion.
• Is it reasonable to skill-test
surgical residency applicants? We
believe our study indicates that
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medical students who become sur
geons do not possess a higher level
of manual dexterity than those who
choose medicine, and that factors
other than simple manual ability
differentiate the proficient surgeon
from the mediocre. From our re
sults we cannot advocate the use of
skill tests in assessing applicants
for surgical residency programs.
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T h e Life and Times of Guillaume
Dupuytren
P. Wylock, MD
Guillaume Dupuytren’s good fortune was the time of his birth. He was a product of
revolutionary change in France, and without it he would never have become a
surgeon. From south central France he came to Paris to become a surgeon and
reached his goal, literally, “on a crust of bread”. Dupuytren is remembered
principally for the hand condition which bears his name; his other numerous and
more-important contributions have been ignored. Never happy outside the operating
room — or perhaps inside it either, due to his mania for perfection — this arrogant
master surgeon constantly clashed with his colleagues, staff and the few friends he
had. When he died at the age of 57 years, he had advanced surgery on many
frontiers.

Guillaume Dupuytren beneficia de l’epoque de sa naissance. Ne avec les bouleversements de la Revolution frangaise, il n’aurait jamais pu devenir chirurgien sans eux.
Venant du centre sud de la France, il arriva a Paris pour devenir chirurgien et il y
parvint malgre le plus grand denuement. On se rappelle surtout de Dupuytren pour
l’affection de la main qui porte son nom; ses contributions nombreuses et plus
importantes ont ete ignorees. Il n’etait jamais heureux hors de la salle d’operation et
peut-etre pas davantage quand il etait dans son enceinte. A cause de sa manie de la
perfection, cet arrogant mattre-chirurgien se disputait constamment avec ses
colleges, le personnel et le peu d’amis qu’il avait. A son deces, a Page de 57 ans, il
avait fait avancer la chirurgie sur plusiers fronts.

C

ontracture of the fingers and
the palm was described in the
early 17th century by Plater, a
professor at Basel University. He
was convinced that the manual ac
tivities of one of his patients — a
sculptor — had caused the flexor
tendons to shrivel up after they had
come loose from their connections
deep in the palm.1 The same phe-

nomenon was diagnosed in the 18th
century by Astley Cooper and Alex
is Boyer, among others. They both
considered this disease incurable.
Yet in the 19th century three fac
tors presented the anatomist and
surgeon Guillaume Dupuytren with
an opportunity to have his name
immortalized.2-3
• On Dec. 5, 1831, he started
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his anatomy course by saying that
he would only discuss one patient
and one disease. The patient was a
40-year-old coachman named Demarteau.
• He described the symptoms of
this disorder in a present-day man
ner. During the course, he demon
strated a dissection of an old man’s
hand, affected by a contracture, and
proved that this deformation was
caused neither by the tendons nor
by the skin, but by a retraction of
the palmar aponeurosis.
• After this clinical and anatom
ical demonstration, he went on to
discuss another patient upon whom
he had carried out a surgical correc
tion. He had been observing this
patient since 1811; his contracture
had evolved in such a way that
Dupuytren decided to operate,
which he did on June 12, 1831,
without using anesthetics. He made
a transverse incision approximately
3 cm long at the midpalmar fold,
fifth ray, then a second incision at
the proximal interphalangeal fold
and a third at the base of the
proximal phalanx. The incision of
the palmar aponeurosis was accom
panied by a “clearly audible crack”.
The fingers were straightened and a
bandage was applied. Healing was
complete by July 2, and an exten
sion splint was applied until Aug.
2 . 4 -7

To conclude that historic day in
December 1831, he operated on the
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hand of Jean Joseph Demarteau,
who was neither a coachman nor
the first patient he had treated for
contracture.3-8

The Life Story of Guillaume
Dupuytren
In that rich period of French
medicine, the era of Larrey, Roux,
Delpech, Bichat and Laennec, Du
puytren was the most ambitious,
the most aggressive and the most
talented, maybe as a consequence of
his “relatively” humble origin. He
was born in 1777, the son of a
not-particularly well-off lawyer. In
1789, at the age of 12 years, he
was taken to Paris to finish his
studies. His family had a few sur
geons in its ranks, hence his voca
tion. In the 17th century a Michel
Dupuytren had lived in Pierre-Buffiere, where he worked as a surgeon
and at the same time kept a tobacco
shop. Guillaume’s grandfather,
Francois Dupuytren, had practised
in the same town in 1759.
As a result of the fundamental
changes brought about by the
French Revolution, Guillaume had
the opportunity to develop himself.
He embarked on his medical studies
and soon became an authority on
anatomy.
At the age of 18 years, he suc
cessfully passed the examination for
prosector. Authorities such as Chopart, Percy, Sabatier, Boyer and
Desault were members of the exam
ining board. He was put in charge
of all autopsies at the famous Hotel
Dieu hospital in Paris, where he
performed almost 1000 autopsies
annually. He became so competent
that he was exempted from military
service.
The Hotel Dieu hospital was situ
ated on both banks of the River
Seine, near the Notre Dame cathe
dral. A hospital ward was built on
the bridge linking the hospital
474

buildings. In those days the hospital
had 1600 beds available but, in a
period when anesthetics and an
tiseptics were nonexistent, the
death rate inevitably was very high.
In this period Dupuytren suffered
much hardship, so much so that the
oil he needed to keep his lantern
burning had to be prepared from
the fat of corpses.
In 1801, at the age of 24 years,
he became head of the anatomy
department, and the following year
he was appointed surgeon, second
class. He became a doctor in medi
cine in 1803. His thesis “Proposi
tions sur quelques points d’anatomie, de physiologie et d ’anatomie
pathologique” was dedicated to
Boyer. He was the founder in 1803
of the “Societe Anatomique”. In
1808, he obtained the prestigious
appointment as member of the sur
gical staff at the Hotel Dieu hospi
tal.
In 1811 the position of professor
of operative medicine became va
cant. Dupuytren applied, together
with three others — Roux, Marjolin
and Tartra. The theoretical and
practical examinations were ex
tremely difficult. After fierce com
petition, Dupuytren won, and on
Feb. 10, 1812 he was appointed to
the position. His thesis on lithoto
my was considered a masterpiece.
In 1815, at the age of 38, he
became chief surgeon at the Hotel
Dieu hospital, the highest surgical
appointment in France. Dupuytren
performed his duty with honour,
thanks to his superior qualities, up
until he died, in 1835, from a lung
empyema resulting from tuberculo
sis. Whilst Cruveilhier, Bouillaud
and Broussais were discussing
whether or not to drain this empy
ema, Dupuytren himself held the
opinion that it was better to die
from the disease than from the
operation.
Fellow surgeons and students
from all over France gathered to

CIS, VOL. 32, NO. 6, NOVEMBER 1989

pay their last respects to him. His
students carried his coffin to his
final resting place in the Pere Lachaise cemetery as an ultimate
homage to their master.9-10

Who Was Dupuytren?
Dupuytren had a noble and strik
ing physique. He was a sturdy,
solidly built man with a big head.
On lithographs he is depicted as
having a fine nose, a small mouth,
which made him the target of ridi
cule, dark penetrating eyes and a
thick neck. He wore a lace collar, a
waistcoat and a coat, the fashion of
the day (Fig. 1).
Apparently, he was an arrogant
and eccentric man, but he had the
“gift of the gab” and he worked
hard. According to one of his pu
pils, he would stride through the
corridors like a “god on earth”,
pontificating and oblivious to the
people around him. He enforced his
authority by his sheer presence;
everyone respected him and there

FIG. 1. Guillaume Dupuytren (17771835). (Reproduced from Delhoume L:
Dupuytren (1777-1835), J.B. Bailliere
et Fils, Paris, 1935.)

GUILLAUME DUPUYTREN

would be a solemn silence whenever
the master spoke. “Je me suis

trompe quelques fois, mais je crois
m ’etre trompe moins que Ies
autres” (“I made some mistakes,
but I think less than the others”)
are famous words of Dupuytren.
As with so many geniuses, Du
puytren was an awkward person,
both toward his assistants and his
patients, except children whom he
liked very much. He was aggressive
and insolent, probably out of self
protection, as he feared that his
reputation might be threatened by
others.
He was not averse to intrigue or
to ignoring other people’s work,
nor did he have any qualms about
plagiarizing. An early example of
this was when he broke with one of
his pupils, Rene Laennec, who ac
cused him of being too self-cen
tred.11 Rene Laennec would later
invent the stethoscope. All this was
quite harmless compared with the
way he would manipulate his teach
ers Boyer and Pelletan to further
his personal ambitions. He managed
to make Boyer his lifelong enemy
by breaking off his engagement to
Boyer’s daughter on the day before
they were due to marry, Jan. 25,
1810. Later he did marry and had
one child, Adeline, but the marriage
broke up in 1826. Boyer’s daughter
later married Dr. Roux, Dupuytren's rival, not only in surgery but
also in love. Roux eventually suc
ceeded Dupuytren as chief surgeon.

whom he was very rude. When he
came to a bed he would start shout
ing at the patient, sometimes grab
bing the poor man by the nose and
forcing him to sit on his knees
before he was allowed to voice his
complaints. (His assistants could
judge by his mood whether he had
won or lost money during the previ
ous night’s gambling.)
At 9:00 the clinical lessons start
ed. They usually lasted 1 hour.
There followed clinical demonstra
tions, which were often combined
with anatomical demonstrations,
the operating schedule being start
ed in the same hall. In the after
noon, Dupuytren had his private
practice which allowed him to earn
a fortune. He made acquaintance
with some members of the nobility,
among them Baron de Rothschild
and Madame de Lavalette who be
came his mistress. Every evening of
the week for 20 years he insisted on
visiting the new patients and those
recently operated on.
In 1818, at the age of 40 years,
Dupuytren performed 378 opera
tions, reduced 178 fractures and
opened up 300 abscesses. In that
year some 2363 patients were ad
mitted to hospital and of the 378
patients he operated on, 228 recov
ered. These are indeed impressive
figures, especially in a period when
anesthesia and antiseptics were un
known.

Dupuytren’s Work
Dupuytren’s Daily Schedule
Every day, before breakfast, Du
puytren did his rounds of the
wards, at 7:00 in the winter and 1
hour earlier in summer. A bell was
rung to announce his arrival, and
he was met by the matron, “La
Superieure”. Surrounded by his as
sistants, students and foreign
guests, he visited his patients, to

Dupuytren was not only known
for his description of palmar fi
bromatosis. He was a highly re
spected anatomist, pathologist and
physiologist. He is known as the
most brilliant surgeon in the period
before antiseptics and anesthesia
were discovered. Moreover, he was
a competent teacher.12
He was well known for his treat
ment of bone cysts, aneurysms and

fractures. The bimalleolar ankle
fracture is also referred to as Du
puytren’s fracture. He performed
mandibular resection for a sarcoma
in 1812. He treated aneurysms by
compression and performed a sec
tion of the sternocleidomastoid
muscle for torticollis. He success
fully ligated the external iliac artery
and subclavian artery. He also per
formed cataract operations, lithoto
mies and artificial anal reconstruc
tions.13
Although he has often been ac
cused of plagiarism, Dupuytren did
make some clever observations; 30
years (in 1831) before Langer, he
described the directions of the lines
of the skin and their meaning, and
Langer later acknowledged this.14
He also gave a detailed description
of the anatomy of the facial and
phrenic nerves. He classified burns
into six different categories, and he
advised treatment with silver nitrate
solution (130 years before Moyer).15
Dupuytren also treated hernias.
Nevertheless, we had to wait until
anesthetics and antiseptics were dis
covered before careful anatomic re
covery could be accomplished as it
is today. Before that, hernia repair
had to be carried out swiftly be
cause of the pain; moreover, it was
a dangerous operation because sep
sis occurred frequently. For this
reason, only major hernias were
treated, and in these cases the ana
tomical proportions were usually
completely distorted. A major liga
tion was usually performed on the
hernial sac. A visitor once observed
how even Dupuytren cut into the
bowel at the original skin incision
during two subsequent demonstra
tions. Dupuytren also misjudged
the frequent death of young adults
as a result of peritonitis. He
thought the problem was at the
cecum rather than at the appendix.
His experience with the injured
of the Napoleonic Wars and the
Revolution of 1830 led him to write
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with authority about trauma.1617
Dupuytren did not write much
during his lifetime. His lecture
notes come to us courtesy of his
students and were edited as “legons
orales”.

Contributions to Plastic
Surgery
Dupuytren’s comments and con
tributions to plastic surgery came
from his broad directions in general
surgery rather than from a specific
inclination toward reconstructive
surgery.1317
He performed cleft lip operations,
but had problems with the premax
illa in bilateral cleft lip patients. He
showed the same impatience with
the projecting premaxilla that he
did with a troublesome patient.18 He
performed columella reconstruction
with a lip flap and reductions of
fractures of the zygomatic bone.

France During the Life of
Dupuytren
Dupuytren lived through a period
of tremendous upheaval in France.
At the time of his birth, Louis XVI
(1754-1793) was still in power.
The French Revolution and the
storming of the Bastille on July 14,
1789 was a milestone in French
history. The States-General deposed
the king and declared themselves
the constitutional legislators. The
feudal system came to an end and
was replaced by a bourgeois democ
racy. Medical colleges were freed
from scholasticism and archaic prin
ciples. “ Practical” medicine was ad
vocated instead of “theoretical”
medicine. Education was ap
proached clinically. For the first
time, the medical colleges were
opened to poorer students wanting
to study medicine.
“Liberte, egalite, fraternite” were
no idle words. Dupuytren was lucky
476

to have been born just before that
period. He was an exponent of the
revolutionary changes which had
taken place in France and without
which he never could have become
a physician.19
In 1792, Louis XVI was deposed
and a republic was established. The
struggle between the Jacobins and
the Girondins was at its fiercest.
During that period the civil mar
riage was introduced as separate
from the church marriage.
Louis XVI was decapitated in
1793, and his wife Marie-Antoinette
suffered the same fate some 10
months later. This period was domi
nated by the reign of terror con
ducted by Robespierre, and it was
the heyday of the guillotine. In
1795, a “Directoire” of five direc
tors was installed. The Southern
Netherlands were annexed by
France.
In 1799, Napoleon Bonaparte
seized power in a coup and became
a consul. In 1804, he had himself
crowned emperor and embarked on
his campaigns of conquest. In
1812, the Russian campaign was
conducted and Moscow besieged.
But the retreat of his “grande armee” was a disaster. After Napo
leon was exiled to Elba in 1814,
Louis XVIII, brother of Louis XVI,
became king of France. At the
Congress of Vienna, in 1815, Bel
gium and the Netherlands were
united into one kingdom under Wil
liam I.
Yet Napoleon returned for 100
days. He deposed Louis XVIII and
gathered a new army but was deci
sively defeated at the Battle of
Waterloo (on June 18, 1815).
Louis XVIII returned to power, to
be succeeded in 1825 by King
Charles X who attempted to re
establish absolute monarchy. After
the revolution in Paris in July 1830,
Charles X was forced to abdicate in
favour of the bourgeois king, Louis
Philippe d’Orleans.
The real aim of the French Revo

CJS, VOL. 32, NO. 6, NOVEMBER 1989

lution of 1789 was in fact not
realized until 1830.
At that time Dupuytren was the
court physician to Charles X, and
he gave the exiled king financial
support which amounted to 1 mil
lion francs, a fortune in those days.

Dupuytren’s Students and
Influence
Dupuytren had pupils from all
over Europe, even from the United
States. Medicine in France was in
full bloom. The ground that had
been lost in the 18th century was
quickly regained during the 19th
century, and French medicine had a
great influence on European medi
cal science. There was Corvisart,
who rediscovered percussion; Bi
chat, who established that our or
gans are made up of tissue; Laennec, who discovered auscultation;
Magendie, who pointed out that
physiologic tests formed the corner
stone of research and Claude Ber
nard, who introduced determinism
as the basis of biologic and physio
logic research.
Apart from Dupuytren there were
other talented French surgeons like
Velpeau, Malgaigne and Nelaton.
Comhere and Michaud are perhaps
the best known Belgian pupils of
Dupuytren.
What is not so well known is that
Dupuytren’s fame had reached as
far as the United States.2021 On the
east coast the flourishing towns of
Boston, New York, Philadelphia
and Charleston were important
trading centres. The gigantic fleet
of packet boats, great three-mast
sailing ships which established a
regular connection between the old
and new worlds contributed to this.
Surgeons like J.C. Warren (17781855) and his son J.M. Warren
(1811-1857) were pupils of Du
puytren. They were both professors
of surgical science at Harvard Uni
versity. Along with other brilliant
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surgeons, they stood out at the
beginning of a new and successful
era in American medicine.

Conclusions
Guillaume Dupuytren was cer
tainly not liked, but he was respect
ed and admired by his colleagues as
the “ Napoleon” of French surgical
science. He was both coarse and
intriguing. Baron Pierre Percy
(1754-1825), an eminent military
surgeon, described him as “the first
of surgeons and least of men” .
Jacques Lisfranc (1790-1847), sur
geon at the La Pitre hospital, called
Dupuytren the brigand of the Hotel
Dieu. The patients were terrified in
his presence, yet at the same time
they venerated him as a deity. The
respect he got when he said in a
cold manner “ I will cure you” was
indescribable.
He remained cool-headed and
calm when a patient died on the
operating table, and when he felt
that his time had come, he wished
to die in the hands of God, without
surgical treatment. Right up to the
end he did not tolerate any competi
tion.
Dupuytren was a controversial
figure whose mottoes were: “riert
n ’est tant a redouter pour un
homme que la mediocrite” (“noth
ing save mediocrity is to be feared”)
and “peu lire, beaucoup voir, beaucoup faire” (“read little, see much,
do much”).22
I gratefully acknowledge the assistance
of Dr. Stan Monstrey.
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Canadian Association of General Surgeons
Resident Research Award
The Canadian Fund for the Advancement of General Surgery will award a prize to
the resident in general surgery submitting the best research paper.

Prize
1) Return Airfare, hotel expenses, and a per-diem allowance to present the work
at the Annual Meeting of the Canadian Association of General Surgeons to
be held in conjunction with the Annual Meeting of the Royal College of
Physicians and Surgeons of Canada, Toronto, Ont., Sept. 14-17, 1990.
2) $500.

Eligibility
Any resident or fellow in general surgery. The research must have been performed
during surgical training at a Canadian medical school.

Abstract and Brief Description
An abstract must be submitted to the Royal College, but CAGS must be
designated as the first choice for presentation. The abstract must be
accompanied by a brief expanded description of the work performed. This
should be a maximum of two double-spaced pages and include the following
headings: Title, Introduction, Materials and Methods, Results and Discussion.
Applicants must also submit a letter confirming their status as a resident or fellow
and indicating that the work is submitted for the resident research award
competition.

Deadline
1. P later F: Observationum in hominis
affectibus plerisque, corpori et animo,
functionum iaesione, dolore. aliave molestia et vitio incommodantibus, libri
tres. Basil, 1614: 140
2. Hueston JT: Baron Dupuytren. Med J
Aust 1960; 47: 808-812
3. Idem: Dupuytren and his contracture. In

Mar. 9, 1990.

Inquiries should be addressed to:
Dr. Gerald M. Fried
Chairman, CAGS Research Committee
Montreal General Hospital
1650 Cedar Avenue, # 9863
Montreal, Quebec H3G 1A4
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CLASSIFIED ADVERTISING

As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The deadline is 1
month before issue date. Regular classified rates (for each insertion): $45.00 for the first 40 words or less, additional words 60p each
(additional $17.00 for frame). Special Display under 100 words, 2'/4 in. X 2 in., $110.00. $6.00 charge (first insertion only) for CJS box
numbers. Display rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
VASCULAR SURGEON: MB - Applications
are invited for the geographic full-time posi
tion o f Vascular Surgeon, Department of Sur
gery, University of Manitoba and Health Sci
ences Centre. Candidates must have senior
specialty qualifications in vascular surgery in
the country of current practice and must be
eligible fo r registration with the College of
Physicians and Surgeons of Manitoba. Certifi
cation in vascular surgery by the Royal Col
lege of Physicians and Surgeons of Canada is
preferred. Preference will be given to candi
dates w ith training in, and a major commit
ment to , research. Salary and academic rank
will be commensurate with experience and
qualifications. Both men and women are en
couraged to apply. In accordance with Cana
dian immigration requirements, this advertise
ment is directed to Canadian citizens and
permanent residents. Interested candidates
should apply in writing, enclosing a curriculum
vitae, to: Dr. R.J.W. Blanchard, Professor
and Head, Department of Surgery, Health
Sciences Centre, G C 401-820 Sherbrook
St., Winnipeg, MB Canada R3A 1 R9.
—S 8 9 - 4 2

CLINICAL BURN FELLOWSHIP: ON - A
12-month clinical burn fellowship is available
at the Toronto Regional Adult Burn Centre, at
the Wellesley Hospital, beginning July 1,
1990. The unit is a very well-staffed, new,
ultra-modern, self-contained burn centre, with
110 adult patients per year. Position totally
funded. Clinical research available. Extensive
research funding in place. Please contact: Dr.
Walter Peters, Suite 224, Turner Wing,
Wellesley Hospital, 160 Wellesley St. E.,
Toronto, ON M 4Y 1J3. Tel: (416)
9 2 6-7790.
-S 8 9 -3 7

county of Lambton catchment area has a total
population of 120 000. Superior recreation
facilities for persons who enjoy sailing and
other water sports, golf and curling, etc., are
available. For further information call or write
to: K.E. Dickie, MD, FRCSC, Chief of Sur
gery, Sarnia General Hospital. 220 N. Mitton St., Sarnia, ON N7T 6H6. Tel: (519)
3 3 2 -0 2 1 0 (office), or P.N. Mehta, MD,
FRCSC, Chief of Surgery. St. Joseph's
Hospital, 2 90 N. Russell St., Sarnia, ON
N7T 6S3. Tel: (519) 336 -7 8 6 0 (office).

GENERAL SURGEON: ON - Excellent op
portunity exists in Sarnia/Lambton County to
develop a lucrative private practice covering
the full scope of general surgery. The Sarnia
hospitals provide a total of over 350 active
care beds with above-average support ser
vices. An interest in trauma surgery would be
useful in connection with patients admitted to
the Sarnia General Hospital Level II Emergency
Trauma Program. The city of Sarnia and

TRANSPLANT FELLOWSHIP, UNIVERSI
TY HOSPITAL, LONDON: ON - University
Hospital, London, Ontario has three openings
for fellows in multi-organ transplantation,
starting July 1, 1990. Our 2-year fellowship
program includes experience in clinical and
experimental transplantation. We expect to
perform 40-50 heart, heart-lung and lung
transplants; 70 liver transplants: 80 kidney
transplants and 5 bowel transplants in 1990.
Candidates who have completed their training

HEAD OF PEDIATRIC ORTHOPEDICS
British Columbia Children’s Hospital/
University of British Columbia
Vancouver
British Columbia, Canada
British Columbia Children’s Hospital, a 240-bed ter
tiary, multi-disciplinary and acute care hospital, serving
a population of between 2-1/2 to 3 million people, fully
affiliated with the University of British Columbia, Facul
ty of Medicine, requires a Head for the Pediatric
Orthopedic Department. The current Department of
Pediatric Orthopedics comprises four pediatric ortho
pedic surgeons, who are committed to maintaining a
high standard of teaching for undergraduate medical
students and residents in orthopedics as well as other
specialties.
The successful candidate will have an FRCSC or
equivalent; be eligible to practise medicine in British
Columbia; will be recognized as a skilled surgeon and
an outstanding teacher; will have superior leadership
qualities and planning abilities with previous ex
perience in a senior administrative position; and will
maintain an active interest in clinical and laboratory
research.
Interested candidates should forward their curriculum
vitae to:
Hjalmar W. Johnson, MD, FRCSC
Acting Head
Division of Urology, Department of Surgery
University of British Columbia
c/o Room 1L7, B.C. Children’s Hospital
4480 Oak Street, Vancouver, BC
V6H 3V4
S 8 9 -3 9
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CAMP HILL
MEDICAL

CENTRE

ChiEF
department of

SURGERY

C am p Hill Hospital • Halifax Infirmary Hospital

Camp Hill Medical Centre, a 750-bed facility providing community, regional
and provincial referral services, invites applications for the position of
Chief of Surgery. The Centre represents the recent consolidation of Camp
Hill and Halifax Infirmary Hospitals.
The combined Department of Surgery includes 17 surgeons providing
general, thoracic, vascular, or orthopedic and plastic surgery and four oral
surgeons comprising the Division of Dentistry, Oral and Maxillofacial
Surgery. A total of 150 active treatment beds are located on the two sites.
The Department is affiliated with teaching programs at Dalhousie
University.
The Chief of Surgery will be responsible for providing academic and
clinical leadership in the Department, developing programs at both
h o s p ita ls , and p a rtic ip a tin g in p la n n in g fo r a new 5 4 0 -b e d
acute care facility.
The successful candidate will have an FRCSC, be eligible to practise
medicine in Nova Scotia, be recognized as a skilled surgeon and teacher,
have superior leadership qualities and planning abilities and have previous
experience in an administrative position.
In a cco rd a n ce w ith C a n a d ia n im m ig ra tio n re q u ire m e n ts, th is
advertisement is directed to Canadian citizens and permanent residents
of Canada. Camp Hill Medical Centre is an equal opportunity employer.
Interested candidates should forward their curriculum vitae to:
Dr. S.F. Boudreau
Chairman of Surgical Search Committee
Camp Hill Medical Centre
1335 Queen Street
Halifax, Nova Scotia
B3J 2H6

S 8 9 -4 0

in anesthesia, internal medicine, general sur
gery or pediatrics, and are eligible for educa
tional or general licensure in Ontario, will be
given priority. Submit resumes to: Dr. David
R. Grant, Director, Transplant Unit, PO
Box 5339, University Hospital, London,
ON N6A 5A5.
-S89-38

PLASTIC SURGERY SECTION HEAD:
MB - Faculty of Medicine, University of
Manitoba, invites applications for the po
sition of Plastic Surgery Section Head.
This contingent, geographic full-time posi
tion includes a University of Manitoba
appointment as Associate Professor in
the Department of Surgery, Section of
Plastic Surgery, and provides opportunity
for private practice. Applicants must be
eligible for registration with the College of
Physicians and Surgeons of Manitoba and
hold certification in plastic surgery by the
Royal College of Physicians and Surgeons
of Canada. Demonstrated academic ac
complishments, administrative ability and
expertise in the development o f teaching
and research programs and patient care
required. Both men and women are en
couraged to apply. Salary will be com
mensurate with experience. In accordance
with Canadian immigration requirements,
this advertising is directed to Canadian
citizens and permanent residents. Appli
cants should forward their completed cur
riculum vitae, together with names of
three referees, to: Dr. R.G. Danzinger,
Chairman, Search Committee, c/o De
partment of Surgery, St. Boniface Gen
eral Hospital, 4 0 9 Tache Ave., Winni
peg, MB R2H 2A6.
-S89-41

INTENSIVIST — DIRECTOR ICU
Peel Memorial Hospital, a 500-plus-bed community hospital, is seeking an
intensivist for its Intensive Care Unit. The intensivist must be prepared to take a
leadership role in providing primary care to all ICU patients and must be able to
work in a cooperative and collaborative manner with a backup team of internists,
anesthetists and surgeons.
Responsibilities will include ensuring that appropriate policies and procedures for
the effective operation of the ICU are established. The successful candidate will be
the leader of a multi-disciplinary team committed to excellence in caring for
critically ill patients.
Candidates must be qualified and interested in working with both medical and
surgical ICU patients. In addition, there will be opportunity for the candidate
to practise within his specialty outside the ICU setting.
Suitable candidates for this position will possess:
— Fellowship in Royal College of Physicians and Surgeons (respirology,
cardiology, or other medical subspecialty, anesthesia, or surgery).
— Additional training in critical care medicine (minimum 1 year).
— Demonstrated skill and experience in critical care.
— Strong leadership skills.
— Excellent communication skills.
Preference will be given to candidates who would be considered eligible for
certification as an intensivist through the Royal College of Physicians and
Surgeons when this becomes available.
Peel Memorial Hospital is located in the rapidly growing community of Brampton,
35 km from Toronto. The hospital is an extremely busy community hospital
which has adopted many innovative programs.
Interested and qualified candidates should submit their curriculum vitae to:
Dr. W. Lucas
Chief of Staff
Peel Memorial Hospital
20 Lynch St.
Brampton, ON
L6W 2Z8
—S89-43
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Activity against a great m ajority of significant
pathogens — for m ost patients, appropriate
bactericidal coverage with single-agent
antibiotic: PRIMAXIN® I.v.
Clinical efficacy — Kager and Nord evaluated
164 patients w ith intra-abdom inal infections
and observed 91% cure or im provem ent.1
Good tolerability profile — sim ilar to
cefazolin/t Avoids the potential nephrotoxicity
or ototoxicity experienced w ith the
aminoglycosides.
No cross-resistance has been observed between
imipenem and other beta-lactam antibiotics.5
PRIMAXIN® I.V. is not active against Corynebacterium group JK,
Fusobacterium varium, Mycobacterium spp., Chlamydia spp., Streptococcus
faecium, Pseudomonas maltophilia, and some strains of: F cepacia,
P. pseudomallei, m ethicillin-resistant staphylococci, and Flavobacterium spp.
1. Kager, L , Nord, C.E.: lm ipenem /cilastatin in the treatment of intra
abdominal infections: A review of worldwide experience. Rev Infect Dis
7(suppl 3): S518-S521, July-August 1985.
2. Calandra, G.B., Ricci, F.M., Wang, C„ Brown, K.R: Safety and tolerance
comparison of im ipenem /cilastatin to cephalothin and cefazolin,
J Antimicrob Chem other 12 (suppl D): 125-131, 1983.
3. Quinn, J.P et al.: Resistance to imipenem in Pseudomonas aeruginosa:
Clinical experience and biochemical mechanisms. Rev Infect Dis 10(4):
892-898, July-August 1988.

*IS -:

Monotherapy with

PRIMAXINiv.

(imipenem and cilastatin sodium for injection)

ijflppi

A BETTER CHOICE THAN
AMINOGLYCOSIDE COMBINATIONS
FOR EMPIRIC THERAPY OF MANY
INTRA-ABDOMINAL INFECTIONS

18

t Please consult M onograph for full details on adverse reactio n s
® Trademark Merck & Co., Inc./Merck Frosst Canada Inc., R.U.
TEN-89-CDN-2164-JA
For prescribing information see page 440
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CARDIOVASCULAR SUTURES
Improved Cardiovascular Needles

Needles Resist Bending

• Special highly adherent silicone
lubricant further reduces
resistance...first pass, last pass

• New, stronger needle configuration

• Securely attached to the suture

• Superior sharpness
• Lower penetration force reduces
strain on needle - minimizes
bending and breaking
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